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ABSTRACT 
July, 1990 
A Molecular approach to Huntington disease in Southern Africa. 
Leslie Greenberg, MRC Unit for Inherited Skeletal Disorders, 
Department of Human Genetics, University of Cape Town Medical 
School, Observatory, Cape Town, SOUTH AFRICA. 
The discovery of a polymorphic DNA probe (G8) showing genetic 
linkage to Huntington disease (HD) has facilitated presymptomatic 
testing and antenatal diagnosis of HD. Before implementation of a 
genetic service of this nature in Southern Africa (SA) however, 
several problems needed to be resolved. These include the degree 
of heterozygosity of certain G8 marker loci and the suitability 
of these markers for linkage analysis, the possibility of non-
allelic mutations causing the HD phenotype and the moral, 
ethical and psychological problems that might arise from the 
practical application of such a preclinical test. 
Ten SA HD families originating from different backgrounds have 
been studied for linkage between HD and the D4Sl0 locus (G8). 
Allele frequencies for markers at the D4Sl0 locus have been 
established in different non-Caucasoid population groups and 
linkage has been demonstrated in SA families using the Hindlll, 
EcoRI and Mspl polymorphisms, detected by G8. A maximum lad score 
of 8.14 at a recombination fraction (0) of 0.00 has been 
calculated using a combined haplotype of the Hindlll and Mspl 
polymorphism. 
During the course of the investigation a hitherto unreported 
genetic DNA variant was detected, using a subclone of G8, in a SA 
kindred of mixed ancestry. In addition there was evidence of 
possible recombination within the D4Sl0 locus in this one family. 
An intensive linkage study in a SA black HD family was undertaken 
using markers on chromosome 4 known to be linked to HD. A lad 
score of 1.16 at a 8 of 0.00 was calculated using eight probes 
from different loci on the short arm of chromosome 4. 
A questionnaire survey was conducted to assess the understanding 
and attitudes of at-risk individuals in Cape Town (CT) to 
predictive testing and antenatal diagnosis. The data obtained 
strongly indicated the need for a well-organised testing protocol 
with adequate pre-test counselling. 
From the results obtained during this project, a protocol was 
designed for the implementation of a molecular genetic predictive 
service for HD in CT based on the specific needs of the persons 
concerned. 
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CHAPTER ONE 
AIMS, OBJECTIVES AND BACKGROUND REVIEW 
1. 1 INTRODUCTION 
Interest in Huntington disease (HD) in Southern Africa (SA) was 
generated in 1977 when M Hayden undertook a national survey of the 
disorder in South Africa. This condition is one of the best 
described genetic disorders and the HD locus was the first 
autosomal locus to be mapped to a specific chromosome using 
molecular markers. In recent years the question of presymptomatic 
prediction for the at-risk person has become a very controversial 
and emotionally charged topic. As a result, the literature on the 
disease is now voluminous. 
The condition was previously known as Huntington's Chorea (HC) . 
However the designation Huntington disease is now used to 
eliminate the confusion of the limiting term 'chorea In 
addition, according to accepted practice, the possessive form of 
the eponym has been discarded. Throughout this thesis, the 
abbreviation 'HD' will be used. 
In order to give a perspective on the subject, a brief overview 
of the problems in establishing a genetic service for HD in SA is 
given in Chapter 1. The aspects mentioned in this chapter are 
discussed in greater detail in the thesis and are appropriately 
referenced therein. 
3 
1.2 AIMS AND OBJECTIVES OF THIS STUDY 
The aims of this investigation are as follows; 
1.2.1 The application of DNA markers for molecular linkage 
analysis and identification of the haplotypes segregating with HD 
in SA. Any recombinants that are found will be used in 
international collaborative studies for the localisation of the 
HD gene. 
1.2.2 To investigate the occurrence of any non-random association 
between G8 marker alleles and HD. 
1.2.3 To establish allele frequencies of some G8 markers in three 
different population groups of the RSA. 
1.2.4 To determine if non-allelic heterogeneity exists in HD 
families with different genetic backgrounds. 
1.2.5 To objectively assess the attitudes of at-risk persons in 
Cape Town towards predictive testing and antenatal diagnosis. 
1.2.6 On the basis of the results obtained from 1.2.4 to 1.2.5 
to establish a programme for predictive testing and antenatal 
diagnosis of HD in Cape Town. 
4 
1.3 DEMOGRAPHIC DATA 
1.3.1 Area studied: 
Collection of data for this study was made throughout the Republic 
of South Africa and Namibia. South Africa is divided into four 
major provinces; the Cape, Transvaal, Natal and Orange Free 
State; the Black 'Homelands' and independent Black States; 
Transkei, Ciskei, Venda and Bophuthatswana (Figure I.I). 
1.3.2 Population: 
One of the objectives of this study was to establish allele 
frequencies at the D4Sl0 locus in the black, white and mixed 
ancestry population groups in SA in order to design and implement 
a presymptomatic testing service for all SA HD families. To 
accomplish this, it was necessary to group or classify the people 
of SA according to their genetic origins. Such classification had 
an innocuous biological basis and was used only in a scientific 
and genetic context. 
In this thesis, ten families with a history of HD were studied 
and belong to three ethnic groups; the indigenous black people of 
the Transvaal, the Cape population of mixed ancestry, and the SA 
whites of European origin. 
5 
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FIGURE Ll 
A map of South Africa. 
The three indigenous black peoples that were investigated live in 
the Northern Transvaal (Tvl) and are each a linguistic subgroup of 
the Bantu-speaking peoples of SA, to which all the SA Negro tribal 
groups or chiefdoms belong. In accordance with current convention, 
the term 'tribal group' is used throughout this thesis. 
The Tswana are of Western Sotho origin, the Pedi of Eastern Sotho 
origin and the Venda who according to van Warmelo (1962) 
"this group is distinguished by a language 
peculiar to themselves, though reminiscent of 
both Sotho and Karanga, and by a culture 
sufficiently characteristic to separate them 
clearly from other Southern Bantu." 
Since their languages have obvious similarities and two of the 
tribal groups have also been shown to cluster together in a 
genetic distance study based on the alleles at 14 loci (Jenkins, 
1972), the results have been pooled as being representative of the 
SA black population of this region (Tvl). 
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The mixed ancestry population in the Cape Province of SA, where 
the study was undertaken, according to Botha and Pritchard (1972) 
and 
• form an anthropologically distinct population 
group" 
• on historical grounds the origin of the Cape 
Coloured is found in three main ethnic groups: 
the Southern African races and invnigrants from 
Asia and Western Europe." 
The Southern African component of this mixed ancestry population 
includes the San (Bushman), Khoi-Khoi (Hottentot) and Bantu-
speaking Negroes. Additional genetic endowment was provided by 
negro slaves imported from Madagascar and the West African coast, 
Asian immigrants from Ceylon, India, Java and Sumatra and 
Caucasians from Western Europe. On the basis of Botha and 
Pritchards' findings of blood group frequencies, the genetic 
makeup of the SA population of mixed ancestry is a compilation of 
approximately 34% Western European, 36% Southern African and 30% 
Asian genes. 
A recent investigation of the polymorphism frequencies of HLA-D 
loci in South Africa confirmed that the SA of mixed ancestry 
population in the Cape are genetically intermediate between the SA 
black population in the Cape (the Xhosa tribal group) and the SA 
population of European origins (Oudshoorn, 1989). 
The SA white population group is of Western European origin, 
mainly from Dutch, French and British stock. 
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In accordance with conventional usage the three ethnic groups in 
SA which were the subjects of this study are referred to as 
either SA of mixed ancestry or of black African or of European 
origins throughout this thesis. 
The term SA Black in the frequency study is used to denote the 
broad group of Southern Africans of black origin from the Tvl 
region where the study of HD in black African families was 
undertaken. 
9 
1.4 MOLECULAR BACKGROUND 
Huntington disease (HD) is a lethal neurodegenerative disorder 
characterized by progressive mental and physical disability. The 
condition is transmitted as an autosomal dominant trait and the 
symptoms, although devastating in severity, do not usually appear 
until the third to fifth decade of life. As a result of the late 
onset, most affected individuals have already procreated before 
they realise that they carry the gene for HD. Each child of an 
affected parent has a 50% chance of having inherited the gene and 
HD can thus be unwittingly transmitted from generation to 
generation in an affected family. Until recently there had been 
no reliable method of presymptomatic or prenatal diagnosis of HD 
and genetic counselling was based solely on family history and 
pedigree analysis. 
In 1983 a DNA marker, GB, (D4S10 locus) was identified and found 
to be linked to HD in a number of families. By 1987, 
investigations worldwide using GB, had found linkage in 63 
families from different genetic backgrounds. 
The discovery of this molecular marker for HD was a significant 
breakthrough as it raised the possibility of developing a 
presymptomatic test for the disorder. This led to the 
establishment of pilot programmes aimed at preclinical detection 
and antenatal diagnosis of HD in Canada, the United States and 
other countries . 
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The molecular focus of the project which forms the subject of this 
thesis is the application of the currently available DNA markers 
for predictive testing in SA families with HD. The usefulness of 
any marker for linkage analysis is dependent on the frequency of 
the different alleles in the ethnic group in question, as allele 
frequencies may differ significantly in population groups of 
different origins. 
It is therefore essential to establish the frequency of 
restriction fragment length polymorphisms (RFLPs) at the D4Sl0 
locus in the different SA population groups in order to determine 
which markers will be informative. Furthermore, prior to 
implementing predictive and prenatal testing for at -risk 
individuals, it is necessary to estimate the recombination 
fraction between HD and the markers to be used in SA HD patjents 
as the error rates in presymptomatic testing are critically 
dependent on the recombination fraction. 
Southern Africa has the ideal situation for investigating the 
possibility of HD being a genetically heterogeneous disorder, by 
virtue of the diverse origins of its various ethnic groups. 
Affected black patients may have a unique form of HD as the gene 
for HD in Southern African whites is known to have originated in 
North-Western Europe; in general, few genes have reached the black 
African population from European sources. In this context, a 
comprehensive molecular investigation of a black African family 
with a history of HD was undertaken in this study. 
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1.5 SOUTHERN AFRICAN BACKGROUND TO HUNTINGTON DISEASE 
In 1977, M.R.Hayden, who at the time was a research fellow in the 
Department of Human Genetics at the University of Cape Town (UCT), 
undertook a national survey of HD in the Republic of South 
Africa (RSA). His findings formed the subject of a Doctoral 
Thesis, a monograph and several publications. Extensive follow-up 
has been conducted subsequently, and by 1982 over 157 affected 
individuals in more than 50 supposedly unrelated families had 
been examined and diagnosed by this department. 
Predictive testing for HD has to date been designed as a first 
world service. In SA the socio-economic situation is more complex 
and before offering this test to affected families, several 
difficulties will have to be overcome. 
These include the ethical, psychological and sociological problems 
that might arise from the clinical application of such a 
preclinical test; taking into account the financial constraints 
upon medical services in Southern Africa. 
By evaluating the results of research already being conducted 
worldwide and with careful consideration of the SA situation with 
special regard to the cultural differences and social attitudes of 
the different population groups, this study provides the 
foundation for the eventual establishment of a genetic predictive 
service for HD in SA. The successful formulation of a protocol 
for predictive testing for HD in SA could be used as a prototype 
for the establishment of similar services in developing countries 
and for numerous other late-onset genetic neurodegenerative 
disorders. 
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1.6 PLAN OF THE THESIS 
The thesis is divided into four main sections: an introduction, 
the molecular study, the questionnaire survey and conclusions, 
practical applications arising from this project and 
recommendations. 
Section One is an outline of the aims of the thesis and an 
historical background review, followed by a brief description of 
the SA situation with regard to HD. 
Section Two deals with the molecular aspects of this study. There 
is a brief introduction to the molecular approach followed by the 
methods and materials used during the course of the project. There 
follows a detailed description of an intensive linkage study which 
was undertaken in SA black HD families. The results of the 
molecular study are followed by a discussion on each aspect of the 
study. A separate chapter is devoted to a new genetic variant 
which was detected during the course of the study and this is 
followed by a discussion on the complications arising from this 
finding. 
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Section Three deals with the questionnaire survey which was 
conducted in Cape Town; methodology and results are followed by a 
discussion on the results of the survey and the implications 
thereof. This is followed by the proposed programme for the 
implementation of predictive testing of HD in the Cape which was 
submitted to the Medical Superintendent of Groote Schuur Hospital 
as a result of this research project. 
Section Four includes a concluding comment on each aspect of the 
study, as well as practical applications which have been 
implemented as a direct result of this project. Finally, 
recommendations are offered for the existing HD service and 
future research into HD in SA. 
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CHAPTER TWO 
HUNTINGTON DISEASE: HISTORY, CLINICAL ASPECTS AND 
EPIDEMIOLOGY 
2.1 HISTORY OF HUNTINGTON DISEASE 
Many references were made in early literature to a late onset 
hereditary disease characterized by involuntary movements and 
progressive mental deterioration. In 1872 George Sumner Huntington 
submitted his classical and only publication "ON CHOREA" to the 
Medical and Surgical Reporter, Philadelphia. Three generations of 
medical practitioners in George Huntington's family had treated 
the disease in families in East Hampton, Long Island, New York 
(Martin, 1984). George Huntington (Fig. II.I) based his article on 
his own observations and experiences as well as those of his 
father and grandfather (Critchley, 1984). In this publication 
Huntington described the clinical and genetic characteristics so 
accurately that his name has been associated with the disease ever 
since (Myers et al., 1985). 
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Figure .!!.:.l 
Dr George Huntington after whom the disease is named. 
From: Zabriskie E (1953) In: Webb Haymaker (ed) Founders 
of Neurology, 1st edn. 
Courtesy: Charles C Thomas, Publisher, Springfield, Ill. 
Russell N De Jong, Ann Arbor 
Professor P Beighton: THE MAN BEHIND THE SYNDROME. 
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He wrote of the disease 
"and now I wish to draw your attention more 
particularly to a form of the disease which 
exists, so far as I know, almost exclusively on 
the east end of Long Island. It is peculiar in 
itself and seems to obey certain fixed laws." 
Furthermore: 
11 The hereditary chorea, as I shall call it, is 
confined to certain and fortunately a few 
families, and has been transmitted to them, an 
heirloom from generations way back in the dim 
past. It is spoken of by those in whose veins 
the seeds of the disease are known to exist, with 
a kind of horror, and not at all alluded to 
except through dire necessity, when it is 
mentioned of as that disorder." 
(Huntington, 1872) 
Regarding the clinical features he wrote: 
"There are three marked peculiarities in this disease: 
1. Its hereditary nature. 
2. A tendency to insanity and suicide. 
3. Its manifesting itself as a grave disease only 
in adult life" 
(Critchley, 1964). 
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2.2 CLINICAL FEATURES 
The clinical features of HD have been well documented in early 
literature and recently, most extensively by M.R Hayden in his 
monograph HUNTINGTON'S CHOREA (Hayden, 1981). The main 
characteristics are outlined below for the sake of perspective. 
The cardinal features of HD are chorea and dementia. The first 
symptoms usually occur in the third to fifth decade of life and 
both the motor abnormality and intellectual deterioration progress 
inexorably for 15 to 20 years. These manifestations are commonly 
accompanied by prominent psychiatric symptoms including severe 
depression. The physical symptoms include uncontrollable jerking 
and twitching movements of the head, neck, legs and arms, as well 
as abnormalities of gait. The chorea (dance-like movements), when 
present, is accompanied by constant flexing and extension of the 
fingers and tic-like grimaces of the face. As the disease 
progresses the abnormal movements become more pronounced. 
Eventually, sufferers are unable to walk or stand alone. Speech 
becomes slurred and this affects the patients' ability to 
communicate coherently. There is increasing difficulty with 
swallowing which results in feeding problems and eventual 
emaciation. This inability to swallow often leads to aspiration 
pneumonia or fatal choking on food in the terminal stages of the 
disease. Death usually occurs 15 to 20 years after the first 
clinical symptoms appear. 
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Mental changes are an integral feature of HD and lead to profound 
dementia as the disease progresses. Dementia was defined by Pearce 
and Miller (1973) as 
Na symptom characterized by a decline of intellect 
and personality which reflect a disturbance of 
memory, orientation, the capacity for conceptual 
thought and often of affect." 
Furthermore they stated that 
N Huntington's chorea is one of the best examples 
of a hereditary illness characterized by dementia." 
(Pearce, 1973). 
Emotional disturbances can occur as early as ten years before the 
onset of physical manifestations. Following the availability of a 
presymptomatic test for HD it has been demonstrated that 
neuropsychological impairment may be present earlier than was 
previously recognised in individuals at risk for HD (Jason et al., 
1988). The most common psychological symptom is depression, 
accompanied by sudden outbursts of anger, occasional 
uncontrollable violence, irritability, decreased attentiveness, 
change in work performance and general inadequacy in coping with 
day-to-day living (Koehler and Sass, 1984). The incidence of 
suicide and attempted suicide among at-risk individuals and 
patients in the early stages of the disease is higher than that of 
the general population (Schoenfeld et al., 1984a; Farrer, 1986). 
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As previously mentioned, HD is a late-onset genetic disease with 
the first clinical symptoms usually appearing in mid-life but 
there is also a juvenile form of HD with earlier onset and more 
rapid deterioration. This condition is not a separate clinical 
entity but rather a reflection of variable phenotypic expression 
(Farrer and Conneally, 1987). 
There is no cure for HD and although no specific treatment will 
halt the progressive neurodegeneration, neuropharmacological 
medicinal agents may alleviate symptoms to some extent. 
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2.3 NEUROPATHOLOGY OF HD 
The caudate nucleus of the brain is the region that appears to be 
primarily affected in HD. The neuropathological changes are 
widespread cell atrophy, particularly in the frontal cortex and in 
the small striatal cells of the caudate and putamen (Martin and 
Gusella, 1986). This selective premature cell death does not seem 
to be associated with any specific detectable biochemical defect, 
although experimental tissue culture studies have indicated a 
possible circulating neurotoxin which could be involved in the 
pathogenesis of HD (Perry et al., 1985 and 1987). 
Ventricular dilation caused by the striatal atrophy may be 
demonstrated by Computerized Axial Tomography (CAT) in the 
advanced stages of the disease. Recent work with Positron Emission 
Tomography (PET) has thrown further light on the fundamental 
neuropathological process of HD (Mazziotta et al., 1987; Berent et 
al., 1988). It is now possible to accurately diagnose patients 
with minimal neurological or psychiatric symptoms and no obvious 
CAT changes using PET scan (Hayden et al.,1986). This technique 
may also be used to support information from DNA linkage studies 
for preclinical detection of HD, two to three years prior to the 
clinical onset of the disorder (Hayden et al.,1987a; Hayden et 
al., 1987c). 
More recently, the use of Single Photon Emission Computed 
Tomography (SPECT) imaging of HD patients has revealed a 
remarkable reduction in regional uptake of cerebral blood flow 
markers in vivo (Reid et al., 1988). The authors claim that this 
method has advantages over PET scan and that the equipment is more 
accessible. 
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2.4 GENETICS OF HD 
HD is inherited as a classical autosomal dominant trait. The gene 
for HD can be transmitted by either parent to the children, of 
either sex; each child of an affected parent has a 50% chance of 
inheriting the HD gene. The mutation is said to be completely 
penetrant and all HD gene carriers will ultimately manifest the 
disorder unless they die from an unrelated cause before the 
expected age of onset. The disease is reported to have amongst the 
lowest known mutation rates recorded for any inherited disorder 
(Stevens and Parsonage, 1969 ). A recent publication suggests 
that a new mutation has occurred at the HD locus in a large 
German family; if this is indeed the case, there is then a 
possibility of several distinct mutations at the HD locus (Wolff 
et al . , 1989) . 
There is no 
heterogeneity. All 
evidence as yet for non-allelic genetic 
families studied worldwide who express the 
disease apparently carry mutations at the same locus on chromosome 
4 (Conneally et al., 1989). However, there is considerable 
variation in the age of onset (Conneally, 1984a) as well as in 
the initial clinical presentation of the disorder. This 
variation in clinical expression may well be a consequence of 
differences in individual genetic background (epistatic 
phenomenae) (Fol stein et al., 1983). 
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Nevertheless, in view of the fact that HD has been reported in 
most countries throughout the world, the possibility of allelic 
heterogeneity cannot be ruled out (Jenkins and Conneally, 1989; 
Sax et al., 1989). 
The unexpected finding that individuals who are homozygous for the 
defective HD gene are not only viable but are clinically 
indistinguishable from sibs who are heterozygous adds further 
intrigue to the genetic makeup of HD ( Wexler et al., 1987; Myers 
et al., 1989). 
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2.5 PREVALENCE OF HD 
HD has been diagnosed throughout the world, but by far the 
majority of affected persons have been of Western European origin 
(Critchley, 1964). A classic example is that of the Spanish sailor 
in the mid-seventeenth century who is reputed to have brought the 
HD gene to Lake Maracaibo in Venezuela, which currently has the 
largest known HD family in the world (Wexler et al., 1987). 
According to Hayden (1981), the first published results of 
epidemiological surveys were from England and Sweden. In his book, 
HUNTINGTON'S CHOREA, he provides a comprehensive summary of 
reported prevalence rates of HD in different countries. Table 11-1 
is a compilation of data from recent publications and gives 
prevalence figures from 1981-1990 which can be added to Table 3.1 
on pages 34 and 35 of Hayden's monograph. 
At a workshop held in Vancouver, Canada, in 1989, the World 
Federation of Neurology Research group on Huntington's Chorea 
estimated an overall prevalence of HD to be 4-6 affected 
individuals per 100,000 of the world population. Finland, SA 
(Blacks) and Japan were notable exceptions (see Table 11-2), in 
that the incidence in these countries appeared to be much lower. 
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TABLE 11-1 
Geographic distribution and reported prevalences of 
Huntington disease. 
Compiled from publications dating from 1981-1990. 
Area Persons 
with HD 
UNITED STATES 
Maryland 212 
South Carolina 
Whites 
Blacks 9 
North American 
Indian 1 family 
PERU 1 family 
CANADA >300 
Population 
Xl06 
4.217 
Prevalence 
5.5 
4.8 
0.97 
VENEZUELA 65 +-0.04 -+16000 
UNITED KINGDOM 
SWales 153 1.728 8.5 
NWales 34 0.621 5.5 
Grampian 
region 198 0.44 9.94 
SOUTH AFRICA 
Blacks 8 
FINLAND 26 0.5 
SWEDEN 450 8 5.6 
AALAND 3 0.02 1500 
FRANCE 158 3.9 4.04 
(Pas-de-Calais) 
Reference 
Folstein et al., 
1987 
Wright et a 1 . , 
1981 
Morris et a 1 . , 
1990 
Morris et a 1 . , 
1990 
Fox et al., 
1989 
Young et al., 
1986 
Quarrell et a 1., 
1988 
Simpson and 
Johnston 
1989 
Joubert and 
Botha 
1988 
Palo et a 1 . , 
1987 
Palo et a 1 . , 
1987 
Palo et a 1 . , 
1987 
Petit and 
Solomez 
1985 
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TABLE 11-2 
Congress reports of the World Federation of Neurology 
Research Group on Huntington's Chorea. Vancouver, 1989 
Area Persons Population Prevalence Reference 
with HD 
NORWAY 161 
ITALY 491 
JAPAN 
NEW ZEALAND 180 
SOUTH 
AUSTRALIA 
4.2 
3.33 
3.8 
3.0 
1.1 
5.4 
7.0 
Heiberg 
1989 
Frontali 
1989 
Kanazawa 
Lintott 
1989 
Turner 
1989 
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With an autosomal dominant inherited disease, it is known that 
each child of an affected parent is at 50% risk of having 
inherited the gene for the disorder. As HD is a late onset 
disease, at any given time, the number of individuals who are at 
high risk of having inherited the HD gene and therefore also at 
risk of possibly transmitting the disorder is considerably 
greater than the number who will eventually present with HD 
(Harper et al., 1979). 
As it is now possible to identify the presymptomatic gene carrier 
for HD, an acceptable protocol for predictive testing for this 
disease must be drawn up. Counselling of HD families with regard 
to procreation should be non-directive and should be focused on 
helping individuals with their decisions. The possibility of 
achieving a general reduction in the future incidence of the 
disorder is of prime concern. It can now be suggested to younger 
individuals or couples that they delay their plans for 
childbearing in view of the possibility of a predictive test for 
HD becoming available. This would help them in making decisions of 
this nature (Harper, 1985b). 
28 
29 
CHAPTER 3 SITUATION IN SOUTHERN AFRICA 
Page 
3.1 Huntington disease in Southern Africa ... 30 
3.2 Genealogy of Huntington disease in 
Southern Africa ........................ . 33 
CHAPTER THREE 
SITUATION IN SOUTHERN AFRICA 
3.1 HUNTINGTON DISEASE IN SOUTHERN AFRICA 
HD was initially considered to be relatively rare in SA and until 
1977 there were very few cases of the disease reported in this 
country. Moreover, there were few publications emanating from the 
continent of Africa concerning HD. In a nation-wide project in 
1977, numerous SA families with HD were investigated and 
documented by Hayden and his colleagues from the Department of 
Human Genetics, UCT (Hayden et al., 1980a). The prevalence of HD 
in SA at that time is shown in Table 111-1. It was stated that 
these figures were probably underestimates of the true frequency 
of HD in SA. In the light of information accumulated in the past 
decade it has become apparent that the figures were relatively 
accurate and therefore represent a fair estimate of the current 
prevalence of HD in SA. 
The prevalence of HD in the Cape Province in 1977 is shown in 
Table 111-2 and can be compared with the number of living persons 
with HD at present within a 100km radius of Cape Town (Fig. V.I) 
based upon data obtained from our records in June 1990. These 1990 
figures were derived from pedigree data which have been obtained 
from family members and have not been confirmed or medically 
verified. 
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For this reason the figures should be regarded with reserve but it 
is likely that they are reasonably accurate and therefore provide 
a perspective of the current situation. 
It is generally accepted that for every affected person there are 
an estimated ten at-risk individuals in the immediate family 
(Hayden et al., 1980b). From the 38 kindreds in the Cape Town area 
it can therefore be assumed that there are approximately 800 
individuals who are at risk for inheriting HD ( Table V-2). 
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TABLE 111-1 
Prevalence of Huntington Disease in South Africa (1977) 
(after Hayden et al., 1980a). 
Number 
Whites 97 
Mixed 53 
ancestry 
Black 3 
TABLE 111-2 
3 -6 Population x 10 Prevalence x 10 
4.367 
2.432 
16.647 
22.2 
21. 7 
0.1 
Prevalence of Huntington disease in the Cape Province (1977) 
(after Hayden et al., 1980a) and living persons with Huntington 
disease in the Cape Province (1990). 
Number Population Prevalence Number Population 
1977 X 103 * 1990 
Mixed 48 2.094 22.9 77 2.397 
ancestry 
Whites 32 1.207 26.5 30 1.209 
Blacks 2 1.674 0.5 0 1.402 
* Based on the 1970 population census taking into 
account the average growth rate. 
** Based on the 1985 population census, according 
to the Bureau for Information Statistical Services. 
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3.2 GENEALOGY OF HUNTINGTON DISEASE IN SOUTHERN AFRICA 
In his thesis "Huntington's Chorea in South Africa" submitted in 
1979, Hayden emphasised that there were several origins of the 
gene for HD in SA, the predominant sources being UK, Holland, 
France and other countries in Western Europe. 
He wrote: ·The story of the origins of HD in SA 
is essentially a story of the multiple 
waves of inunigration to this country, 
primarily from Western Europe, which 
were the results of different accidents 
of history such as the establishment of 
the seafaring companies, wars and the 
discovery of gold on the Witwatersrand" 
(Hayden, 1979). 
The prevalence figures for HD in the white Southern Africans of 
European origin and those of mixed ancestry were similar (Table 
111-1). This was not an unexpected finding in view of the Western 
European contribution to the genetic constitution of people from a 
mixed ancestry background. The HD gene in these two groups can 
therefore be presumed to be of the same origin. In contrast, the 
gene for HD in four Black familes reported in 1988 from the 
Northern Transvaal, possibly represents a new mutation as there is 
very little, if any, Caucasian admixture in Southern African 
blacks. The linkage analysis on a black African family with HD 
that was undertaken by the Department of Human Genetics, UCT, as 
part of a collaborative study is detailed in Chapter 6. 
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SECTION II 
MOLECULAR STUDY 
Chapter 1 INTRODUCTION TO THE MOLECULAR APPROACH: 
Chapter~ MATERIALS AND METHODS: 
Chapter~ LINKAGE STUDY OF HUNTINGTON DISEASE IN SA 
BLACK FAMILIES: 
Chapter I RESULTS AND DISCUSSION: 
Chapter~ A NEW GENETIC VARIANT DETECTED DURING THIS STUDY: 
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CHAPTER FOUR 
INTRODUCTION TO THE MOLECULAR APPROACH 
4.1 HISTORY OF THE MOLECULAR BACKGROUND TO HUNTINGTON DISEASE: 
In 1976 DC Wallace wrote 
"Huntington's Chorea must be 
one of the most widely studied 
examples of Mendelian inheritance in 
Man and yet it remains one of the 
least well understood." 
Ten years later the following statement appeared in the Chicago 
Tribune, March 1986, in an introduction to gene therapy using 
recombinant DNA technology 
"The goal is to alleviate 
human disease - and to do it with a 
power that has heretofore been 
reserved for the Gods." (Merz, 1986) 
The past decade has seen great advances in the field of molecular 
genetics. The challenge now is use these advances to progress 
from the DNA level to the analysis of the corresponding gene 
product which, in the case of HD, has not yet been elucidated. 
The initial step was taken in 1983 when James Gusella and his 
colleagues in Boston, Massachusetts discovered a molecular marker 
(G8) that cosegregated with HD. This marker could be used to 
follow the inheritance of the disorder in informative families and 
permitted early detection of the HD gene before the first clinical 
signs appeared (Gusella et al., 1983) . 
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4.1.1 Localisation of the HD gene: 
The original GB marker was regionally localised to the terminal 
region of chromosome 4 by examining DNA from patients with Wolf-
Hirschhorn syndrome, a birth defect involving heterozygous 
deletion of part of the short arm of chromosome 4 (Gusella et al., 
1985). Subsequent fine mapping of the HD linked D4Sl0 locus, 
defined by the polymorphic DNA marker GB, using in-situ 
hybridisation (Landegent et al., 1986) with somatic cell hybrids, 
localised the HD gene to a terminal band of the short arm of 
chromosome 4 (4pl6.l) (Magenis et al., 1986). 
Since the initial breakthrough, many laboratories world-wide have 
been applying new molecular technology in an attempt to get closer 
to the HD gene locus. The primary aim is to find a marker distal 
to GB that flanks the mutant gene. By identifying flanking markers 
that are closer to the HD gene the region of interest is more 
narrowly defined and there is less DNA to be sequenced in order 
to identify the gene itself. 
Chromosome jumping (Richards et al., 1988), field-inversion gel 
electrophoresis (Pritchard et al .,1989a), and the construction of 
a NotI linkage library (Pohl et al., 1988) have all contributed to 
the isolation of new markers closer to the HD gene locus. 
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The most distal probe to GS, D4S90 (Youngman et al., 1988) is now 
being used as a starting point for identifying DNA fragments 
closer to the HD gene. Doggett et al (1989) have used D4S90, 
pulsed - field gel electrophoresis and a yeast artificial 
chromosome vector to construct a physical map that extends from 
the D4S90 marker to the telomere of chromosome 4. This map places 
the likelihood of the HD gene to within 325 kilobases of the 
chromosome 4p telomere. 
Initially, no instances of genetic recombination were reported 
between the GB marker and HD. However several have now been 
detected, placing GB approximately four centimorgans (cM) from the 
HD gene locus with 95% confidence intervals of 2-4cM (Haines et 
al., 1986). The accuracy of using GS in predictive testing is thus 
compromised by a 4% recombination frequency between GB and the HD 
gene. 
Until the gene is located, any recombination event identified 
between the marker used and the gene locus will provide an extra 
landmark for the mapping of new probes and the localisation of the 
HD gene (MacDonald et al., 1989b). In this context, international 
collaboration between researchers is essential, as each 
recombination event is unique and invaluable in this work. 
A physical map of the chromosomal region 4p16.3, the area 
expected to contain the HD mutation, has recently been constructed 
using more than 20 probes (Bucan et al., 1990). 
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The ultimate goal, once the gene has been isolated and sequenced, 
is to use this genetic code as a template to convert the 
nucleotide sequence back to a protein sequence. This would be a 
major step towards unravelling the basic pathogenesis of HD. 
Knowledge of the HD gene sequence would enable the use of direct 
gene probing for prenatal and presymptomatic diagnosis and reduce 
the necessity for involved family studies. 
4.1.2 Probes for linkage analysis: 
Several new RFLPs have been identified for linkage analysis for 
predictive testing, using single copy probes from the expanded GS 
locus. The polymorphism information content (PIC) of the expanded 
locus in 1987 was about 90% and 64 different haplotypes had been 
identified in families from diverse genetic backgrounds (Wasmuth 
et al., 1987). 
By 1989, many more linked loci and as well as markers with the 
characteristics of VNTR probes (variable number of tandem repeats) 
had been identified near the HD gene. Robbins et al . (1989) 
reported that D4S95 was the most useful DNA marker for 
presymptomatic testing. 
These advances increased the accuracy and applicability of linkage 
analysis and reduced the time and cost of presymptomatic and 
prenatal diagnosis for HD (MacDonald et al., 1989). 
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4.1.3 Immediate applications; prenatal diagnosis: 
An extremely important application of the use of genetic markers 
is that prenatal diagnosis is now possible for informative 
individuals. An antenatal diagnostic service could be offered as 
soon as a predictive testing protocol is established (Hayden et 
al., 1987b). 
A further practical application of the use of genetic markers is 
as follows: prenatal diagnosis could be offered where the result 
would determine either that the fetus has a low likelihood of 
having inherited the gene for HD or has the same risk as for the 
at-risk parent (Fahy et al., 1989). In other words, any test 
result obtained for the fetus would not alter the estimated 
likelihood of HD in the parent at risk (Fig.IV.I). 
This approach is known as 'no news, good news testing' or 
exclusion testing. Prenatal exclusion testing can therefore be 
offered to a pregnant woman if either she or her partner has an 
affected parent (Quarrell et al., 1987; McIntosh et al., 1989). In 
general, this test is used when DNA is unavailable from crucial 
family members. The test is also an option for at-risk parents who 
do not wish to learn of their own HD status. 
40 
Some centres in fact have already embarked on pregnancy exclusion 
testing before implementing full predictive testing for HD. This 
approach allowed time for development and evaluation of a suitable 
protocol (Harper et al., 1988). 
Bloch and Hayden (1987) pointed out two important consequences of 
this test that were not originally considered. The fact that the 
so called 'no news' outcome increases the risk of the fetus having 
inheriting the HD gene from 25% to the same risk as for the at-
risk parent (around 50%) needs to be carefully explained to the 
persons choosing this option for prenatal diagnosis. In addition, 
a 'no news' test result 'links' the risk status of the fetus to 
that of the at-risk parent. For example, if the parent does not 
develop HD, then neither will the fetus. More recently Millan et 
al. (1989) reported on the additional problem of the laboratory 
performing the actual test having had access to too much 
information and so actually performing a predictive test on an 
individual who did not wish to be tested. The burden of knowing 
that someone has the gene for HD and not allowing this knowledge 
to influence decision making in any way, needs to be considered 
by laboratories offering prenatal diagnosis for HD. Furthermore, 
the possibility of presymptomatic testing being done on minors 
without their consent has also been identified as being an 
unexpected complication of exclusion testing (Quinn, 1989). 
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Figure IV.1 
Principle of the prenatal exclusion test . 
Information may be given concerning the fetus 
without altering the estimated likelihood of HD 
in the at-risk parent. 
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4.1.4 PET scans and predictive testing: 
Finally, it has been suggested that at centres where the equipment 
is available, a PET scan of the caudate glucose utilization may 
help to confirm DNA studies in at-risk individuals or could be 
used for those persons in whom DNA studies are not helpful (Hayden 
et al., 1987a). 
On the basis of their findings, Hayden's group suggested that in 
addition, PET may also provide an opportunity of detecting the 
condition when DNA results may be incorrect due to recombination. 
Abnormal striatal glucose utilization has been found to precede 
the onset of HD symptoms and it is thought that the first 
detectable signs of change occur only in the three years prior to 
the onset of the disease. Careful use of PET scans combined with 
DNA linkage analysis could therefore provide optimum results for 
presymptomatic testing of HD ( Hayden et al., 1987c). 
However, others have not found this method to be as successful 
(Young et al., 1987; Perlmutter and Raichle, 1987). Caution must 
therefore be exercised in advocating this technique which should 
only be utilised for predictive testing by those centres which 
have full confidence in their results. 
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4.1.5 Future applications: 
Ultimately, provision could be made for some kind of gene therapy 
to alleviate the symptoms of the disease or prevent the onset 
thereof. It may also be possible to rectify the defect by means 
of genetic engineering. In future, therapeutic intervention 
following the early diagnosis of the presymptomatic gene carrier 
could possibly retard the inexorable neurodegenerative process 
(Shoulson et al., 1989). 
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4.2 HETEROZYGOSITY AT THE MARKER LOCUS 
In order for a marker to be informative, the different genotypes 
must be easily discernable and it must be possible to distinguish 
the allele that segregates with the disease in a family from the 
one associated with the normal version of the gene (Maestri et 
al., 1987). The usefulness of any marker for linkage analysis is 
therefore dependent on the frequency of heterozygosity in the 
population group in question (lkonen et el., 1990). 
It was therefore essential to establish allele frequencies for 
RFLPs at the D4S10 locus in different population groups in SA in 
order to determine which markers would be informative. 
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4.3 QUESTION OF HETEROGENEITY AT THE GENE LOCUS 
For the marker to be 100% reliable it is essential that the 
disease should not be genetically heterogeneous (i.e. alternative 
loci involved in the expression of the trait). To date, a total of 
63 HD families worldwide have been examined for linkage with G8; 
a combined lod score of 87.69 at 8 = 0.04 (95% confidence interval 
0.018-0.071) has been calculated, indicating that there is no 
evidence for non-allelic heterogeneity at the HD locus (Conneally 
et al., 1989). SA has the ideal situation for the examination of 
HD families of diverse genetic backgrounds, some from genetically 
isolated populations, in order to address this issue. 
Genealogical investigations of the mixed ancestry group in SA are 
difficult to carry out. This is due to the lack of accurate 
documentation of the registration of births prior to 1895 and also 
to the lack of knowledge in this group of their antecedents' 
origins. However, due to the genetic constitution of this group 
it may be presumed that the gene for HD in the mixed ancestry 
population group had its origin in Western Europe. This assumption 
is based on the fact that it has been established that the gene 
for HD in the SA population of European origins almost certainly 
originated in Western Europe (Hayden et al., 1980c). 
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The black African peoples, in particular the Pedi, Tswana and 
Venda from the Northern Transvaal, where the black HD families 
live, are indigenous to SA. In general, few genes have reached 
these populations from European sources and it is very likely that 
this is a new origin of the HD gene and not the original North 
Western European gene. It is therefore possible that these 
individuals may have a unique form of the HD gene. The results of 
the linkage analysis of two black African HD families completed as 
part of a collaborative study are discussed in detail in Chapter 
6. 
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CHAPTER FIVE 
MATERIALS AND METHODS 
5.1 COLLECTION OF DATA 
On the basis of a nation-wide project carried out by the 
Department of Human Genetics, UCT, in 1977, a South African 
Huntington disease Registry was established (Hayden and 
Beighton, 1982a). This data base contained details of affected 
persons and essential information pertaining to their families. 
The extensive data and documentation that had been accumulated and 
since maintained, was used in the current project as a starting-
point for the initial contact and the tracing of families with a 
history of HD (Hayden et al . , 1987d). Patients were appraised at a 
specialised HD clinic at Groote Schuur Hospital (GSH) where they 
and their families were seen on a regular basis by a Neurologist 
and a Medical Geneticist. 
South Africa is a large, predominantly rural country and major 
population centres are separated by sparsely inhabited regions. 
The logistics of travelling to visit patients all over the 
country, the counselling of at- risk individuals and the 
collection of blood specimens from family members as well as 
language and cultural barriers posed enormous problems. 
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Although HD patients were seen and appraised in other major 
centres throughout the country, for the current project it was 
decided to concentrate on HD families living within a radius of 
100km of Cape Town (Fig. V.l). Genetic nursing sisters from our 
Department undertook home visits in the Cape Town area to collect 
blood and counsel HD family members. However, families were often 
widely dispersed and vital key members were reported to be living 
in relatively inaccessible areas of the country; in these 
circumstances National Department of Health Genetic Sisters traced 
and visited the family members. 
, 
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Figure V.l 
Map of the Cape Province to indicate the area 
covered in the study. 
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5.2 DNA BANKING CENTRE 
5.2.1 Evolution of the HD DNA banking centre: 
In 1986 a DNA banking centre for HD was established at the 
Department of Human Genetics, UCT, similar in design and concept 
to the Canadian HD DNA banking centre (Anderson et al., 1986). A 
full time genetic co-ordinater was appointed for a six month 
period to establish contact with HD families in SA. Letters were 
sent to all the known HD families informing them about recent 
developments, with special reference to the new molecular 
technology and requesting their participation in establishing the 
DNA bank. 
Affected patients who are crucial for family linkage studies may 
die prior to the establishment of a predictive service. To avoid 
family members subsequently being denied a presymptomatic test by 
virtue of the unavailability of DNA from deceased relatives, 
special appeals were made to affected individuals in HD families 
to donate blood for DNA banking, while the accuracy and 
reliability of the test was being assessed. 
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5.2.2 Approach to HD families: 
In the information sheet that was distributed (Appendix I) it was 
explained that the 'bank' was a storage facility where blood 
specimens would be kept until such time as the test became 
available. The necessity for participation of the whole family, 
affected and unaffected members, was explained. It was emphasized 
at all times that no results would be given following the drawing 
of the blood specimen and that some of the DNA would be subjected 
to preliminary analysis while the balance would be stored until 
such time as linkage studies could be performed. 
Illiteracy was a problem for some persons in understanding the 
information sheets and oral explanations using cultural and 
societal precepts and simple diagrams were used to help clarify 
difficult concepts. 
In HD, confidentiality is of utmost importance and affected 
families were assured that personalised information of this nature 
would be maintained in the strictest confidence. Subjects were 
requested to sign a consent form indicating that they understood 
these procedures (Appendix II). 
As far as possible, patients and their families were examined by 
a clinician who was experienced in the diagnosis of HD, before 
blood was drawn for the DNA bank. Comprehensive family histories 
and clinical details were obtained for the purpose of compiling 
accurate pedigrees. 
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5.2.3 Professional contact and general education to 
increase awareness of HD: 
DNA Banking Centre Information Sheets (Appendix III) were sent to 
general practitioners known to have been involved with the 
management of HD families, requesting them to obtain blood 
specimens for the banking centre. Mental Health hospitals 
throughout the country were approached and sent the relevant 
information in an attempt to trace new patients. The author also 
lectured to nursing sisters, social workers, lay organisations and 
Psychiatrists about the concept of predictive testing and its 
implications in order to stimulate interest and raise the 
awareness of HD . 
In June 1987, the first meeting of the Southern African Society of 
Human Genetics was held at Rustenburg, Transvaal. The author read 
a paper detailing the progress in the establishment of the DNA 
banking centre, as well as the current work being undertaken with 
newly acquired molecular probes (Appendix IV). It was proposed at 
this meeting that the Department of Human Genetics at UCT should 
be responsible for preparing for linkage studies of HD in SA. 
It was agreed that all centres would send DNA specimens to our 
laboratory for banking and molecular workup (Fig. V.2). In turn, 
each centre would be responsible for the counselling and 
management of patients in their own region. 
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Figure V.2 
Map of South Africa and Namibia with the major centres 
indicating the extent of the DNA banking service area. 
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Due to the logistic problems of servicing the whole country from 
one centre, it was subsequently agreed that a similar centre be 
established in the Transvaal. DNA stored at either centre, would 
be released reciprocally upon receipt of written consent from the 
person concerned. 
Joubert and Botha (1988) reported on four black families with HD 
in the Northern Transvaal and our Department was approached to 
undertake a collaborative study. Due to the small number black 
persons known to have HD, this large series of black African HD 
patients offered a unique opportunity for linkage analysis. A 
field trip was undertaken into the Lebowa area by the author and 
a Medical Geneticist from the Department of Human Genetics, UCT, 
to visit these families and collect blood for DNA isolation and 
storage (Fig V.3). An assessment was made of these affected 
individuals' needs and also their attitudes to HD. Liaison was 
established with local social workers for the purpose of referral 
should any questions or problems arise at a later stage. 
To date, at the UCT DNA Banking Centre, 45 families from different 
parts of SA from whom DNA has been collected, isolated and 
stored have been documented (Table V-1 and Table V-2). During the 
establishment of this service close liaison was maintained between 
the laboratory and medical staff, departmental nursing sisters and 
State Health Genetic services. The co-operation of all concerned 
at both local and national levels ensures that the service runs 
efficiently. 
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Figure V.3 
Map indicating the Lebowa region where the 
study of SA black HD families was undertaken. 
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TABLE V-1. 
DNA Banking Centre: National figures for 1990. 
Ethnic Total HD Unaffected Spouses 
group patients family members 
Mixed 223 60 132 31 
ancestry 
Whites llO 30 61 19 
Tswana 22 2 17 3 
Pedi 21 5 12 4 
Venda 17 1 14 2 
TOTAL 393 98 236 59 
30 June 1990. 
TABLE V-2. 
DNA Banking Centre: Figures for the Cape Province for 
1990. 
Ethnic Total 
group 
Mixed 212 
ancestry 
White 87 
TOTAL 299 
30 June 1990. 
HD 
patients 
57 
23 
80 
Unaffected Spouses 
family members 
125 30 
49 15 
174 45 
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5.3 COLLECTION OF BIOLOGICAL MATERIAL 
Blood samples (30ml) for DNA isolation were collected from 
consenting individuals by venepuncture into vacutainer tubes 
containing EDTA. When possible, 10ml was processed within four 
days after being stored at 4° C and DNA was purified using standard 
laboratory techniques (Vandenplas et al.,1984). The balance of the 
frozen blood was stored at -20° C to be isolated separately as a 
precaution against laboratory error. DNA was stored at -70° C in 
two aliquots from the different isolations. DNA samples that were 
currently being used for restriction were stored at -20° C. Blood 
which was unable to be processed immediately was stored in 10ml 
aliquots at -70° C and isolated at a later date. Samples collected 
from other centres were transported without delay by air and 
stored at 4° C until they reached the laboratory. 
In 1987 it was decided to increase the amount of blood taken at 
the time of collection by an amount of 10ml for the purpose of 
paternity testing, as some instances of questionable paternity had 
arisen from the linkage data. These samples were sent to tissue 
typing laboratories for testing, using different blood group 
systems, including HLA tissue typing (Du Toit et al., 1989) and 
the results were stored in their records. Information obtained 
from such testing was never divulged and was used strictly to 
elucidate questionable linkage results. 
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The necessity for extra blood specimens can now be overcome with 
the use of the new VNTR probes using the same principle as or in 
conjunction with DNA fingerprinting (Jeffries et al., 1985). 
When the father of an HD patient died suddenly, it was essential 
for us to obtain DNA from the deceased to perform linkage analysis 
on the family. Permission was obtained from the family and a 
fibroblast cell line was established from explants of a skin 
biopsy specimen taken from the deceased person and DNA was 
isolated. Cells are now stored in liquid nitrogen for further 
culture if required. (For method see chapter 5.6.5) 
Recombination events identified between molecular markers and the 
HD gene locus are of vital importance for the physical 
localisation of any new probes. In addition, the use of pulsed 
field gel electrophoresis requires large fragments of unsheared 
DNA. Consequently it was decided to immortalize cell lines from 
all HD patients. To date lymphocytes from five patients have been 
transformed, using standard techniques and are stored in liquid 
nitrogen. 
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5.4 FAMILIES SELECTED FOR LINKAGE ANALYSIS 
The ten HD families selected for linkage analysis were primarily 
chosen on the basis of family size. Those with the greatest number 
of living HD patients, manifesting in two successive generations, 
were given preference (Table V-3). 
Six families were of mixed ancestry, two of European origin (Dutch 
and French/Mauritian stock) and two were of SA black origin (Pedi 
and Tswana). 
The prerequisites for family selection that became apparent during 
the study were: 
i. The number of informative matings 
ii. The frequency of heterozygosity of the markers in affected 
individuals 
iii. The family structure and availability of relatives for 
genotyping. 
In the absence of some of these prerequisites it is essential to 
be able to infer the G8 haplotypes in untyped individuals and to 
establish phase in affected individuals. 
All affected individuals included in the study were examined by a 
clinician experienced in the diagnosis of HD. Individuals with an 
equivocal clinical status were regarded as being 'at-risk' and not 
as being affected. Children under the age of 16 years were only 
typed where necessary to establish the parental haplotypes. In 
instances where a parent was deceased, genotypes were inferred 
from those of the progeny. 
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TABLE V-3. 
HD Families selected for linkage analysis 
Family 
MAl 
MA2 
MA3 
MA4 
MAS 
MA6 
Pll 
T9 
E20 
E40 
Ethni c 
group 
mixed 
ancestry 
mixed 
ancestry 
mixed 
ancestry 
mixed 
ancestry 
mixed 
ancestry 
mixed 
ancestry 
Pedi 
Tswana 
European 
(French) 
European 
(Dutch) 
Total no . 
of family 
members 
61 
140 
110 
64 
23 
40 
57 
33 
31 
22 
Persons 
reputed 
to be 
affected 
13 
19 
14 
7 
4 
4 
10 
6 
6 
7 
Deceased 
HD 
patients 
7 
8 
9 
4 
2 
1 
7 
4 
3 
5 
DNA 
obtained 
from HD 
patients 
5 
10 
6 
4 
2 
3 
4 
2 
3 
2 
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There were living HD patients available for study in two 
successive generations in family MAI, but there were no direct 
instances of parent to child transmission of the disorder in the 
five living HD patients. 
In family MA2 there were three instances of meiotic transmission 
of HD in the ten patients available for study. 
Families MA3, MA4 and MA6 all had living HD patients available for 
study in two successive generations but no instances of direct 
meiotic transmission of the disease in the affected individuals. 
In MAS only two HD sibs were available for study. 
One of the two black African families in the study, Pll, had DNA 
available from HD patients in two successive generations while the 
other, T9, only had DNA available from two HD sibs. 
In both SA families of European origins (E20, French; E40, Dutch) 
the only HD patients available for study were from the same 
generation. 
The numbers of HD patients, unaffected family members, at-risk 
individuals and spouses who were included in the study are shown 
in Table V-4 and the pedigrees of all the families in the study 
can be seen in Figs VII.3 and VII.4. 
In order to ensure and maintain confidentiality at all times, all 
individuals genotyped were coded from the start of the study and 
referred to by their laboratory numbers. 
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In the pedigrees presented in this thesis, the sex and order of 
birth have been changed to maintain anonymity. All participants 
were assured that their DNA would be stored in the DNA bank and 
that only a portion would be used for research purposes. All 
results are regarded as research data and will not be used for any 
predictive testing. 
Once an acceptable programme for presymptomatic testing of HD in 
SA has been established and implemented, fresh DNA samples will be 
obtained from those individuals who are deemed to be strictly 
necessary for linkage analysis within a family. In the event of 
DNA stored in the bank being unobtainable for a predictive test 
for any reason, written consent will have to be obtained from the 
individual for its release and use in presymptomatic testing. 
During the course of the study, 42 HD patients were genotyped 
representing 43% of all the HD patients whose DNA is stored in the 
HD DNA banking centre (Table V-5). In five cases DNA samples were 
used from HD patients who had died before linkage analysis was 
performed, emphasizing the necessity for DNA banking from all HD 
family members for future use in presymptomatic testing. 
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TABLE V-4. 
Totals of SA HD family members genotyped in this study. 
Family 
MAl 
MA2 
MA3 
MA4 
MAS 
MA6 
Pll 
T9 
E20 
E40 
Ethnic 
group 
mixed 
ancestry 
mixed 
ancestry 
mixed 
ancestry 
mixed 
ancestry 
mixed 
ancestry 
mixed 
ancestry 
Pedi 
Tswana 
European 
(French) 
European 
(Dutch) 
HD 
patients 
5 
10 
6 
4 
2 
3 
4 
2 
3 
2 
41 
Unaffected At-risk 
family individuals 
members used for 
over 60 genotype 
years assignment 
5 10 
2 15 
3 7 
2 7 
0 6 
0 4 
0 11 
2 4 
0 3 
1 4 
15 71 
Total no . of individuals genotyped in the study 154 
Spouses 
2 
2 
3 
4 
2 
3 
4 
2 
3 
2 
27 
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TABLE V-5. 
Number of HD patients genotyped during the study 
compared with the number of patient blood stored in the DNA bank. 
Ethnic 
group 
Mixed 
ancestry 
European 
origins 
Tswana 
Pedi 
Venda 
Totals 
HD patients' DNA 
stored in bank 
60 
30 
2 
5 
1 
98 
HD patients' DNA 
genotyped in study 
31 
5 
2 
4 
0 
42 
52X 
17X 
lOOX 
SOX 
ox 
43X 
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5.5 DNA PROBES USED IN THE CAPE TOWN STUDY 
Initially, in 1985, DNA was isolated from patients with HD and at-
risk individuals from two large families in Cape Town (MAI and 
MA2). DNA was digested with restriction enzymes HindIII and 
EcoRI, restriction fragments were electrophoretically separated on 
0.6% agarose gels and Southern blots were prepared. These blots 
were sent to the laboratory of James Gusella in Massachusetts 
where they were hybridized to two subclones of the original GB 
probe (pK082 and pK083). Linkage was found in both these families 
and the results were presented at a local congress as part of a 
collaborative study (Goldblatt et al., 1986). 
In 1986 we obtained the GB probe and three of its sub clones 
(pK081, pK082 and pK083) from the Boston group. This DNA 
fragment (GB), now designated D4Sl0, had been mapped to the 
terminal region of the short arm of chromosome 4, thus localising 
the HD gene to bands 4pl6->pl5 ( Zabel et al., 1986). Fig. V.4. 
Linkage analysis using these probes was initially undertaken in 
three large families of mixed ancestry (MAI, MA2, and MA3). The 
subclones of GB that were used were pK081 and pK083 which both 
recognise EcoRI polymorphisms and pK082 which identifies the 
HindIII polymorphism (Table V-6). 
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HD 
RESTRICTION MAP OF THE PROBES USED IN THE 
CAPE TOWN STUDY 
H5.52 
~ 
C5.5 
~ pK081P~3 
GS 
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Figure V.4 
5kb 
-
Restriction map indicating the polymorphic sites in 
the D4Sl0 locus. 
E=EcoRI H=HindIII M=MspI. 
The relevant polymorphic sites used in this study have 
been indicated by an asterisk (*).HindIII RFLPs detected 
with genomic clone pK082, MspI with HS.52 and EcoRI with 
pK083 and pK081; pK081 is indicated with a dotted line 
as the exact position of this probe has not been 
determined (Gusella, personal communication). 
Reproduced in part from Skraastad et al. (1989). 
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Centromere 
TABLE V-6. 
G8 Subclone 
Probe name 
pK082 
pK081 
pK083 
H5.5 
Probes used in the Cape Town study 
Restrict ion 
enzyme 
Hi ndII I site 1 
site 2 
EcoRI 
EcoRI 
Mspl 
Fragment 
size(kb) 
17.5 / 15 
4.9 / 3.7 
6.o I 5.5 
14 / 9 
3.5 / 2.8 
Reference 
Gusella et al. 
1983 
Gusella et al. 
1983 
Gusella et al. 
1983 
Skraastad et al. 
1989 
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Difficulty was experienced with double heterozygote parents and 
homozygosity of the marker in the affected individual. Often the 
disease appeared to be segregating with the more frequent marker 
and was thus uninformative ( Fig VII.4; MA1,MA2, and MA3). 
M Skraastad et al., (1986) reported the isolation of a cosmid, 
C5.5, which increased the heterozygosity in the Dutch population 
from 68% to 96%. In 1987 we obtained the Dutch group's subclones 
HS.52 and FS.53 which had proven most informative for them. As the 
majority of our Afrikaner families originated from Holland in the 
17th century, we anticipated a similar polymorphism frequency in 
some of our SA population groups (Bakker et al., 1987) (Tables 
VII-2 and VIl-6) . 
The subclone HS . 52 is a Bglll clone from one end of cosmid C5.5 
which is, in turn, a 5.5kb EcoRI fragment of the original GB probe 
found 48kb from the EcoRI RFLP on the centromeric end of GB 
(Skraastad et al.,1989). (Fig. V.4) This probe proved to be most 
useful and increased the informativity in two SA families (Table 
VII-19; MAI and MA3). 
The position of these subclones relative to the original GB probe 
and the relevant restriction sites are indicated in Fig. V.4. 
Results of our linkage studies substantiate the orientation of 
these restriction sites (Chapter 8.2). 
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5.6 GENOMIC DNA HYBRIDIZATION 
In my investigations the following standard techniques (Vandenplas 
et al., 1984) were used, with some modifications 
preparation of DNA from EDTA anticoagulated blood 
restriction enzyme digestion 
electrophoretic fragment separation 
Southern blotting 
filter hybridization 
autoradiography 
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The changes made to these techniques during the course of this 
study include: 
5.6.1 
5.6.2 
5.6.3 
'Blotto' was used in place of Denhart's solution. 
Hybond N membrane (Amersham) was used in place of 
nitrocellulose to facilitate multiple rehybridization 
of the filters. 
A year after the project began, Amersham, the suppliers 
of Hybond N membrane, changed the blotting method to 
ensure the transfer of DNA fragments> 10kb in size. 
This involved acid nicking and alkali blotting. 
5.6.4 It was found that very poor results were obtained using 
probe H5.52 and the standard nick translation 
method. Oligolabelling of the plasmid insert DNA was 
routinely performed with this probe using the method 
adapted by Chris Mathew (Personal communication). 
5.6.5 Modified method for DNA isolation from cultured 
fibroblasts. 
73 
The modified methods that were used are as follows: 
5.6.1 ~ Blotto' hybridization (Johnson D et al., 1984) 
Filters were prehybridized for 30 min at 65° C in 3 X SSC (1 X 
is 0.15M NaCl, 0.015M trisodium citrate), 60 min at 65° C in 3 X 
SSC and 0.25% powdered milk (Carnation low fat= 'Blotto') and 
then for 30 min at 65° C in 3 X SSC, 0.25% powdered milk and 0.1% 
SDS (sodium dodecylsulphate). The denatured labelled probe was 
then added to 5 - 8ml of this final prehybridization solution and 
incubated in a heat-sealed plastic bag in a shaking waterbath for 
at least 48 hrs at 65° C. Post hybridization washes also included 
0.25% powdered milk in place of Denhart's solution. The final 
stringency washes were routinely performed in 0.1 X SSC and 0.1% 
SDS (w/v) at 65° C for 1 hr (2 changes of stringency washes). 
5.6.2 Removal of probe and re-use of blots. (Amersham protocol) 
Membranes were not allowed to dry after hybridization and washing. 
They were stored at -20° C until they were 'stripped' of the 
previously used probe. To remove the probe the filters were 
incubated for 30min in 0.4M NaOH in a shaking waterbath at 45° C, 
transferred to 0.1 X SSC, 0. 1% (w/v) SDS and 0.2M Tris HCl pH 7.5 
and left shaking at 45° C for a further 30 min. Following the 
'stripping', the blots were autoradiographed to check that the 
probe had been successfully removed. The filters were then 
prehybridized and hybridized with a new probe as before. 
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5.6.3 Acid nicking of DNA fragments >lOkb and alkali blotting {Amersham recommended protocol} 
After electrophoresis for 24hrs at 45V to separate the larger 
fragments, the 0.6% agarose gel was placed in 0.25M HCl for 
lOmin. The gel was then rinsed in distilled water, placed in 
denaturing buffer, completely covering the gel and shaken gently 
at room temperature for 30 min. It was then lifted out of the 
denaturing solution, blotted to remove any excess liquid and 
equilibrated in an alkali transfer buffer (0.25M NaOH and 1.5M 
NaCl) for 15min. A capillary blot (standard Southern blot) was 
then set up, using alkali transfer buffer in the place of the 
usual 20 X SSC. 
5.6.4 Oligolabelling of the plasmid insert DNA for probe 
H5.5. 
The solutions used were all from the Amersham multiprime DNA 
labelling systems kit. 
50ng of probe in distilled water was boiled for 3min to denature 
the DNA and then placed on ice for lOmin. 
Reagents were added to the DNA in the Eppendorf tube in the 
following order: 
Multiprime buffer llUl 
BSA 4pl 
32 P dCTP 50r£i 5µ1 (3000 Ci/mmol) 
Polymerase 2µ1 
Total reaction vol. 50µ1 
The reaction mixture was left overnight at room temperature in a 
lead pot. The following day the reaction mixture was extracted 
with an equal volume of phenol:chloroform and the free nucleotides 
were separated by chromatography on a small column of Sephadex G-
50 as per usual for nick translation of DNA probes. 
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5.6.5 DNA isolation from Fibroblasts 
2 X 25ml Flasks of confluent fibroblasts were trypsinized and re-
suspended in 0.5ml PBS (Phosphate buffered saline ). The cell 
suspension was then homogenized after the addition of 3 mls lysis 
buffer and the same procedure followed as for lymphocytes. Roughly 
IOO~g DNA was recovered from one isolation. 
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5.7 LINKAGE ANALYSIS 
The basis for linkage analysis studies is that two loci which 
are located close to each other on the same chromosome tend to co-
segregate. Independent segregation is observed where recombination 
events occur between loci. The chance of recombination increases 
with the distance between the loci. 
As previously stated, international studies of genetic linkage 
between HD and GS have generated a combined lod score of 87.69 at 
9 = 0.04 (95% confidence interval 0.018-0.071). This means that 
the accuracy of using GS in predictive testing is compromised by a 
4% recombination frequency between GS and HD (Conneally et al., 
1989). Prior to implementing predictive and prenatal testing for 
at-risk individuals in SA, the recombination fraction between HD 
and the markers in SA HD patients needed to be calculated as the 
error rates in presymptomatic testing would be critically 
dependent on this recombination fraction. 
The computer program LIPED (Ott, 1974) was used to analyse the 
genetic linkage data with a modification for age dependent 
penetrance (Table V-7). No allowance was made for the possibility 
that age of onset has a familial basis (Farrer and Conneally, 
1985). 
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The lod scores between the markers and the HD locus were 
calculated using recombination fractions from 0.00 to 0.40. 
Individual lod scores were established for each marker as well as 
for a combined haplotype for the ten families studied ( Tables 
VII-18 to VII-22 ). 
Confidence limits were estimated by the method recommended by 
Conneally et al. (1985) and the computer program HOMOG was used to 
test for heterogeneity (Ott, 1985). The HD frequency was taken as 
0.0001 and the marker frequencies were set according to the 
population group of the HD family analysed. 
All living HD patients, their parents, unaffected sibs over the 
age of 60 years and at-risk individuals whose genotypes were 
essential for assigning haplotypes were included in the analysis. 
Whenever the inclusion of an at-risk individual under the age of 
60 years resulted in a large negative lod score at all the values 
of 9, these individuals were excluded from the linkage analysis. 
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TABLE V-7. 79 
Liability codes for age dependent penetrance. 
CODE AGE BIRTHYEAR PENETRANCE 
1 0-27 63-90 .02 
2 28-32 62-58 .OS 
3 33-36 57-54 .1 
4 37-41 53-49 .3 
5 42-46 48-44 .4 
6 47-51 43-39 . 5 
7 52-56 38-34 . 6 
8 57-62 33-28 . 7 
9 63-67 27-23 .8 
10 68 > 22 < .9 
* As of 31/12/1989. 
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CHAPTER SIX 
LINKAGE STUDY OF HUNTINGTON DISEASE IN SA 
BLACK FAMILIES. 
6.1 BACKGROUND TO HUNTINGTON DISEASE IN BLACK FAMILIES 
HD is uncommon in African and American black persons (Hayden, 
1981). Apart from a report from Maryland in 1987 (Folstein et al., 
1987), where the prevalence of HD in blacks was found to be 
unexpectedly high, there have been few descriptions in the past 
decade of HD involving black families (Wright et al., 1981). In 
particular, there has been only one report with eight confirmed 
cases of HD in African blacks (Joubert and Botha, 1988). 
Furthermore there is little published on genetic linkage in black 
HD families (Fol stein et al.,1985; Bird et al., 1986; Fol stein et 
al., 1985). 
Due to this low frequency of HD in black persons, together with 
the necessity mentioned in chapter 4.3 for addressing the question 
of heterogeneity at the HD locus, a collaborative project was 
undertaken involving M Hayden, University of British Columbia, 
Canada and J Joubert, Medunsa and Ga-Rankuwa Hospital, Pretoria, 
RSA. The purpose of this study was to establish linkage in one of 
the three black African families reported in 1988 (Joubert and 
Botha, 1988). Numerous markers on chromosome 4, currently being 
used for predictive testing of HD in Canada ( Hayden et al., 
1988a) were used in this investigation. This study was the first 
investigation in Africa of a black kindred with HD using 
molecular linkage analysis. 
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The SA black HD family from the Lebowa region (Fig V.3) that 
was intensively investigated in this study can be seen in Fig 
VI.I. Fig VI.2 is the pedigree of this indigenous black African HD 
family (Pll). 
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Figure VI. l 
A South African black HD family in Lebowa 
6.2 CLINICAL ASPECTS 
Clinical data have already been published on this HD family 
(Joubert and Botha, 1988). In the present investigation, four 
affected family members were examined and clinically diagnosed. 
(It should be noted that in the publication HUNTINGTON DISEASE 
IN SOUTH AFRICAN BLACKS (Joubert and Botha, 1988) the pedigrees 
published of families 1-3 refer to families 2-4 in Table V of the 
article. The pedigree of family 2 is the one referred to in this 
thesis.) 
There were no remarkable differences noted on physical examination 
between these four HD patients and patients seen at the HD clinic 
at Groote Schuur hospital ( from all different SA populations). 
The age of onset in the four HD patients examined were 46, 45, 48 
and 37 years ( Fig VI.2: individuals 111.3, 111.6, · 111.13 and 
IV.25 respectively). 
The unaffected sister in generation III (111.9) was 60 years old 
at the time of the study and was included in the linkage analysis. 
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II 
I 
4 
2 
3 4 5 7 8 9 
1- 4 7 8 9 11 12 6 5 13~8 19-23 24 5 6 10 
Figure VI.2 
Pedigree of the SA black HD family (Pll) in the extended study. 
Squares represent males and circles females. Symbols for 
affected persons are solid and a diagonal line through 
the symbol indicates deceased. 
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6.3 EXTENDED LINKAGE ANALYSIS OF~ BLACK AFRICAN HD FAMILY 
DNA from this family was isolated from whole blood in Cape Town 
and taken by the author to Canada. Additional endonuclease 
restrictions, electrophoretic separation of DNA size-fractions in 
agarose gels of different concentrations according to the 
different expected RFLPs and Southern blotting were performed by 
the author in the Canadian laboratory. Oligolabelling, 
hybridization and autoradiography were carried out according to 
standard laboratory procedures routinely employed in Canada with 
very little variation from the methods used and described in this 
thesis. 
The probes used for this extended linkage study were the subclones 
of the original GB probe used throughout the course of the project 
as well as five newer probes found to be more tightly linked to HD 
and currently being used in predictive testing of HD in Canada 
(Table VI-1 with appropriate references)( Fig Vl.3). 
Computations for linkage analysis were performed in Cape Town 
together with the rest of the study using the LIPED program and 
marker frequencies determined for this population group 
established as part of the collaborative study (unpublished data). 
Individual lod scores between the markers and the HD locus were 
calculated for each marker as well as for a combined haplotype of 
the eight markers used (Fig VIl.5). 
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DNA MARKERS ON CHROMOSOME 4 USED IN THE STUDY OF A 
BLACK HD FAMILY. 
D4S96 678 Mspl segment Ill 
p 
D4S98 731 Sstl 
-
Accl 
D4S95 674 Mbol. segment II 
Taql 
Hindlll 
q EcoRI segment I 
D4S10 G8 Mspl 
500kbI 
D4562 P8 Hincll 
~ : 
Chromosome 4 
Locus Probe Restriction 
Name Name Enzyme used 
Figure Vl.3 
Diagrammatic map showing the DNA markers used in 
the extended study of a black African HD family. 
Probes, enzymes and references as in Table VI -1. 
Reproduced in part from MacDonald et al . (1989). 
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TABLE VI-I 
Probes used in the study of a black African HD family. 
PROBE LOCUS ENZYME REFERENCE 
pK082 D4Sl0 Hi ndI II Gusella et al . , 1983 
pK083 D4S10 EcoRI Gusella et al., 1983 
HS.52 D4Sl0 MspI Skraastad et al., 1989 
731 D4S98 SstI Whaley et al . , 1988 
p8 D4S62 Hi ncl I Hayden et al., 1988b 
678 D4S96 MspI Smith et al . , 1988 
674 D4S95 TaqI Wasmuth et al., 1988 
AccI Wasmuth et al . , 1988 
MboI Wasmuth et al., 1988 
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CHAPTER SEVEN 
RESULTS AND DISCUSSION: 
7.1 ALLELE FREQUENCIES AT THE D4SIO LOCUS 
The polymorphic DNA fragment sizes, allele frequencies and 
polymorphism information content (PIC) values at the D4SIO locus 
in unrelated normal individuals from three different population 
groups in SA are presented in Tables VII-I, VII-2, VII-3, VII-4 
and VII-5. These results are compared with published data from 
Britain, Holland, USA, Germany, Finland and Scotland in Table VII-
6. The individual findings of the three black African tribal 
groups that were studied (Tswana, Pedi and Venda) are shown in 
Table VII-3 (their combined frequency is representative of a broad 
group of the indigenous black African peoples of the Northern 
Transvaal). 
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TABLE VII-1. 
Polymorphisms at the D4S10 locus. 
Probe Enzyme Fragment Size(kb) Allele Reference 
pK082 Hi ndll I 17.5 HI Gusella 
(Site 1) 15 H2 et al .,1983 
pK082 Hi ndll I 4.9 hl II 
(Site 2) 3.7 h2 
pK081 EcoRI 6.0 El II 
5.5 E2 
pK083 EcoRI 14 el II 
9 e2 
H5.5 Mspl 3.5 Ml Skraastad 
2.8 M2 et al., 1989 
TABLE VII-2. 
Probe 
Enzyme 
pK082 
(Sitel) 
HindIII 
N 
PIC 
pK082 
(Site2) 
HindIII 
N 
PIC 
pK081 
EcoRI 
N 
PIC 
pK083 
EcoRI 
N 
PIC 
H5.5 
Mspl 
N 
PIC 
Allele frequencies of D4S10 in the SA population 
groups of black African, mixed ancestry and 
European origins. 
Allele 
Hl 
H2 
hl 
h2 
El 
E2 
el 
e2 
Ml 
M2 
Allele frequency in different populations 
SA 
Black 
(Tvl) 
(81) 0.74 
(27) 0.26 
108 
0.310 
(56) 0.52 
(52) 0.48 
108 
0.375 
(23) 0.24 
(73) 0.76 
96 
0 . 298 
(19) 0.20 
(77) 0.80 
96 
0.269 
(16) 0.17 
(76) 0.83 
92 
0.242 
SA of 
Mixed 
ancestry 
(50) 0.83 
(10) 0.17 
60 
0.242 
(19) 0.32 
(41) 0.68 
60 
0.341 
(33) 0.57 
(25) 0.43 
58 
0.370 
(19) 0.32 
(41) 0.68 
60 
0.341 
(15) 0.28 
(39) 0 . 72 
54 
0.322 
N = Number of Chromosomes 
SA of 
European 
origins 
(47) 0.90 
( 5) 0.10 
52 
0.163 
( 7) 0.13 
(45) 0 . 87 
52 
0.201 
(50) 0.96 
( 4) 0.04 
54 
0.074 
(36) 0.62 
(22) 0.38 
58 
0.360 
(28) 0.42 
(36) 0.58 
64 
0.369 
PIC calculated according to the method recommended by 
Botstein et al. 1980. 
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TABLE VII-3. 
Allele frequency of D4S10 in the Pedi, Tswana and Venda. 
Probe 
Enzyme 
pK082 
(Sitel) 
N 
PIC 
pK082 
(Site2) 
N 
PIC 
pK081 
N 
PIC 
pK083 
N 
PIC 
H5.5 
N 
PIC 
Allele 
Pedi 
Hl (45) 0.77 
H2 (13) 0 . 23 
58 
0.292 
hl (30) 0.52 
h2 (28) 0.48 
58 
0.373 
El (14) 0 . 27 
E2 (38) 0.73 
52 
0 . 317 
el ( 9) 0.17 
e2 (43) 0.83 
52 
0 . 242 
Ml (10) 0.19 
M2 (38) 0.81 
48 
0 . 260 
Tswana 
(18) 0.69 
( 8) 0.31 
26 
0 . 336 
(12) 0.46 
(14) 0.54 
26 
0.373 
( 4) 0.20 
(16) 0.80 
20 
0.269 
( 5) 0.25 
(15) 0.75 
20 
0.305 
( 0) 0 . 00 
(20) 1. 00 
20 
0.0000 
Allele frequencies 
Venda SA Black (Tvl) 
(18) 0.75 (81) 0.74 
( 6) 0.25 (27) 0.26 
24 108 
0.305 0.311 
(14) 0.58 (56) 0.52 
(10) 0 . 42 (52) 0.48 
24 108 
0 . 369 0.375 
( 5) 0.21 (23) 0.23 
(19) 0.79 (73) 0 . 77 
24 96 
0.277 0 . 299 
( 5) 0.21 (19) 0.20 
(19) 0.79 (77) 0.80 
24 96 
0.277 0 . 269 
( 5) 0.21 (15) 0.13 
(19) 0.79 (77) 0.87 
24 92 
0.277 0 . 242 
(SA Black (Tvl) =Pedi,Tswana and Venda together as one group) 
N = Number of Chromosomes 
PIC = calculated according to the method recommended by 
Botstein et al. 1980. 
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There are two polymorphic Hindlll sites identified at the D4S10 
locus by the pK082 subclone of GB. At each site there are two 
possible alleles. The combination of the alleles at these sites 
can be combined as haplotypes named A,B,C, and D according to the 
nomenclature of Gusella (Gusella et al., 1983) (Fig.VII.la). The 
haplotype frequencies and PIC values calculated for the three 
population groups studied in SA are as shown in Tables VII-4 and 
VII-5 and are compared with published results from Britain 
(Youngman et al., 1986). 
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Figure VII .1 
Southern blots showing the RFLPs associated with the GS 
subclones used in the Cape Town study. 
DNA samples digested with 
a) Hi ndl II 
b) EcoRI 
c) EcoRI 
d) Mspl 
and hybridized to pK082. 
and hybridized to pK081. 
and hybridized to pK083. 
and hybridized to HS.52. 
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pK082 Hindlll RFLPs 
A B C D 
--
4,9kb 
- -
3,7kb - -
BB AD AB AB 
Figure VII.la 
Southern blot showing the hybridization of pK082 probe 
to Hindlll-digested genomic . ONA.· Haplotypes were 
determined from the alleles seen for each Hindlll RFLP (sites 1 and 2). (Gusella et al., 1983). 
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Site 1 
Site 2 
PK081 EcoRI RFLPs 
E 22 22 11 11 12 12 
Figure VII.lb 
6.0kb El 
5.5kb E2 
Southern blot showing the hybridization of pK08I probe 
to EcoRI-digested genomic DNA. The EcoRI 6.0kb and 5.5kb 
polymorphic bands are indicated by El and E2 
respectively. (Gusella et al., 1983). 
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PK083 EcoRI RFLPs 
e 22 12 12 11 
Figure VII.le 
14kb el 
9kb e2 
Southern blot showing the hybridization of pK083 probe 
to EcoRl-digested genomic DNA. The EcoRI 14kb and 9kb 
polymorphic bands are indicated by el and e2 
respectively. (Gusella et al., 1983). 
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H 5.52 MsPI RFPLs 
M 12 12 22 12 
Figure VII.Id 
3.5kb Ml 
2.8kb M2 
Southern blot showing the hybridization of HS.52 probe 
to Mspl-digested genomic DNA. The Mspl 3.5kb and 2.8kb 
polymorphic bands are indicated by Ml and M2 
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TABLE VII-4. 
Haplotypes at the 68 locus. 
in the SA population groups studied. 
(Hindlll polymorphic sites) 
There are 2 polymorphic HindIII sites identified at this 
locus by the pK082 subclone of GS. At each site there 
are two possible alleles. + and - denotes the presence 
and absence, respectively, of the HindIII restriction 
site. The combination of the alleles at these sites is 
the haplotype: A,B,C and D according to the nomenclature 
of Gusella (Figure VII.Ia). 
Haplo- Site 1 Site 2 
types 
Frequencies. 
A 
B 
C 
D 
PIC 
13(-) 3.7(+) 
13(-) 4.9(-) 
11 ( +) 3.7(+) 
11 ( +) 4.9(-) 
N 
British haplotype 
SA 
Black 
(Tvl) 
N=l08 
0.40 
0.41 
0.09 
0 .10 
0.588 
SA of 
Mixed 
ancestry 
N=60 
0.59 
0.28 
0.09 
0.04 
0.501 
SA of 
European 
origin 
N=52 
0.72 
0.13 
0.13 
0.03 
0.429 
= number of chromosomes 
British 
N=l02 
0.66 
0.09 
0.22 
0.03 
frequencies according to published data 
Youngman et al. 1986 
PIC = calculated according to the method recommended by 
Botstein et al. 1980. 
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TABLE VII-5. 
Haplotypes at the GS locus 
in the Pedi Tswana and Venda. (Hindlll polymorphic sites) 
There are two polymorphic HindIII sites identified at 
this locus by the pK082 subclone of GB. At each site 
there are two possible alleles. + and - denotes the 
presence and absence, respectively, of the HindIII 
restriction site. The combination of the alleles at 
these sites is the haplotype: A,B,C and D according to 
the nbmenclature of Gusella (Figure VII.Ia). 
Haplo- Site 1 Site 2 
types 
Frequencies. 
A 
B 
C 
D 
PIC 
Pedi 
N=50 
13(-) 3.7(+) 0.38 
13(-) 4.9(-) 0.44 
11(+) 3.7(+) 0.10 
11(+) 4.9(-) 0.08 
Venda Tswana 
N=22 N=24 
0.41 
0.45 
0.00 
0.14 
0.42 
0.29 
0.16 
0.13 
0.639 0.527 0.644 
N = number of chromosomes 
SA Black(Tvl) 
N=96 
0.40 
0.41 
0.09 
0.10 
(SA Black(Tvl) =Pedi, Tswana, Venda together as one group) 
PIC = calculated according to the method recommended by 
Botstein et al. 1980. 
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TABLE VII-6. 
Reported allele frequencies of D4Sl0 from Scotland, UK, 
Holland, Germany, Finland and USA. 
Scottish British Dutch German Finnish USA 
Holloway Youngman Skraastad Riess Ikonen Farrer 
et al et al et al et al et al et al 
1989 1986 1989 1989 1990 1988 
N=64 N=l02 N=54 N=lOO N=46 
pK082 Hl 0.80 0.75 0.75 0.705 0.73 0.79 
Site 1 H2 0.20 0.25 0.25 0.295 0.27 0.21 
pK082 hl 0.08 0.125 0.16 0.06 0.12 0. i'9 
Site 2 h2 0.92 0.875 0.84 0.94 0.88 0.81 
pK081 El 
E2 
pK083 el 0.44 0.50 0.47 0.59 0.60 
e2 0.56 0.50 0.53 0.41 0.40 
5 . 5 Ml 0.40 0.41 0.52 
M2 0.60 0.59 0.48 
N = number of chromosomes 
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The chi-square test for goodness of fit revealed no statistical 
significant deviation from the Hardy-Weinberg distribution in the 
SA population groups studied (Tables VII-7 to VII-16) (Swinscow, 
1977). 
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TABLE VII-7. 
Population 
group 
Genotype frequencies of the Hindlll/pK082 RFLPs (alleles HI and H2) in the SA population groups 
studied. 
Allele Genotype x2 
Hl H2 HlHl H2H2 HlH2 HlHl H2H2 HlH2 
17.5kb 15kb Observed (0) Expected (E) 
SA 81 27 31 4 19 29.5 3.6 20 . 7 0 . 246 
Black(.74) (.26) 
Tvl 
N=l08 
SA of 50 10 
Mixed(. 83) (.17) 21 1 8 20.66 0.87 8.46 0.45 
ancestry 
N=60 
SA of 47 5 21 0 5 21 0.26 4.68 0.26 
European 
origin 
N=52((. 90) (.10) 
-----------------------------------------------------------------
N = Number of chromosomes, 
x2 chi square test at 1 degree of freedom. 
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TABLE VII-8. 
Genotype frequencies of the Hindl1I/pK082 RFLPs (alleles HI and H2) in the Pedi, Venda and Tswana 
from the Tvl. 
Population Allele 
group 
Genotype 
Hl H2 HlHl H2H2 HlH2 HlHl H2H2 HlH2 
Expected (E) 17.5kb 15kb Observed (0) 
Pedi 
N=58 45 13 18 2 9 17.1 1.5 10.3 0.38 
(. 77) (.23) 
8 Tswana 18 
N=26 (.69) (. 31) 6 1 6 6.1 1.2 5.6 0.56 
Venda 18 6 
N=24 (.75) (.25) 7 1 4 6.75 0.75 4.5 0.13 
SA 
Black 
(Tvl) 
N=l08 
81 
(.74) 
27 
(.26) 
31 4 19 29.5 3.6 20.7 
SA Black(Tvl) = Pedi, Tswana and Venda as one group 
N = Number of chromosomes, 
2 X = chi square test at 1 degree of freedom. 
0.24 
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TABLE VII-9. 
Genotype frequencies of the Hindlll/pK082 RFLPs (alleles hl and h2) in the SA population groups studied. 
Population 
group 
Allele Genotype 
hl h2 hlhl h2h2 hlh2 hlhl h2h2 hlh2 
4.9kb 3.7kb Observed (0) Expected (E) 
SA 56 52 12 9 33 14.6 12.4 27 
Black (.52) (.48) 
Tvl 
N=l08 
SA of 19 41 
2.72 
Mixed (.32) (.68) 3 14 13 3 13.87 13.05 0.00 
ancestry 
N=60 
SA of 7 45 0 19 7 0.44 19.68 5.88 0.67 
European 
origin (.13) (.87) 
N=52 
N = Number of chromosomes, 
x2 = chi square test at 1 degree of freedom. 
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TABLE VII-10. 
Genotype frequencies of the Hindlll/pK082 RFLPs (alleles hl and h2) in the Pedi, Venda and Tswana 
from the Tvl. 
Population Allele Genotype 
group 
hl h2 hlhl h2h2 hlh2 hlhl h2h2 hlh2 
4.9kb 3.7kb Observed (O) Expected (E) 
Pedi 30 
N=58 (.52) 
Tswana 12 
N=26 (.46) 
Venda 14 
N=24 (.58) 
SA Black 56 
(Tvl) (.52) 
N=l08 
28 
(.48) 6 
14 
(.54) 3 
10 3 
(.42) 
52 12 
(.48) 
4 19 7.8 6.7 14 . 1 
4 6 2.7 3.7 6.4 
1 8 4 2.1 5.8 
9 33 14.6 12.4 27 
SA Black (Tvl) = Pedi, Tswana and Venda as one group 
2 N = Number of chromosomes, X = chi square test at 1 degree of freedom. 
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x2 
3 . 18 
0.07 
1. 65 
2 . 72 
TABLE VII-11. 108 
Genotype frequencies of the EcoRl/pK081 polymorphisms 
in the SA population groups studied. 
Population 
group 
Allele Genotype 
El E2 ElEl E2E2 E1E2 ElEl E2E2 ElE2 
Expected (E) 6.0kb 5.5b Observed (0) 
SA 23 73 1 26 21 2.8 27. 72 17.5 
Black (.24) (.76) 
Tvl 
N=96 
SA of 33 25 
Mixed (.57) (.43) 9 5 15 9.4 5.4 14.2 
ancestry 
N=58 
SA of 50 4 25 2 0 24.88 0.04 2.1 
European 
origin (.96) (.04) 
N=54 
x2 
N = Number of chromosomes, 
chi square test at 1 degree of freedom. 
1. 95 
0.1 
0.06 
TABLE VII-12. 
Genotype frequencies of the EcoRl/pKOSl polymorphisms 
in the the Pedi Venda and Tswana from the Tvl. 
Population 
group 
Allele Genotype 
El E2 ElEl E2E2 ElE2 ElEl E2E2 ElE2 
6.0kb 5.5kb Observed (0) Expected (E) 
Pedi 14 38 1 13 12 1. 9 13.85 10.14 0.81 
N=52 
Tswana 
N=20 
Venda 
N=24 
SA 
Black 
Tvl 
N=96 
(.27) 
4 
(.20) 
5 
(.21) 
23 
(.24) 
(.73) 
16 
(. 80) 
19 
(.79) 
73 
(.76) 
0 6 
0 7 
1 26 
4 0.4 6.4 3.2 0.63 
5 0.52 7 . 49 3.96 0.82 
21 2.8 27.72 17.5 1 . 95 
SA Black(Tvl) = Pedi, Tswana and Venda as one group 
N = Number of chromosomes, 
x
2 
chi square test at 1 degree of freedom. 
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TABLE VII-13. 
Genotype frequencies of the EcoRI/pK083 polymorphisms 
in the SA population groups studied. 
Population Allele 
group el e2 
14kb 9kb 
SA 19 77 
Black (.20) (.80) 
Tvl 
N=96 
Genotype 
elel e2e2 ele2 
Observed (O) 
0 29 19 
elel e2e2 ele2 
Expected (E) 
1.9 31.02 15 
x2 
3.08 
SA of 19 41 2 13 15 3.07 13.87 13.06 0.71 
Mixed (.32) (.68) 
ancestry 
N=60 
SA of 36 22 12 5 12 11 . 1 4 . 2 13 . 7 0.43 
European 
origin (.62) (.38) 
N=58 
N = Number of chromosomes, 
chi square test at 1 degree of freedom. 
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TABLE VII-14. 
Genotype frequencies of the EcoRl/pK083 polymorphisms 
in the the Pedi, Venda and Tswana from the Tvl. 
Population Allele 
group el e2 
14kb 9kb 
Genotype 
elel e2e2 ele2 
Observed (0) 
x2 
elel e2e2 ele2 
Expected (E) 
Pedi 
N=52 
9 
(.17) 
43 
(.83) 0 17 9 0.75 17.91 7.28 1.18 
Tswana 5 15 0 5 5 0.625 5.62 3.8 1. 073 
N=20 (.25) (.75) 
Venda 5 19 0 7 5 0.53 7.49 3.96 0.83 
N=24 (.21) (.79) 
------------------------------------------------------------------
SA 19 
Black (.20) 
Tvl 
N=96 
77 
(. 80) 
0 29 19 1. 9 31. 02 15 
SA Black(Tvl) = Pedi, Tswana and Venda as one group 
2 N = Number of chromosomes, X = chi square test at 1 degree of freedom. 
3.08 
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TABLE VII-15. 
Genotype frequencies of the Mspl/H5.5 polymorphisms 
in the SA population groups studied. 
Population Allele 
group 
Genotype 
Ml M2 MlMl M2M2 M1M2 
3.5kb 2.8kb Observed (0) 
SA Black 15 77 1 32 13 
(Tvl) (.17) (.83) 
N=92 
SA of 15 39 3 15 9 
Mixed (.28) (.72) 
ancestry 
N=54 
SA of 28 36 6 10 16 
European 
origin (.42) ( . 58) 
N=64 
x2 
MlMl M2M2 M1M2 
Expected (E) 
1. 3 31. 6 12.98 0 . 02 
2.1 13.99 11.07 0 . 84 
5.7 10.76 15 . 68 0.12 
x2 
N = Number of chromosomes, 
chi square test at 1 degree of freedom . 
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TABLE VIl-16. 
Genotype frequencies of the Mspl/H5.5 polymorphisms 
in the Pedi, Venda and Tswana from the Tvl. 
Population Allele Genotype 
group Ml M2 MlMl M2M2 MlM2 
3.5kb 2.8kb Observed (O) 
Pedi 10 38 1 15 8 
N=48 (.21) (.79) 
Tswana 0 20 0 10 0 
N=20 (1. 0) 
Venda 5 19 0 7 5 
N=24 (.21) (.79) 
MlMl M2M2 MlM2 
Expected (E) 
0.87 15.75 7.44 
0 10 0 
0.53 7.49 3.96 
0.09 
0.00 
0.83 
------------------------------------------------------------------
SA Black 15 77 1 32 13 1. 3 31. 6 12.98 0.02 
(Tvl) (.17) (.83) 
N=92 
SA Black(Tvl) = Pedi, Tswana and Venda as one group 
2 N = Number of chromosomes, X = chi square test at 1 degree of freedom. 
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The percentage of heterozygosity for the RFLPs in each population 
group in this study is shown in Table VII-17. The greater degree 
of heterozygosity for the EcoRI RFLPs in the SA population of 
mixed ancestry is possibly due to the genetic admixture of 
European and African peoples (Table VII-2). 
In the ten SA HD families studied, 45% of all individuals were 
heterozygous for at least one of the four polymorphisms used. In 
the normal SA population as a whole, 104 unrelated individuals 
were examined from different population groups, of whom 46% were 
found to be heterozygous. By combining the HindIII and MspI 
polymorphisms 77% of all individuals haplotyped were heterozygous 
at the GB locus. 
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TABLE VII-17. 
Percentage heterozygosity for the RFLPs used in this project 
SA SA of SA of 
Black Mixed European 
(Tvl) ancestry origin 
Hi ndll I 80 59 46 
(haplotype) 
EcoRI 40 53 7 
(pK081) 
EcoRI 36 50 41 
(pKo83) 
Mspl 25 41 47 
(H5.52) 
7.2 DISCUSSION ON THE ALLELE FREQUENCIES ESTABLISHED FOR 
THE DIFFERENT SA POPULATIONS. 
Allele frequencies for the RFLPs at the D4Sl0 locus in unrelated 
normal individuals from three different population groups in SA 
have been established. This was the first comparative study of the 
GB allele frequencies in different non-Caucasoid population 
groups. In most instances, the allele frequencies of the SA 
population group of European origin were in the same range as 
those reported for Caucasians. There were, however, differences 
between the various SA population groups which would influence the 
choice of markers when initially attempting to establish linkage 
in an HD family. For example, it would not be advisable to use the 
pK08I probe on a family of European origin in SA as the 5.5kb 
fragment was rarely seen in this population group (Table VIl-2). 
In addition, the minor alleles in the European population for the 
EcoRI RFLPs were the major alleles in the black African 
population (Table VII-2). 
PIC values of greater than 0,5 are considered to be 'highly 
informative', values between 0,25 and 0,5 as 'reasonably 
informative' and values less than 0,25 as only 'slightly 
informative' as defined by Botstein et al. (1980). The calculated 
PIC values for the HindIII RFLP haplotypes were highly 
informative' for the SA of mixed ancestry and black origins 
whereas the value calculated for the SA of European origins was 
'reasonably informative'( similar to the value reported by 
Youngman et al. (1980) for the British population). In general , 
the calculated PIC values for the other 3 RFLPs were all 
'reasonably informative' apart from that of the pK081 locus in the 
SA of European origin. 
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Furthermore, the frequencies of the Band D haplotypes at the 
HindIII polymorphic site were remarkably higher in the black 
African population; this finding must be taken into account when 
addressing the question of linkage disequilibrium in SA HD 
families (Table VII-4). 
The apparent low frequency of the 3.5kb RFLP (Ml) in the Tswana 
tribal group warrants comment (Table VII-3). Although the number 
of unrelated normal individuals studied was small, it is 
interesting to note that in the ten people studied (20 
chromosomes) every individual was homozygous for the 2.8kb allele 
(M2). However, in the Tswana HD family in this study (Fig. VII.3. 
T9), seven individuals were heterozygous for this RFLP at the GB 
locus. It can therefore be concluded that the low frequency of Ml 
is probably the result of the small number of unrelated normal 
individuals who were studied. Examination of additional normal 
unrelated Tswana individuals would confirm or refute this 
observation. 
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7.3 LINKAGE ANALYSIS AND INDIVIDUAL RFLP LOO SCORES. 
The lod scores for the individual polymorphisms at various 
recombination fractions are shown in Tables VII-18, VII-19, VII-20 
and VII-21 (given to two decimal places as recommended by 
Conneally et al., 1985). In summing lod scores across pedigrees, 
it has been assumed that the same HD locus was involved in all 
cases as there was no significant evidence in favour of 
heterogeneity for the families studied according to the test 
applied. 
It was decided after studying the individual lod scores to 
determine haplotypes by combining the MspI and HindIII RFLPs. 
The lod scores for these haplotypes are shown in Table VII-22. A 
maximum lod score of 8.14 at a O of 0.0 was calculated, thus 
confirming linkage between HD and G8 as was originally found by 
Gusella in 1983. The maximum likelihood estimate of the 
recombination fraction was 0.00, with a confidence limit of 0.00 -
0.058 using the combined haplotypes . 
A simple method of constructing confidence intervals recommended 
by Conneally et al. (1985) was used (Fig VII.2). As the lod score 
for the combined haplotypes (MspI and HindIII) peaked at a 
recombination fraction of 0.00, the lod scores were plotted 
against O values of 0.00 to 0. 20. The point of intersection at the 
lod score of 7.14 which was 1 lod score below the maximum lod 
score obtained in this study, resulted in a O value of 0.058. The 
confidence interval is therefore 0.00, 0.058. 
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Lod Score 
9 
8.5 
7.5 
Confidence Interval for HD vs Haplotype 
Confidence 
7.14 'l"---------~i...... 
7 
6.5 
6------------:-":--:---..lr--:-L------'----........ ---" 
0 0.02 0.04 0.06 0 .08 0.1 
0.058 
Theta 
Figure VI I. 2 
Construction of the confidence interval in this 
linkage study. 
fr=0.058 
Confidence interval = (0.00, 0.058) 
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TABLE VII-18. 
Individual family lod scores: HD versus Hindlll polymorphisms. 
Family 
0.00 
MAI 0.42 
MA2 1.04 
MA3 0.06 
MA4 1.07 
MAS 0 .12 
MA6 0.29 
T9 0.09 
Pll -0.17 
E20 0.22 
E40 0.50 
Total 3.64 
Recombination fraction (9) 
0.05 0.1 0.2 0.3 
0.38 0.35 0.28 0.20 
0.96 0.87 0.68 0.47 
0.05 0.04 0.02 0.01 
0.95 0.82 0.55 0.29 
0.10 0.08 0.05 0.02 
0.24 0.20 0.14 0.08 
0.10 0.09 0.07 0.04 
-0.15 -0 .13 -0.09 -0.04 
0 .19 0 .17 0.13 0.08 
0.43 0.36 0.23 0.11 
3.25 2.86 2.05 1. 26 
Posterior 
probability 
of linkage 
0.4 
0.11 1.00 
0.24 1.00 
0.00 1.00 
0.08 1.00 
0.01 1.00 
0.04 1.00 
0.01 1.00 
-0.01 1.00 
0.04 1.00 
0.03 1.00 
0.55 
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TABLE VIl-19. 
Individual lod scores: HD versus Mspl polymorphisms. 
Family 
0.00 
MAl 1.42 
MA2 0.70 
MA3 1.93 
MA4 0.00 
MAS 0.43 
MAG 0.28 
T9 -0.14 
Pll 0.16 
E20 0.15 
E40 -0.01 
Total 4.92 
Recombination fraction (9) 
0.05 0 .1 0.2 0.3 
1.31 1.17 0.86 0.51 
0.58 0.47 0.29 0.14 
1. 74 1.53 1.10 0.65 
0.00 0.00 0.00 0.00 
0.37 0.32 0.20 0.10 
0.23 0 .19 0.12 0.08 
-0.06 -0.02 0.02 0.02 
0 .12 0.08 0 03 0.01 
0.13 0.11 0.08 0.05 
-0.01 -0.01 -0.00 -0.00 
4.40 3.86 2. 71 1. 56 
Posterior 
probability 
of linkage 
0.4 
0 .17 1.00 
0.04 1.00 
0.21 1.00 
0.00 1.00 
0.03 1.00 
0.03 1.00 
0.01 1.00 
-0.00 1.00 
0.03 1.00 
-0.00 1.00 
0.52 
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TABLE VII-20. 
Individual lod scores: HD versus EcoRI (pK081) polymorphisms. 
Family 
0.00 
MAl -0.23 
MA2 0.26 
MA3 0.17 
MA4 0.01 
MAS 0.18 
MA6 0.27 
T9 0.27 
Pll 0.00 
E20 -0.00 
E40 0.00 
Total 0.94 
Recombination fraction (9) 
0.05 0.1 0.2 0.3 
-0.14 -0.08 -0.02 0.00 
0.22 0.18 0.11 0.05 
0.14 0.11 0.06 0.03 
0.01 0.01 0.01 0.00 
0.15 0.12 0.07 0.03 
0.23 0.19 0.13 0.08 
0.23 0.19 0.11 0.05 
0.01 0.01 0.01 0.00 
-0.00 -0.00 -0.00 -0.00 
0.00 0.00 0.00 0.00 
0.84 0.73 0.48 0.25 
Posterior 
probability 
of linkage 
0.4 
0.00 1.00 
0.01 1.00 
0.00 1.00 
0.00 1.00 
0.01 1.00 
0.04 1.00 
0.01 1.00 
0.00 1.00 
-0.00 1.00 
0.00 1.00 
0.08 
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TABLE VI I-21. 
Individual lod scores: HD versus EcoRI (pK083) polymorphisms 
Family 
0.00 
MAl 0.21 
MA2 -1.18 
MA3 1.28 
MA4 -0.02 
MAS 0.02 
MA6 0.08 
T9 0.19 
Pll 0.68 
E20 -0.06 
E40 0.51 
Total 1.69 
Recombination fraction (8) 
0.05 0.1 0.2 0.3 
0.19 0.17 0.11 0.06 
-0.97 -0.66 -0.25 -0.07 
1.16 1.03 0.76 0.46 
-0.02 -0.01 -0.00 0.00 
0.01 0.01 0.00 0.00 
0.06 0.05 0.02 0.01 
0.15 0.12 0.06 0.02 
0.67 0.59 0.33 0.16 
-0.09 -0.10 -0.10 -0.07 
0.44 0.37 0.23 0.11 
1. 61 1. 55 1.16 0.68 
Posterior 
probability 
of linkage 
0.4 
0.02 0.86 
-0.01 0.21 
0.15 0.98 
0.00 0.79 
0.00 0.80 
0.00 0.82 
0.01 0.86 
0.04 0.94 
-0.04 0. 77 
0.03 0.92 
0.21 
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TABLE VII-22. 
Individual lod scores: HD versus combined Hindlll 
and Mspl polymorphisms. 
Family Recombination fraction (8) 
0.00 0.05 0.1 0.2 0.3 
MAl 1. 37 1. 32 1.23 0.98 0.63 
MA2 2.10 1.86 1. 61 1.10 0.62 
MA3 2.33 2.11 1.87 1. 36 0.81 
MA4 0.79 0.70 0.61 0.40 0.20 
MAS 0.36 0.31 0.27 0.17 0.09 
MA6 0.30 0 . 25 0.21 0.14 0.08 
T9 -0.02 -0.03 -0.03 -0.02 -0.01 
Pll 0.00 0.01 0.00 -0.01 -0.02 
E20 0.20 0.16 0.12 0.06 0.02 
E40 0.73 0.62 0.51 0 . 30 0.13 
Total 8.14 7.30 6.39 4.47 2.55 
Posterior 
probability 
of linkage 
0.4 
0.25 1.00 
0.24 1.00 
0.27 1.00 
0.05 1.00 
0.02 1.00 
0.04 1.00 
-0.00 1.00 
-0.01 1.00 
0.00 1.00 
0.03 1.00 
0.09 
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On examination of the RFLP haplotypes in eleven spouses from the 
six families of mixed ancestry, 
population of mixed ancestry in SA, 
could be identified (Table VII-23). 
representing the general 
five different haplotypes 
The most frequent haplotype 
associated with the disease in four of the six HD families of 
mixed ancestry did not represent the most common haplotype in the 
general population. In fact, only two of the five different 
haplotypes appeared to be linked with HD. The HD gene appeared to 
be cosegregating with haplotype V more often than expected 
(Fisher's p=0.0034) which is suggestive of non-random association 
in these SA HD families of mixed ancestry. 
Pedigrees and some of the genotypes of the ten families studied 
are shown in Fig VII.3 and Fig VII.4. 
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Figure VI I. 3 
Pedigrees of the ten SA HD families studied with 
haplotypes of the combined Mspl and Hindlll RFLPs. 
Key to Figure VII.3 
The Hindlll polymorphic sites are combined as haplotypes 
designated by A,B,C,and D according to the nomenclature 
of Gusella (Gusella et al.,1983). The Mspl 3.5kb and 
2.8kb polymorphic bands are indicated by 1 and 2 
respectively. 
Squares represent males and circles females. Symbols for 
affected persons are solid and a diagonal line through 
the symbol indicates deceased. 
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Key to Figure VII.3 · 
The Hindlll polymorphic sites are combined as haplotypes 
designated by A,8,C,and D according to the nomenclature 
of Gusella (Gusella et al.,1983). The Mspl 3.5kb and 
2.8kb polymorphic bands are indicated by 1 and 2 
respectively. 
Squares represent males and circles females. Symbols for 
affected persons are solid and a diagonal line through 
the symbol ind icates deceased. 
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Key to Figure VI 1.3 
The Hindlll polymorphic sites are combined as haplotypes 
designated by A,B,C,and D according to the nomenclature 
of Gusella (Gusella et al.,1983). The Mspl 3.5kb and 
2.8kb polymorphic bands are indicated by 1 and 2 
respectively. 
Squares represent males and circles females. Symbols for 
affected persons are solid and a diagonal line through 
the symbol indicates deceased. 
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The Hindlll polymorphic sites are combined as haplotypes 
designated by A,B,C,and D according to the nomenclature 
of Gusella (Gusella et al .,1983) . The Mspl 3.5kb and 
2.8kb polymorphic bands are indicated by 1 and 2 
respectively. 
Squares represent males and circles females. Symbols for 
affected persons are solid and a diagonal line through 
the symbol indicates deceased. 
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Figure VII.4 
Pedigrees of the ten SA HD families studied with the 
EcoRI RFLPs. 
Key to Figure VII.4 
The EcoRI/pK081 6.0kb and 5.5 kb RFLPs are depicted 
by El and E2 respectively. The EcoRI/pK083 14kb, 9kb and 
11kb RFLPs are depicted by el, e2 and e3 respectively. 
Squares represent males and circles females.Symbols for 
affected persons are solid and a diagonal line through 
the symbol indicates deceased. 
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The EcoRI/pK081 6.0kb and 5.5 kb RFLPs are depicted 
by El and E2 respectively. The EcoRI/pK083 14kb , 9kb and 
11kb RFLPs are depicted by el , e2 and e3 respectively . 
Squares represent males and circles females .Symbols for 
affected persons are solid and a diagonal line through 
the symbol indicates deceased. 
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Key to Figure VII.4 
The EcoRl/pK081 6.0kb and 5.5 kb RFLPs are depicted 
by El and E2 respectively. The EcoRl/pK083 14kb, 9kb and 
11kb RFLPs are depicted by el, e2 and e3 respective~y. 
Squares represent males and circles females.Symbols for 
affected persons are solid and a diagonal line through 
the symbol indicates deceased. 
132 
u 
m 
rl 
' ell 
E11 
D 
m 
(V 
' e12 
E 11 
' e12 
Ell 
. 
e12 
E11 
l 
e12 
E11 
e12 
Ell 
Key to Figure VII.4 
e12 
Ell 
E20 
---..-----J 
E40 
ell 
Ell 
ell 
Ell 
e12 
Ell 
' e12 
Ell 
The EcoRl/pK081 6.0kb and 5.5 kb RFLPs are depicted 
by El and E2 respectively. The EcoRl/pK083 14kb, 9kb and 
11kb RFLPs are depicted by el, e2 and e3 respectively. 
Squares represent males and circles females.Symbols for 
affected persons are solid and a diagonal line through 
the symbol indicates deceased. 
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TABLE VII-23 . 
(a) Haplotypes in the SA population of mixed ancestry and 
those associated with HD. 
The distribution of the combined HindIII and MspI 
polymorphisms in the general SA population of 
mixed ancestry. Associated HindIII and MspI 
haplotypes in 6 HD families of the same ethnicity. 
(H5.5probe Ml= 3.5kb allele M2 = 2 . 8kb allele) 
Probe (Restriction Enzyme) 
pK082 (HindIII) 
HS.5 (MspI) 
General population of mixed ancestry 
(22 chromosomes) 
Haplotype associated with HD 
in 6 SA HD families of mixed ancestry 
Haplotype 
I II 
A B 
M2 M2 
13 6 
2 
III IV 
B D 
Ml M2 
1 1 
V 
A 
Ml 
1 
4 
(b) Haplotypes in the individual families from mixed 
ancestry, associated with HD . 
Haplotypes of 3 HD patients in MAl 1 1 4 
Haplotypes of 7 HD patients in MA2 7 4 1 2 
Haplotypes of 5 HD patients in MA3 3 2 5 
Haplotypes of 3 HD patients in MA4 4 2 
Haplotypes of 2 HD patients in MAS 2 2 
Haplotypes of 3 HD patients in MA6 2 1 3 
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7.4 DISCUSSION ON THE LINKAGE STUDY OF SA HD FAMILIES. 
Genetic linkage has been confirmed in ten SA HD families from 
different ethnic backgrounds at the D4Sl0 locus using Hindlll, 
EcoRI and Mspl RFLPs. Eight of the ten families investigated were 
informative with the markers used in the study while in the other 
two phase could not be established. The individual lod scores were 
low due to the family structure and number of living affected 
persons and did not appear to be as a result of the detection of 
recombinants. 
The estimated recombination fraction using the combined haplotypes 
in this study was very low since no apparent recombination events 
were observed. Together with the confidence limit of 0.058, this 
information can be usefully applied when a predictive service is 
introduced in SA. 
Although the number of HD patients of mixed ancestry in this study 
was relatively small (23 in six families), the possible non-random 
association between the HD gene and the Mspl/Hindlll haplotypes in 
the SA HD patients of mixed ancestry would imply a founder effect. 
Further examination of HD patients from this population is 
necessary to confirm or refute this observation. 
A major limitation of using linkage analysis for predictive 
testing is the family structure (Harper and Sarfarazi, 1985a). 
DNA from 45 SA families in which a history of HD has been 
documented is being stored at the University of Cape Town DNA 
banking centre (Greenberg 1989). In 66% of these families there 
are not sufficient living affected individuals to establish 
linkage with GB. 
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Confirmation of the above findings could be usefully applied on 
the introduction of predictive service for HD. The use of linkage 
disequilibrium data could allow substantial risk modification for 
some SA HD families of mixed ancestry. In addition, in certain 
instances, predictive testing could be performed on an at-risk 
individual without DNA being available from an affected relative 
(Beaudet et al., 1989). However, as disequilibrium data for one 
ethnic group may differ drastically from data for others, this 
finding, if confirmed, would be o.f benefit only to the Cape 
population of mixed ancestry (Ikonen et al., 1989 ). 
When a predictive testing service is eventually established in SA, 
two additional markers that have recently been obtained will be 
used. D4S95 (Wasmuth et al., 1988) and D4S96 (Smith et al., 1988) 
are presently being investigated for heterozygosity in SA in a 
collaborative study with M Hayden, Vancouver. 
Apart from the fact that these markers are more tightly linked to 
HD, the use of these additional markers should decrease the chance 
of individuals being uninformative due to homozygosity at the 
marker locus. Furthermore, the combined use of more DNA markers 
would increase the informativeness of family structures previously 
thought to be inadequate for linkage analysis when DNA markers 
only from the GB region were used (Hayden et al., 1988a). 
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7.5 RESULTS OF THE LINKAGE STUDY OF A BLACK AFRICAN 
HD FAMILY. 
The individual RFLP lod scores for the different probes used in 
this investigation are listed in Table VII-24. In Table VII-25 the 
linkage analyses of the combined haplotypes (Fig.Vll.5) using 
eight markers is compared with that of the study using only two 
markers in the GS region (Table VII-22:Pll). 
The improved lod score of 1.16 at a e of 0.00 is better than the 
initial lod score of 0.00 at B=O. The limited number of living 
affected individuals in this family however precludes further 
studies to confirm or refute linkage in this family. 
The probe 678 (D4S96) was uninformative in this family study as 
all the individuals investigated with this probe were homozygous 
at the marker locus (for the 1.4kb allele). Additional 
investigation of 25 unrelated Pedi, Tswana and Venda individuals 
also revealed no heterozygosity at this marker locus (unpublished 
data). It is noteworthy that this Mspl restriction site does not 
appear to be present in the all the individuals investigated from 
the SA black population (Tvl) in this study. In addition, there 
was a low frequency of the 3.5kb RFLP in the Tswana tribal group 
(also a Mspl restriction site) reported in Chapter 7.2. 
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04S98 Sstl 
Figure VIl.5 
Condensed pedigree of the SA black HD family (Pll) with 
haplotypes of the 8 markers used on chromosome 4. 
Genotypes of the markers used on chromosome 4 known to be 
linked to HD as listed, with references, in Table VI-1. 
Haplotypes were determined by analysing DNA of the 4 individuals 
in generation III and their offspring and assigning haplotypes 
for the deceased parents. Individual III-6's haplotype was 
inferred from that of his affected son (IV-1). 
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TABLE VII-24. 
Individual RFLP lad scores for recombination fractions Oto 0.40 
HD versus Hincl, Hindlll, EcoRI, Mspl, Accl, Taql, Mbol, Sstl 
polymorphisms. 
Enzyme Recombination fraction (8) 
0.00 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 
Hine!! 0.18 -0.17 -0.15 -0.13 -0.10 -0.07 -0.05 -0.03 -0.01 
HindIII-0.17 -0.15 -0.13 -0.11 -0.09 -0.07 -0.05 -0.03 -0.01 
EcoRI 0.66 0.57 0.49 0.40 0.32 0.24 0.16 0.09 0.04 
MspI 0.16 0.12 0.08 0.05 0.03 0.02 0.01 0.00 -0.00 
Ace! 0.56 0.48 0.40 0.32 0.25 0.18 0.12 0.07 0.03 
TaqI 0.56 0.49 0.41 0.33 0.26 0.19 0.13 0.07 0.03 
MboI 0.28 -0.25 -0.22 -0.17 -0.13 -0.09 -0.06 -0.03 -0.02 
SstI -0.00 -0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
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TABLE VII-25. 
Haplotype lod scores for recombination fractions 0.00 to 0.40 
Haplotype Recombination fraction (9) 
0.00 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 
Hap8 1.16 1.03 0.89 0.75 0.60 0.45 0.31 0.18 0.08 
Hap2 0.01 0.01 0.01 -0.00 -0.01 -0.02 -0.02 -0.01 -0.01 
Hap8 = HD versus combined Hincl, Hindlll, EcoRI,Mspl,Accl,Taql, 
Mbol,Sstl RFLPs 
Hap2 = HD versus combined Hindlll and Mspl RFLPs 
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7.6 ADDITIONAL GENOTYPING OF OTHER BLACK HD PATIENTS. 
As a result of the extended linkage study on the one black African 
HD family (Pll), the combined haplotype that appeared to be 
associated with HD in this family was l-B-1-1-1-2-2 -2 (Hincll, 
Hindlll, EcoRI, Mspl, Accl, Taql, Mbol, Sstl) (Fig. VII.5). The 
second black African HD family (T9) in the study was too small to 
establish linkage, nevertheless the two affected individuals were 
genotyped with the eight probes used in the extended study of the 
other black African family ( Fig VII.4 and Fig VIl.5). 
The genotypes of these two individuals with Accl and Taql are 33 
and 11 respectively. This implies that, assuming linkage with the 
all markers used on chromosome 4 and HD, and that there have been 
no recombination events between the markers used and HD in any of 
the individuals in this study, the genotypes co-segregating with 
HD appears to be different in family T9 to that of Pll. 
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04S95 MboI 11 
04S98 SstI 22 
Figure VII.6 
Condensed pedigree of the SA black HD fami1y (T9) with 
additional genotyping. 
Genotypes of the markers used on chromosome 4 known 
to be linked to HD as listed, with references, in 
Table VI.I. 
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7.7 DISCUSSION ON THE MOLECULAR STUDY OF SIX BLACK 
AFRICAN HD PATIENTS. 
The limited number of living affected individuals in the Pedi 
(Pll) family precludes further linkage studies to improve the lod 
score which is at present not proof of linkage. If tight linkage 
with the markers on chromosome 4 and HD is assumed and no 
recombination has occured between HD and any of the markers used, 
the genotyping of the additional black African HD patients 
indicates that HD is associated with different RFLPs in the two 
black African families. 
Furthermore, in both black African HD families, the disease does 
not appear to be associated with the same haplotype as in the SA 
HD families of mixed ancestry or European origins (Fig. VIl.3). 
The lod scores obtained in this study are low and can only be 
improved on further examination and genotyping of additional HD 
patients. However, the results do imply that the gene for HD is 
associated with different RFLPs in SA HD families from different 
population groups. 
Theilman et al. (1989a), Snell et al. (1989) and more recently 
Dodge et al. (1990) have reported evidence for non-random 
association between D4S95 and HD. Furthermore, it has been found 
that the Accl allele system is a difficult restriction site to 
diagnose as there have been reports of methylation at the D4S95 
locus (Pritchard et al., 1989b; Theilman et al., 1989b). It is 
therefore not possible to compare results from different countries 
without establishing allele frequencies for each population group 
and thereby standardizing data for each laboratory when attempting 
to establish evidence for linkage disequilibrium. 
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Following the additional genotyping of the other black HD patients 
it was decided to genotype eight patients from families of mixed 
ancestry with D4S95 and Taql RFLPs. The preliminary results of 
this additional study have not changed the linkage data on the 
families investigated with Taql RFLPs and D4S95. Further 
investigation with this marker is necessary as the numbers are 
still too few to be of any significance. 
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CHAPTER 8 A NEW GENETIC VARIANT DETECTED DURING THIS STUDY. 
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CHAPTER EIGHT 
A NEW GENETIC VARIANT DETECTED DURING THIS STUDY 
8.1 THE NEW ECORI/Pk083 VARIANT. 
During the course of this study a hitherto unreported genetic 
variation was detected with the pK083 probe when an unexpected 
11kb EcoRI restriction fragment was identified in a nuclear 
section of a family of mixed ancestry. This variant may represent 
a polymorphism but is of a very low frequency and so would be of 
little value in linkage analysis. It caused considerable 
confusion in the linkage analysis of this SA HD family (MA2) 
which will be discussed in detail in the following chapter. 
8.1.1 The family and the variant: 
MA2 is a large SA family of mixed ancestry with a history of HD 
(Fig VIII.l). All individuals in generations III and IV were under 
the age of 60 years at the time of the study and were therefore 
NOT included in the computation of the linkage data. The ages of 
onset of the HD patients in this family were all between 30 and 40 
years or younger. 
On examination of the EcoRI genotypes indentified with the pK083 
probe an affected female (Fig.VIII -1;111.12), her affected brother 
(111.7), two unaffected sibs (III.8 an IIl.10), two cousins 
(III.13 and III.14) as well as two unaffected children ( IV.9 and 
IV.11) had inherited the new 11kb (identified as 3 on Fig .VIII.l ) 
variant. 
The Mendelian inheritance of the rare 11kb polymorphic band 
identified with pK083 and EcoRI is illustrated in an 
autoradiograph in Fig. VIII.2. 
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Figure VIII.I 
Pedigree of a large SA family of mixed ancestry 
in which the new variant was detected. 
2 3 
' 22 
2 
12 22 22 
Key to Figure VIIl.l 
Squares represent males and circles females. 
Symbols for affected persons are solid and a diagonal 
line through the symbol indicates deceased. GS genotypes 
are depicted by 1,2 and 3 indicating the 14, 9 and 11 kb 
bands respectively (EcoRI/pK083 RFLPs). 
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PK 083: - Eco RI RFLP 
2-3 1-2 2-3 1-3 1-2 
Figure VIII.2 
Autoradiograph of the new variant 
detected during this study . 
Key to Figure VIII.2 
1, 2 and 3 represent the 14, 9 and 11kb 
bands respectively (EcoRI/pK083 RFLPs). 
1 
3 
2 
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During the course of this project, a total of 250 people from 
different genetic backgrounds were genotyped with this polymorphic 
system and only the nine individuals reported here have the 
variant band (a total of 135 SA individuals of mixed ancestry were 
genotyped of whom 46 were unrelated controls from the general 
population). 
8.1.2 Linkage data: 
Linkage analysis of this RFLP system revealed that in individuals 
1-6 in generation III and 1-8 in generation IV, HD appeared to be 
inherited with the 9kb fragment (indicated by 2 on Fig.VIII.l). 
However, taking into account that there was a new variant detected 
in this family, it appeared that in the rest of the pedigree, HD 
was associated with the rarer allele, with one notable exception 
(111-9). This assumption was based on the fact that, due to the 
rarity of the 11kb band, it was less likely that the originals ( 
individuals from the general population) in generation II (11-
4,11-6) would bothhave had this rare allele ( unless they were 
related) and it was therefore more probable that the two affected 
males in that generation had had the 11kb band (11-3, 11-5). 
Linkage data of the computer analysis of these results in Table 
VIII-I indicated a negative lod score for all values of 0, when 
only the affected individuals, as well as at-risk persons over the 
age of 60 years were used in the linkage analysis. This result 
indicated the possibility of recombination between HD and pK083, 
the significance of which is discussed in 8.2. 
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TABLE VII 1-1. 
Linkage Data of family with new variant and 
possible recombination within D4S10. 
8 lad-score lad-score lad-score 
minus III-9 combined 
haplotypes of 
EcoRI RFLPs EcoRI RFLPs Mspl & Hindlll 
RFLPs 
0.4000 -0.00 0.04 0.24 
0.3000 -0.07 0.10 0.62 
0.2000 -0.26 0.09 1.10 
0.1000 -0.66 -0.10 1. 61 
0.0500 -0.97 -0.35 1.86 
0.0100 -1.16 -0.81 2.09 
0.0000 -1.17 -1. 07 2.10 
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8.2 DISCUSSION ON THE NEW VARIANT AND THE POSSIBILITY OF 
RECOMBINATION WITHIN THE D4Sl0 LOCUS. 
The new rare variant revealed with pK083 and EcoRI was only 
detected in a single SA HD family. 
Initially it was thought that the variant had increased the 
informativity of the probe in this family, but on examination of 
the pedigree (Fig VIII.l), it was apparent that all individuals 
genotyped from generation III. 1-6 and generation IV.1-8 were 
homozygous at the marker locus ( with the exception of IV-1). 
Assuming that HD is linked to pK083, the disease must have been 
associated with the 9kb allele (indicated as 2 in Fig. VIII.l) in 
this family, but the affected individuals were uninformative at 
the marker locus. With the appearance of the new variant in 
generation III-7,8,10,12,13,14 and generation IV-9,10,11 and 
continuing with the assumption that HD was associated with the 9kb 
allele, it followed that this system would be informative in the 
heterozygous affected individuals (III-7,12,13,14). 
Computation of the linkage data indicated that the above 
assumption was in fact incorrect and there were indications that 
recombination could have occurred between pK083 and HD in this 
family (Table VIII-1). 
The negative lod score at all values of e could be indicative of 
recombination assuming that the new variant first appeared in 
generation I or II in the pedigree and that individuals II.4 and 
II.6 were not related and therefore less likely for both having 
had the new variant(Fig VIII.I). 
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Furthermore when other more distal markers from GB were used, a 
postive lod score of 2.09 at 8 = 0.00 was calculated {Table VII-
22, MA2), thus indicating that recombination had possibly occurred 
within the GB locus. In addition, by removing the one obvious 
recombination event {Fig VIII.I; 111 -9), the lod score peaked at a 
recombination fraction of ~=0.3. {Table VIII-1). These results 
implied that there was more than one possible recombination event 
within the D4S10 locus in this family. 
There had been previous reports of recombination within the D4S10 
locus and the results of the present study substantiated the 
orientation of the restriction sites suggested in Fig.V.4 { 
Youngman et al., 1986, Gilliam et al., 1987, Hollaway et al . , 
1989, Curtis et al., 1989, Skraastad et al., 1989). 
This family study demonstrates the importance of using multiple 
markers at the D4S10 locus and it is now advisable to use newer 
markers that are closer to the HD locus for presymptomatic testing 
for HD {Hayden et al., 1988a). This experience also emphasises 
the necessity for computation of genotype results in linkage 
analysis especially when this type of analysis is to be used for 
eventual predictive testing. 
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CHAPTER NINE 
INTRODUCTION TO THE CAPE TOWN QUESTIONNAIRE SURVEY: 
9.1 REVIEW OF THE ETHICAL ISSUES INVOLVED WITH 
PREDICTIVE TESTING 
Essentially, the situation brought about by the availability of 
presymptomatic testing for HD, is as follows: the genotype of some 
clinically 'normal' individuals can now become known well in 
advance of the signs and symptoms which are the usual indicators 
of the disease. These at-risk persons will thus be put in a unique 
category in that their fate could be revealed to them many years 
before they would normally have been aware of it . Once 
presymptomatic testing for HD becomes available and publicised 
there is the danger that there might be pressure on the at-risk 
person to undergo testing, not only for their own self knowledge 
concerning their risk status, but to inform others who might be 
affected thereby. Family, potential marriage partners, employers, 
business partners and insurance agencies would all be privy to 
information which should be private and personal. The question 
arises as to whether pension funds and prospective employers for 
example have the right to demand presymptomatic testing for HD 
prior to entering into a contract with someone at risk ( Lamport, 
1987). In this context, according to a special article in a recent 
SA medical journal (Taitz, 1990) it would appear that currently in 
SA it would not be an unlawful breach of the rule of medical 
confidentiality if a medical professional were to divulge 
information for the public good, even against the patient's 
wishes. Confidentiality however, is not absolute and each case 
must be considered on its own merits (Benatar, 1990). 
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Furthermore there is the danger that insurance companies could 
insist on presymptomatic testing for at-risk individuals and 
could either deny them cover on the basis of the results or load 
the premiums accordingly. Applications for mortgage loans and 
medical- aid insurance could be jeopardized by an increased risk 
result of a presymptomatic test for HD. 
A new aspect of the basic problem of balancing the needs and 
rights of the individual with the demands and interests of society 
has become apparent. As society is always stronger in this 
conflict, special care must be taken to safeguard the legitimate 
interests of the individual. The rights of the individual must at 
all times be protected and should not be discarded in preference 
to other interests (Kolata, 1986). 
A.E.H Emery published a paper in 1980 titled 
'Whether or not predictive tests'. 
He wrote 
• In my experience, having discussed this matter with many at 
risk individuals, most would prefer to live in the hope of 
being unaffected rather than risk being told that there is a 
certainty of becoming affected." 
Furthermore: 
• Taking all these considerations into account, is it 
justified to pursue research on predictive testing? My 
feeling is that this would only be justified once an 
effective treatment has been found; then, many of the 
problems now associated with predictive tests would 
disappear. The main concerns of research in this disorder 
should be furthering our understanding of the cause and above 
all, finding an effective treatment." 
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These sentiments were also expressed by others prior to the 
availability of a predictive test.(Stevens, 1971; Stern and 
Eldridge, 1975; Thomas, 1982 ). 
The discovery of a molecular marker for HD and the definite 
possibility of a 96% accurate predictive test for certain 
individuals, has resulted in numerous surveys being undertaken 
worldwide to ascertain the attitudes of at-risk individuals 
towards presymptomatic testing. The general consensus is that 
most people would in fact, want to know their risk status, though 
some stated that they still had certain reservations and would 
prefer to wait until the test was 100% accurate (Evers-Kiebooms et 
al., 1987; Markel et al., 1987; Kessler et al., 1987; Mastromauro 
et al., 1987; Meissen and Berchek., 1987). 
There is a growing opinion amongst professionals that the medical 
profession should not become submerged in the new technology and 
that predictive testing should be withheld until something 
positive could be offered to those for whom the risk is increased 
( Robert, 1985; Shaw, 1987; Smurl and Weaver, 1987). However, 
consideration must be given to the fact that there are possible 
legal aspects regarding counsellors obligations to provide the 
test. (Bains, 1986). 
In any event there are at-risk individuals who maintain that / the 
uncertainty of whether or not they will eventually develop the 
disease is too much to bear. Some have indicated that they would 
rather know that they had inherited the gene for HD and so end the 
ambiguity. Possession of this knowledge would enable them to 
prepare and plan their lives accordingly. They would be able to 
make decisions regarding marriage and procreation, long term 
business and/or career planning and about informing children of 
their risk status. 
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In addition, preparation could be made for the care of the patient 
and the maintenance of the family after the onset of the disease 
(Dalby, 1986; Crauford and Harris, 1986). 
As one person explained: 
•1 need to know whether retiring will mean 
buying a motor home or hiring a nurse.• 
A woman, aged 32, taking part in the predictive testing programme 
in the UK said that she needed to know what her risk status was, 
as, amongst other things, she wanted to learn to drive. She said 
she realised that it would not be advisable to do so if the test 
were to be positive (personal communication). 
In general, it would appear that people at risk were more 
concerned about finding out if they were gene carriers and how 
they would live with the results rather than how society would use 
this information against them. 
Finally, there is the danger of introducing a new psychiatric 
illness; one where an individual knows that he has a 96% chance of 
developing a dreadful, lethal, incurable condition sometime in the 
future. This knowledge could limit and drastically alter his 
entire adult life and not just the last ten to fifteen years 
after the onset of the disorder (Levine, 1986). 
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As genetic testing finally leaves the realm of the hypothetical, 
there are several issues that now have to be faced. A number of 
these are listed in the proposed protocol in the appendix 
(Appendix V). Based on the experiences of a number of pilot 
studies and following a great deal of debate internationally, a 
consensus has emerged that implementation of such a prediction 
service is totally dependent on the availability of extensive 
psycho-social support for HD families. Sophisticated professional 
counselling is necessary to make the at-risk person aware of the 
options available and the implications thereof in order to reach 
an informed decision about predictive testing ( Bird, 1985 ). 
Appropriate and continuing support which helps individuals to 
cope with the consequences of their decisions and to enable 
optimal adjustment to the situation are fundamental to a service 
of this type. 
The social dilemmas created by the test are at least as important 
as its scientific ramifications; stumbling blocks are likely to 
arise as similar techniques are applied to other diseases in the 
future. By maintaining the highest possible degree of preparedness 
and providing continuing support and availability of therapeutic 
services, the negative consequences that might result from 
presymptomatic testing can possibly be avoided or the effects 
thereof, minimised. 
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Evers-Kiebooms et al. (1989) aptly stated 
N It is clear that interdisciplinary collaboration between 
geneticists, psychologists, social workers and psychiatrists 
will be necessary to ensure that this new diagnostic 
possibility will allow the testees to integrate this 
experience positively in the fulfilment of their future 
lives.• 
HD families need to be reassured that it is the condition, not the 
HD patient, that we wish to eradicate Essentially, at-risk 
individuals need to be given the opportunity to make informed 
decisions about their lives in an environment of caring, support 
and understanding. 
The major goal of presymptomatic testing for HD should be to 
enable at-risk individuals to enhance the quality of their lives. 
In the long run, it is possible that the gene frequency will 
decrease, which would be an added bonus (Hayden et al., 1987e). 
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9.2 INTERNATIONAL EXPERIENCE WITH PRESYMPTOMATIC TESTING 
There have been many reports emanating worldwide regarding the 
attitudes of patients and their relatives towards predictive 
testing of HD. A list of some articles publi~hed from different 
countries in the past decade is shown in Table IX-1. In each case, 
the more recent or most relevant publication has been cited. 
It was reported in 1984 that 73% of persons from HD families 
canvassed in Boston, before the discovery of the linked marker, 
indicated that they would take a presymptomatic test should it 
become available (Schoenveld et al., 1984a). By 1986, once the 
test was already being offered in certain centres, this figure 
decreased to 62%, which was a significant change in attitude 
(Mastromauro et al., 1986). Subsequently, similar findings have 
been reported by other centres that have already started 
presymptomatic testing: the proportion of persons who eventually 
enrolled in the predictive programmes was much smaller than was 
expected on the basis of previously expressed intentions to 
undergo the test. In addition, during the pilot predictive 
testing project in Boston between 1986 and 1988, 19 of the 47 
persons (i.e.40%) who requested a presymptomatic or prenatal 
genetic linkage test voluntarily withdrew from the programme after 
extensive pre-test counselling (Meissen et al., 1988). 
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It is further accepted that probably 40% of this group will not 
have an appropriate family structure to be able to perform the 
present linkage test (Farrer et al.,1988). 
Based on these findings and the experiences of other similar 
programmes, (Quaid et al., 1989), it can be concluded that only 
a small proportion of individuals, who are at risk of having 
inherited the HD gene, will eventually receive presymptomatic test 
results. 
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TABLE IX-1. 
Published reports of attitudes towards presymptomatic 
testing for Huntington Disease from different countries 
(1979-1989). 
Country 
UK 
London 
Australia 
Melbourne 
Wales 
South Wales 
France 
North West 
USA 
California 
USA 
Kansas 
Belgium 
USA 
Michigan 
USA 
New England 
Authors 
Barette and 
Marsden 
Teltscher 
Polgar 
Tyler and 
Harper 
Pettit and 
Salomez 
Kessler 
et al. 
and 
Meissen and 
Berchek 
Year of 
publication 
1979 
1981 
1983 
1985 
1987 
1987 
Evers-Kieboorns 1987 
et al. 
Markel 
et al. 
Mastrornauro 
et al. 
1987 
1987 
Canada Fox et al. 1989 
British Columbia 
UK 
Manchester 
USA 
Maryland 
Crauford 
et al. 
Quaid et al. 
1989 
1989 
Title 
Attitudes of families to some 
aspects of Huntington's chorea. 
Objective knowledge about 
Huntington's disease and 
attitudes towards predictive 
tests of persons at risk. 
Attitudes of subjects at risk 
and their relatives towards 
genetic counselling in 
Huntington's chorea. 
Huntington's disease, interest 
of clinical and epiderniologic 
data for genetic counselling. 
Attitudes of persons at risk 
for Huntington disease towards 
predictive testing. 
Intended use of 
testing by those 
Huntington disease. 
predictive 
at risk for 
Attitudes towards predictive 
testing in Huntington's disease: 
a recent survey in Belgium. 
At-risk 
toward 
prenatal 
disease. 
persons' attitudes 
pre symptomatic and 
testing of Huntington 
Attitudes towards presyrnptornatic 
testing in Huntington disease. 
Predictive 
Huntington 
of a pilot 
Columbia. 
testing for 
disease: Description 
project in British 
Uptake of pre symptomatic 
predictive testing for 
Huntington's disease. 
Knowledge, 
decision to 
attitude, and 
be tested 
the 
for 
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Since the inception of predictive testing for HD, parents have 
requested presymptomatic testing for their children for various 
reasons but it has been strongly urged that the testing should not 
be offered at the request of a third party (Morris et al., 1988; 
Bloch and Hayden, 1990). Following widespread discussion amongst 
professionals and lay groups it has been internationally agreed 
upon that children should not be tested (Harper et al.,1990; Went, 
1990). 
In conclusion, although there was much concern for the adverse 
consequences of predictive testing (Kessler, 1987a) there have 
been favourable reports to date as to the beneficial effects of 
two very well-organized presymptomatic testing programmes (Bloch 
et al., 1989; Brandt., 1989). 
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9.3 THE SOUTH AFRICAN SITUATION AND PREDICTIVE TESTING. 
9.3.1 ~ background to the SA situation: 
Predictive testing has to date been designed as a first-world 
service. In SA, however, which is a mixture of first and third-
world, the situation is more complex; the issues involved in the 
practical implementation of such a service are considerably 
different to those in Western Europe and North America. These 
include the current political and socio-economic situation in SA, 
its multi-ethnic society and the physical size of the country. 
Cultural differences and social attitudes have a direct influence 
on the development of such a service in developing countries. 
Careful examination of cross-cultural ethics is critical to the 
SA situation as the basic ethical principles that guide human 
investigation need to be interpreted and applied within the 
different cultural settings. 
Due to the socio-political situation in the country there is a 
general low standard of education. Consequently, the overall 
awareness of HD and more specifically the lack of insight as to 
the immediate and longterm implications for a presymptomatic HD 
gene carrier, is a major concern. 
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9.3.2 The facilities available for investigation and 
management of HD in Cape Town: 
In 1987, at the inception of this project, there were and still 
are very limited facilities available for HD patients and their 
families in Cape Town. There was an HD out -patient clinic at 
Groote Schuur hospital (GSH) where patients were seen on a regular 
basis for neurological assessment and management. 
psychiatric hospitals, Valkenberg and Lentegeur, 
Two Provincial 
had a number of 
HD in-patients who were in the advanced stages of the disease. 
Although these hospitals are State-run, due to the high cost of 
keeping a patient in an institution, there was very limited space 
available for patients in these institutions. For example, the 
cost of keeping one patient in an institution has doubled since 
1981 and the current cost is quoted as being Rl5,000.00 per year 
per patient (Smart, 1981; 1990 figure, personal communication). 
Private nursing services were very expensive and were therefore 
not generally affordable by the majority of the Cape Town HD 
families. In addition there was the Cape Mental Health Society 
(State subsidised) and a newly established HD lay society where HD 
family members were referred for support. 
HD and its problems are a financial burden for the affected 
individual, the family involved and the community as a whole. The 
tremendous cost of hospitalisation, medication, social support and 
loss of savings cannot be carried or absorbed personally in a 
third world setting. For these reasons, the cost of a programme 
for the prevention of a disorder such as HD must be carefully 
assessed and considered. 
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9.3.3 Implications for HD in the third world: 
Firstly, the social implications and understanding of the 
disease, for the patient, his family and the community at large, 
have to be very carefully examined. HD is a family disease; the 
patient is the nucleus around whom approximately ten people 
revolve, each suffering from the far reaching social consequences 
of the disorder. The affected person is the first one who attracts 
medical attention to the family, however it is often the 
unaffected spouse who is more likely to need the most assistance 
in coping (Hayden et al., 1980b). 
In some HD families, at-risk persons have gone ahead with 
marriage and procreated, having kept secret their genetic history 
from their spouses. In this way denial propagates the disease. 
Ignorance or inadequate information of HD has, on the whole, 
produced more problems than has the knowledge of the disorder and 
its genetic risks (Harper et al., 1979). In a third world 
situation where the emphasis is on primary care, and the levels 
of education are low, this situation is aggravated. HD is not 
just the passing on of a gene unwittingly from affected parent to 
child, but is also a frightening and inaccurate store of knowledge 
combined with a panic stricken strategy for living. This 
combination of factors creates a vicious circle of disease, fear, 
ignorance and further disease. 
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Of vital importance in HD families is often the attitude of the 
non-affected parent because this affects the family as a whole 
(Korer and Fitzsimmons, 1985). It is therefore essential that the 
spouse be correctly counselled and well educated about the 
disease and the predictive test (Tibben et al., 1990). Once again, 
this demands a well organised programme with highly trained 
specialist counsellors which is not practicably possible in the 
SA setting at present. 
9.3.4 The feasibility of predictive testing in SA: 
In order to establish a predictive testing service in SA, existing 
auxiliary medical services and other disciplines will have to be 
co-opted. The primary task will be to increase the awareness of HD 
and impress on those concerned the implications of the predictive 
test. With a better understanding of the disorder, families will 
feel free to use the available community resources without the 
deplorable stigma of the disease ( Kenen and Schmidt, 1978). 
Maximum utilization has to be made of all available resources 
recognising that there are minimal tertiary education centres and 
limited media resources. 
Finally, the logistics of back-up services, particularly in the 
rural areas, which necessitate the involvement of highly trained 
medical personnel such as neurologists, psychiatrists, 
psychologists, geneticists and social workers are major problems 
in developing a predictive service of this nature in the third 
world. The diverse social and ethnic background differences and 
the gross lack of adequate counselling facilities, even in urban 
areas, are also contributory factors to these problems. 
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The size of the country, the complexity of the socio -political 
situation and the organisation of medical health services in SA 
provide a real challenge in devising an acceptable and reliable 
predictive testing service. The potential of the proposed service 
extends well beyond this one disease. There are other late onset 
genetic neurodegenerative disorders such as the cerebellar ataxias 
and familial Alzheimer disease, for which diagnostic genetic 
linkage will probably be available in the next few years. The 
implementation of a prediction service for HD in SA should provide 
guidelines for similar services in other situations. 
With the financial constraints on medical services in SA during 
the past few years, the emphasis has been on primary medical care. 
The dilemma of sacrificing health care finance for individuals 
faced with third world diseases such as Tuberculosis, Kwashiorkor 
and Leprosy in favour of finance for first world medical 
practice ( genetic services and predictive testing) is one that is 
often faced by medical researchers in SA. 
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9.4 AIMS OF THE CURRENT CAPE TOWN QUESTIONNAIRE SURVEY 
9.4.1 Previous experience: 
During the course of the aforementioned national 
identify all patients with HD in SA (Hayden et al., 
survey to 
1980a), HD 
family members were asked whether they would themselves have a 
presymptomatic test should it become available. The results 
presented in Table IX-2 show the responses to the possible 
utilisation of a hypothetically 100% safe and reliable predictive 
test. At that time 50.75% of the at-risk individuals approached 
indicated that they would take such a test should it become 
available. It was noted that there was a tendency towards a lower 
acceptability of such a hypothetical test in the SA population of 
mixed ancestry ( Hayden, 1979 Page 286). 
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TABLE IX-2. 
Responses to the possible utilization of a 
hypothetical predictive test. 
Reproduced in part from Hayden, 1979. 
At-risk persons Yes No Uncertain Total 
White 
(X) 
Mixed ancestry 
(X) 
33 
(59%) 
34 
(45%) 
67 
10 
(18%) 
23 
(30%) 
33 
13 
(23%) 
19 
(25%) 
32 
56 
76 
132 
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9.4.2. Aims of the present SA survey: 
In 1987, when HD predictive testing was already available in 
certain countries, a questionnaire survey was conducted by the 
author to assess the attitudes and eventually the needs of at-
risk individuals towards such testing. This survey was adapted to 
the needs of the very diverse population and was designed to 
assess the subjects' socio-economic characteristics; their 
understanding of the genetic, scientific and therapeutic aspects 
of HD and their attitudes towards and acceptance of predictive 
testing. 
The main objective of the survey was to evaluate the knowledge and 
expectations of at-risk individuals to predictive testing and 
prenatal diagnosis in order to provide adequate psycho-social 
support systems catering for the needs of the different members of 
the community. 
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CHAPTER TEN 
METHODOLOGY: 
CHAPTER IO.I QUESTIONNAIRE DESIGN:. 
A proposal for the intended survey was submitted to and approved 
by the Groote Schuur hospital medical faculty ethics committee 
before commencement. 
There were four parts to the questionnaire. Sections A and B 
related to personal details of the subjects and their knowledge of 
HD, Sections C and D related to the subjects' attitudes towards 
future predictive testing (Appendix VI). 
Section A of the questionnaire entitled 'PERSONAL INFORMATION' 
was designed to appear only to address the sociodemographic 
characteristics of the individual. However, questions regarding 
the participants' personal details were followed by four very 
important additional groups of questions. This design was intended 
to make the respondents feel completely at ease and not aware that 
they were being 'tested' at this stage. 
The reason for this approach was as follows:- during the 
designing of the questionnaire it was discovered, although a 
prerequisite for participation was that the subjects should be 
aware of their risk status, there was no other way for the 
investigator to confirm this fact. It followed that it was not 
possible to ask people how they felt about the possibility of a 
change to their risk status (i.e. a predictive test) if they were 
not already aware of their present risk status. 
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It must be emphasized that this questionnaire was never intended 
to educate individuals regarding their risk status, but to assess 
their understanding of the disease, acceptance of their own risk 
status and knowledge of the predictive test. The primary aim of 
Section A of the survey was to inform the testers about the 
testees knowledge of their risks. 
The vital additional questions included in Section A were designed 
to assess the subjects': 
i. Exposure to HD (objective knowledge of the disease) 
Table X-la. 
ii. 
iii. 
i V. 
Intentions regarding future procreation 
(subjective attitude to HD) Table X-lb. 
Knowledge of the statistical risk and acceptance of 
their own risk status (acknowledgment and 
acceptance of risk) Table X-lc. 
Knowledge about predictive testing for HD 
(acknowledgement and acceptance that there was a 
possibility of changing their present risk status) 
Table X-ld. 
Section B entitled 'KNOWLEDGE OF HD' was designed to assess the 
subjects' 
i. Awareness of the symptoms and progress of HD. 
ii. Knowledge of the genetics of HD. 
iii. Source of knowledge about HD and the available 
resources. 
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Section C was designed as a formal 14 point questionnaire based on 
a hypothetical question: If a test was available to diagnose HD 
long before the onset of symptoms; Would you ••••• ? 
This section was formulated to take the individual through the 
various options, following presymptomatic testing, in order to 
assess:-
i. Their reasons for wanting the test. 
ii. Their attitudes towards predictive testing for 
themselves (Subjective). 
iii. Their attitudes towards predictive testing for 
others (Objective) . 
iv. Their perceptions of how they would feel about the 
results and their intentions following testing. 
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Table X-1. 
Questions from Section A to assess the subjects' objective 
knowledge of and attitudes to HD as well as their acknowledgement 
of their own risk status and knowledge of predictive testing. 
a) HAVE YOU LIVED WITH OR CARED FOR THE HD PATIENT? (or any other contact) 
IF YES, FOR HOW LONG? 
HOW LONG HAS THE PATIENT HAD HD? 
WHAT DO YOU CONSIDER TO BE THE BIGGEST PROBLEM FOR: i) the patient with HD? 
ii) the family? 
b) DO YOU INTEND TO HAVE ANY/MORE CHILDREN? 
IF YES, HOW MANY? 
IF NO, WHY NOT? 
c) HOW ARE YOU RELATED TO THE HD PATIENT? ARE YOU AT RISK OF INHERITING HD? 
IF YES, WHEN DID YOU LEARN THIS? (what age) WHERE AND HOW? 
d) DO YOU KNOW OF A TEST THAT SHOWS WHETHER YOU WILL GET HD? 
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• 
Section D was a repeat of Section C and was to be completed at a 
later date, following counselling. The intention being that this 
would enable analysis of the at-risk individuals' attitudes 
towards predictive testing both before and after appropriate 
counselling. 
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10.2 ENROLMENT OF PARTICIPATING VOLUNTEERS 
Family members of patients seen at the HD clinic at Groote Schuur 
Hospital and members of the Huntington Society of South Africa, a 
lay organisation, were informed of the questionnaire survey and 
invited to participate in the programme. 
Individuals who volunteered to complete the questionnaire were 
only accepted to participate in the survey if they met all the 
following criteria: -
i. had prior knowledge of their risk status. 
ii. had had direct contact with someone with HD and 
knew about the progressive nature of the 
disease. 
iii. were 18 years or older. 
Volunteers were seen either at the HD clinic or at the Department 
of Human Genetics, UCT. The interviews were conducted on an 
individual basis by the author and a medical genetics counsellor. 
The questionnaire was explained to the subject, and Sections A and 
B were completed. After assessment of the responses, certain 
participants were asked to complete Section C at a second 
interview and any queries arising therefrom were answered by the 
medical genetics counsellor. A further interview was to be 
arranged for the subject to complete Section Data later date. 
A research number was granted so that participants would not have 
to pay for the use of hospital facilities whilst participating in 
the survey. A special clinic was established to handle any 
psychological problems which might have arisen from participation 
in the survey. 
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All participants were issued with a survey number and only the 
author had access to the key. Confidentiality was guaranteed and 
maintained throughout the programme. The questionnaires were 
translated into both official languages (English and Afrikaans) 
and made available to the participants in their language of 
preference. 
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10.3 COMPLICATIONS: 
A major problem in the recruitment of volunteers for participation 
in the survey was that young, unaffected individuals could be 
seriously affected psychologically in the long term if they were 
unaware of the chances of developing the disease. 
For this reason, it was stipulated that subjects be 18 years or 
older and should have acknowledged that they were aware of their 
risk status before they could be approached to complete Section C 
and D of the questionnaire. These criteria were strictly adhered 
to and at no time were individuals canvassed or coerced to 
participate. The first part of the survey (Section A and B) was 
not intended to inform people about their risk status but 
primarily to assess whether they were aware that there was a risk. 
Three participants were illiterate and their responses were 
recorded by the author verbatim. 
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CHAPTER ELEVEN 
RESULTS, DISCUSSION AND PROGRAMME PROPOSAL: 
11.1 SURVEY DATA 
Forty requests to participate in the survey were made to HD family 
members in the greater Cape Town (CT) area; 30 people were 
approached by the Huntington Society of South Africa (HSSA) and 
only 10 people volunteered from this group. A further 10 
volunteers were recruited at the HD clinic. 
Of the 20 respondents who completed Sections A and B of the 
questionnaire, 15(75%) were female and 5 (25%) were male; 15 
(75%) were of mixed ancestry and 5 (25%) from European origins. 
The minimum age of the at-risk group was 19 years and the maximum 
age 68 years. According to the individuals' family history, the 
genetic risk status for having inherited the gene for HD for 17 
(85%) of the participants was 50% while 3 (15%) were at 25% risk. 
Neither the age of the participant at the time nor the age of 
onset of HD in the family were taken into account in estimating 
the risk status. The sociodemographic characteristics of this 
sample are summarised in Table XI-1. 
The responses to certain questions in both Sections A and B 
indicated that there was an element of denial in the SA at-risk 
population. These questions together with the replies are shown in 
Tables XI-2 and XI-3. 
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TABLE XI-2. 
Questions and replies regarding the subjects' 
knowledge of the genetics of HD and their 
own risk status. 
Questions Replies 
SA of 
Mixed 
ancestry 
N=l5 
Yes No Don't 
Know 
1. ARE YOU AT-RISK 6 5 4 
OF INHERITING HD? (40%)(33%)(27%) 
SA of 
European 
origin 
N=5 
Yes No Don't 
Know 
4 1 
(80%)(20%)( 0%) 
2. WHAT ARE THE 10 5 5 
CHANCES THAT A (67%) 
PARENT WITH HD 
(33%) (100%) 
WILL PASS THE 
CONDITION ON TO 
HIS CHILDREN? 
( Subject either 
knew or was not 
sure) 
3. DO YOU KNOW 3 6 6 
OF A TEST THAT (20%)(40%)(40%) 
SHOWS WHETHER 
YOU WILL GET HD? 
(N = number) 
3 1 1 
(60%)(20%)(20%) 
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TABLE XI-3. 
Question regarding the subjects' knowledge of the 
predictive test. 
Question Respondents from 
HC clinic 
Yes No Don't 
know 
DO YOU KNOW 1 4 5 
OF ANY TEST (10%) (40%) (50%) 
THAT SHOWS 
WHETHER YOU 
WILL GET HD? 
Respondents from 
Lay society 
Yes No Don't 
know 
5 3 2 
(50%) (30%)(20%) 
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From the results in Table XI-2 (question 2) it was evident that 
although 75% of the participants were aware of the genetic 
implications of being a member of an HD family (15 of the 20), 
only 50% acknowledged that they were at risk (10 of the 20)(Table 
XI-2, question 1). 
However, ALL the respondents were at high risk of having inherited 
the gene for HD (Table XI-1). In addition, six individuals of the 
total survey sample implied that they were aware that there was a 
possible predictive test. Upon further analysis of the responses 
to the question relating to their knowledge of the predictive 
test, it became apparent that there was a remarkable difference 
between the group that was recruited through the HD clinic to that 
from the lay society ( Table XI-3). Very few individuals who 
responded from the HD clinic (10%) acknowledged that they 
definitely knew of a test, whereas 50% of the respondents from the 
lay society acknowledged the possibility of a test. In response to 
the question inquiring from which source individuals had gained 
most of their knowledge about HD and with reference to the 
question regarding whom they would approach should they require 
more information about HD, there was no significant difference 
between these two groups (Table XI-4). 
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Only four individuals were approached to complete Section C of the 
questionnaire. Selection was based on the individuals ' overall 
knowledge of the disease and their awareness of their own risk 
status. 
The demographic characteristics of this group are tabulated in 
Table XI-5. It is not possible to analyse these results 
statistically due to the small number and the diversity of the 
four persons and an attempt to standardise the results would 
render them meaningless. Because of these limitations and in order 
provide a perspective of the SA situation, some of the actual 
answers given are tabulated in Table Xl-6 and the results are 
discussed in the following section (Chapter 11.2). 
Owing to the small number of participants in the final survey, it 
was felt that Section D of the questionnaire was superfluous and 
was therefore abandoned. 
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TABLE XI-4. 
Questions and replies regarding individuals' source 
of information about HD and whom to approach. 
Question Respondents from 
HD clinic 
Respondents from 
lay society 
m. f. HSSA. other m. f. HSSA. other 
FROM WHICH SOURCE 6 0 
DID YOU GAIN MOST 
OF YOUR KNOWLEDGE 
OF HD? 
WHO WOULD YOU 9 0 
APPROACH SHOULD 
YOU REQUIRE MORE 
INFORMATION ABOUT 
HD? 
1 3 6 3 
0 1 7 0 
m = Medical, f = Family/friends, 
HSSA = Huntington Society of South Africa 
other= Books or own experience. 
1 0 
2 1 
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TABLE XI-5. 
Sociodemographic details of the four subjects who 
completed Section C of the questionnaire survey. 
Males:Females 
Age in years 
Number of children 
Education level 
High school 
Tertiary level 
SA of 
Mixed 
ancestry 
N=2 at 50% risk 
0:2 
68, 41 
1, 4 
2 
0 
(N = number) 
SA of 
European 
origin 
N=2 at 50% risk 
1: 1 
41, 29 
2, 2 
0 
2 
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TABLE XI-6. 
Questions relating to the four participants' 
attitudes to the possible results of predictive testing 
and their actual responses. 
Questions 
i. HOW WOULD YOU FEEL 
IF YOUR TEST WAS 
POSITIVE? 
Replies 
" Satisfied knowing my family 
and husband will stand by 
me." 
" It would be like the end of 
the world." 
" Cha 11 enged." 
"Would have to accept the 
fact." 
ii. HOW WOULD YOU FEEL "Happy." 
IF YOUR TEST WAS 
NEGATIVE? "Relieved." 
iii. WOULD YOU REQUIRE 
HELP IN COPING 
WITH THE RESULTS 
EITHER WAY? IF SO 
WHO WOULD YOU GO 
TO? 
" Rel i eved. " 
" Extremely relieved." 
"No, but if it is necessary 
that I will have to be sent 
to hospital, I would prefer 
to be near home." 
"The HD clinic." 
"My family/ someone who knows 
about HD." 
"HD society and Genetics 
clinic." 
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11.2 DISCUSSION OF RESULTS 
After careful analysis of the replies obtained in the survey and 
as a result of the attitudes of SA HD patients and their families 
to HD, as experienced at the routine HD clinic at GSH, it was 
apparent that the problems of day-to-day survival were more 
immediate than events a generation away. 
Although the sample size in this study was small (20), this number 
was in itself significant, considering the number of at-risk 
individuals in the region where the survey was conducted. As 
stated in Chapter V, it was estimated that there were 
approximately 890 individuals from the 42 kindreds in the Cape 
Town area who were at risk for inheriting the gene for HD. Based 
on pedigree analysis and information obtained from patients and 
family members, a conservative estimate indicated that there were 
a minimum of 458 at-risk individuals living within 100km radius of 
Cape Town at the time of the survey. 
The Huntington Society of SA (HSSA) was established in CT in 1986. 
The aim of this lay organisation is to act as a support group for 
HD families and to educate people about the disease. Although 
concerted efforts have been made to contact all known HD 
families, the HSSA currently has a membership of only 60. Despite 
the fact that specific mention was made of the questionnaire 
survey at three separate meetings of this association, only ten 
people from this group eventually volunteered to participate. 
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The HD clinic is a special clinic at GSH run jointly by the 
Departments of Neurology and Human Genetics. HD patients and their 
families are seen on a regular basis for neurological assessment 
and management. Patients are re-evaluated every three months and 
are often accompanied by carers: generally the spouse or a first 
degree relative. 
Of the 89 HD patients in the Cape Province documented in Table 
III-3 only 15 attended the clinic regularly between January 1987 
and December 1988 (>6 visits), whereas a total of 30 patients 
were seen over that period. Twenty-two of the 89 patients were 
institutionalised, four of whom were brought regularly to the 
clinic; of the two HD patients that are serving prison sentences, 
one was seen on a regular basis at the clinic. 
These facts imply that there was a certain reticence amongst CT HD 
families to appeal for medical or group assistance . This 
reluctance in requesting help was probably as a result of the 
stigma attached to the disease (Kenen, 1978). The desire for 
privacy was therefore respected and no other attempts were made 
to canvass individuals in any way. 
The ethnic distribition of the participants in the SA 
questionnaire survey was similar to that observed at the HD DNA 
banking centre (Table V-2). The disproportionate ratio of 
male:female ( chi-square exceeds the critical value at p = 0.05) 
was probably due to the fact that the majority of carers, who were 
canvassed at the HD clinic, were female. 
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With regard to the participants' exposure and resulting objective 
awareness of the symptoms and progress of the disorder, the 
majority (80%) were very well aware of the features of HD. All 17 
(Table XI-1) who were at 50% risk of having inherited the gene for 
HD had previously or were presently caring for a relative with HD 
at the time of the survey. The three individuals who were at 25% 
risk had had little exposure to HD but were well informed about 
the disease and knew about the genetics of HD. No significant 
information was obtained regarding the influence of HD on the 
intentions of at-risk individuals regarding procreation. 
Seventeen participants already had had children and gave advanced 
age and family size as their reasons for not wanting more. 
One person who had no children replied that he did not want any, 
but failed to indicate why. Two individuals failed to answer both 
questions (desire to have children and reason why if no). 
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It was distressing to learn of the limited extent of the 
individuals' awareness of their own risk status. Judging from the 
replies tabulated in Table XI-2 it would appear that certain 
individuals had an inability or unwillingness to apply their 
genetic knowledge of HD to their own situations. The implications 
of the apparent lack of knowledge of the predictive test was 
indicative of denial, as all individuals who participated in the 
survey, had had blood taken for the HD DNA banking centre. At that 
time, each individual was informed of the possibility of a 
predictive test as this was the whole rationale for banking DNA 
(Chapter 5.2.). In addition, when the questionnaires were 
distributed the reason stated for the survey was to design a 
suitable protocol for the implementation of predictive testing of 
HD in SA. Denial, as a defence mechanism which can be defined as 
pathological, is not an unique observation; Martindale (1987) 
reported on pathological defences seen in some at-risk individuals 
as well as the defences adopted by some professionals coming in 
contact with HD families. However, the results in Table XI-3 
indicated that 50% of the respondents from the lay society 
acknowledged that they knew about the test whereas 90% of those 
from the HD clinic either denied any knowledge of the test or 
indicated that they did not know. It is clear that repeated 
exposure to the concept of predictive testing as a result of 
joining a support group and the willingness to be identified as an 
at-risk person influenced the awareness and acceptance of the 
respondents from the lay society to the test. 
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The four respondents who completed Section C of the questionnaire 
all indicated that they would take the test, irrespective of 
whether it was 96% accurate or not and that they would all 
recommend that others take the test. 
Furthermore, they all stated that they would have their own 
children tested and suggested testing children at an early age, 
preferably in their teens. 
All four respondents already had had even children and were not 
planning any more due to advanced age and family size. However, 
two indicated that, hypothetically, if, at an earlier age, had the 
test been available, they would still have had children if their 
test had been positive. Two replied that they would not have 
procreated. Three of the four respondents would have had a 
prenatal test but one of these would not have had the pregnancy 
terminated if the test had been positive. One respondent indicated 
that she would neither have had a prenatal test nor opted to 
terminate . 
These responses implied that the introduction of predictive 
testing for HD would significantly affect life decisions for the 
four respondents who participated in Section C this survey. 
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No SA Blacks participated in this questionnaire survey as the only 
black African families with HD in SA known to us were all in the 
Transvaal, which was out of the study area. However, the author 
noted when on the field trip to Lebowa, that the main concern of 
HD family members was for the social security benefits that could 
be obtained for the HD patient and that there was very little 
concern for the hereditary aspect of the disorder. Whilst they 
knew that the disease was 'in the family' it was seen as 'an act 
of God' and accepted as such. 
Recently, in the context of a discussion on AIDS it was stated 
that there were differences in opinions on counselling between 
Western and African health workers. Dr M V Gumede from the 
Kwamashu Polyclinic, Zululand, Natal is quoted as saying that 
0 death holds no terror in the black co11111unity. 
AIDS is grouped among 'Izishawa' in Zulu, 
understood in the West as 'Acts of God'. No 
extraordinary counselling measures were 
therefore needed 0 (MRC news, 1988). 
The same dictum would probably apply to HD. 
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The results and observations made during the course of the survey 
indicate that the implementation of a presymptomatic testing 
programme for HD in SA is a difficult task. Clearly, the first 
priority will be to ensure adequate pre-test counselling with the 
main emphasis on education and enlightenment. In order to 
accomplish this successfully, the available professional and 
community resources need to be identified, educated and informed 
of the problems relating to HD to enable them to provide 
psychosocial support for HD families. An integrated professional 
team approach to counselling for HD needs to be established (Fig 
XI.I). The natural consequence would be to utilise these 
facilities as a follow-up support system to deal with the 
psychological impact of predictive testing. 
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Figure XI. l 
Schematic representation of the combined professional 
team approach to counselling for HD. 
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11 .3 REVIEW OF THE ORIGINAL DEVELOPMENT PROGRAMME 
In 1987 a proposed protocol for the development and implementation 
of a predictive testing service for HD in SA was drawn up 
(Appendix V.). The technological aspects, questionnaire survey, 
education programme and the establishment of a counselling 
service already completed are detailed in this thesis. As 
previously stated, it was found advisable to restrict the study to 
the Cape Town area and the eventual proposal was designed for this 
area of study and submitted to the local hospital authorities. 
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11.4 PROPOSALS FOR THE IMPLEMENTATION OF PREDICTIVE 
TESTING FOR HUNTINGTON DISEASE IN THE CAPE. 
In 1989 a proposal was submitted to the Medical Superintendent of 
Groote Schuur Hospital (GSH) for the implementation of a 
predictive testing service for HD in the Cape. 
The submitted proposal included details of the completed service-
orientated development and stated the major requirements for the 
inception of the comprehensive service. These included a full-time 
laboratory technologist and a GSH social worker allocated to the 
programme for one day each week. In addition it was stressed that 
it was necessary for a high level committee to be convened to 
establish policy on the moral and ethical issues which related 
specifically to SA. 
As this proposal represented the culmination of all the work 
outlined in this research project, it is presented here. 
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PROPOSAL FOR THE IMPLEMENTATION OF PREDICTIVE TESTING FOR 
HUNTINGTON DISEASE IN THE CAPE 
I.INTRODUCTION 
Huntington Disease (HD) is an autosomal dominant 
neuropsychiatric disorder that usually manifests in 
mid life with abnormal involuntary movements, 
personality change and dementia. In the past, 
genetic counselling for the statistical risk of 
inheriting HD was based solely on family history 
and pedigree analysis. Now, prediction can be made, 
with approximately 96% accuracy, in informative 
families, using molecular technology and linkage 
analysis. 
Following a great deal of debate in overseas 
centres, a consensus has emerged that 
implementation of such a prediction service is 
totally dependent upon the availability of 
extensive psycho-social support for HD families. 
Sophisticated professional counselling is necessary 
to make the 'at-risk' person aware of the options 
available and implications thereof in order to 
reach an informed decision about predictive 
testing. Appropriate and continuing support to help 
individuals cope with the consequences of their 
decision are fundamental to a service of this type. 
The Department of Human Genetics, UCT, is now in a 
position to offer a molecular predictive testing 
service for Huntington Disease. In view of the 
financial implications and complex ethical and 
moral issues concerning presymptomatic testing and 
antenatal diagnosis of a disease for which there 
is no cure and very little treatment, any decision 
to implement predictive testing must rest with 
higher authority. 
2. MOLECULAR SERVICE: 
The current molecular test for HD involves linkage 
analysis using restriction fragment length 
polymorphisms (RFLPs) that are closely linked to 
the HD gene locus. This type of analysis requires 
the use of blood samples from numerous family 
members. (It is preferable that specimens are 
obtained from three generations of living affected 
individuals in order to establish which variation 
in the marker is co-inherited with the abnormal 
gene in each family) 
Interest in this disorder in South Africa was 
generated in 1977 when a national survey was 
undertaken by the Department of Human Genetics, 
UCT. 
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A collaborative Huntington disease clinic was 
subsequently established at GSH and thereafter, 
service orientated development was undertaken in 
our molecular laboratory using resources from the 
Cape Provincial Administration (CPA), UCT and the 
Medical Research Council (MRC). 
A perspective of the magnitude of the problem can 
be gained from the following statistics: 
HD IN THE CAPE TOWN AREA 
AT RISK 
AFFECTED 
FAMILIES 
485 
80 
40 
3. EXISTING SERVICE: 
DNA BANK: 
( 70% Cape Province). 
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67 
37 
A 'Core Team' has been established which will be 
available to provide the counselling service and 
the technology for HD predictive testing. This team 
consists of: 
A medical geneticist to undertake the counselling. 
A molecular scientist who has established the DNA 
test in our molecular laboratory. 
A psychologist (i) to organise and carry out the 
psychological tests necessary in patient selection. 
(ii) to be available for any 
psychological problems that may arise both pre- and 
post test and for long term support of patients, 
if necessary. 
(iii) to be available for 
the ongoing support service of 'at-risk' 
individuals who do not wish to take the test but 
require psychological counselling. 
A genetic nursing sister (i) to organise the 
appointments and be a link between patient and team 
(ii) to collect the 
necessary blood specimens from patients and key 
relatives. 
A neurologist for neurological assessment and 
management of the HD patients and to exclude early 
evidence of HD already manifesting and so preclude 
the patient from unnecessary testing. 
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4. REQUIREMENTS FOR THE IMPLEMENTATION OF A 
PREDICTIVE TESTING SERVICE FOR HD. 
The initial stages of development have been 
completed and we are in a position to offer a 
molecular predictive service for HD. 
A definite decision is now necessary as to the 
advisability and practicability of offering this 
costly test in SA. The majority of our patients are 
from the low literacy, low education, low income 
population, and they will have to make 'informed 
decisions' about extremely difficult, complex and 
emotive issues. The question arises as to whether 
the progra11111e is feasable in view of the present 
shortage of available resources and skilled 
personnel. 
Staff still required and key specialists needed 
mainly for consultation and advice if and when 
specific problems arise. 
a) ~ full-time technologist to carry out the DNA 
analyses. 
b) A Social Worker (1 day per week) Huntington 
disease is a family disease and we are often 
required to call for assistance from social workers 
to help family members cope with day-to-day 
problems associated with HD. The social workers at 
GSH have many co11111itments and it is often not 
possible for them to attend to HD problems 
i11111ediately. With the implementation of predictive 
testing a specific social worker would have to be 
allocated to HD to handle these day-to-day problems 
as well as to be familiar with possible problems 
that can arise as a result of predictive testing. 
Psychosocial support after testing is an essential 
pre-requisite for a predictive testing protocol. 
c) A Psychiatrist who will be interested and 
prepared to be involved when required. ( available 
for consultation: 1 session per week) 
d) An Obstetrician/Gynaecologist ( available for 
consultation: 1 session per week) 
• for discussion on prenatal diagnosis with 
exclusion option 
• for prenatal testing; chorionic villus 
sampling(CVS) and amniocentesis and for discussion 
on what parenting options we may offer, e.g. 
artificial insemination donor (if male carrier), 
donor egg in vitro fertilization(IVF) (if female 
carrier), adoption. 
for termination of pregnancy (TOP) when 
indicated 
for contraceptive advice and sterilization 
e) Psychologist At present our team 
psychologist, has one session per week allocated to 
HD. If predictive testing is implemented, he may 
need more time allocated for the service. 
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5. SPECIFIC PROBLEMS AND NEEDS 
If the decision is made to provide ancillary staff 
and to implement the service, it will be necessary 
to convene a high level committee to establish 
policy on moral and ethical issues which relate 
specifically to Southern Africa. 
Examples of some of the issues that will have to be 
resolved are:-
(i) The ethics of presymptomatic and 
antenatal diagnosis of a progressive lethal 
condition that may only manifest in the third and 
fourth decade of life and for which there is no 
cure and much stigmatization. 
(ii) The ethics of exclusion prenatal 
diagnosis; does one insist on prior agreement to 
termination of pregnancy if there is no new 
information following testing (no exclusion)? 
Problem of victimization of child if the parent 
then manifests HD. 
(iii) Legal rights of counselling team to 
reject someone from the test programme as being 
'unsuitable' on psychological grounds that may 
raise the issue of the team being 'paternalistic' 
in judgment. 
(iv) Who has the 'right' to the results? Only 
the 'at-risk' individual? The spouse? The 
parents? Other siblings? 
What about life insurance disclosure? What about 
employers? What if patient (positive) is a pilot, 
a surgeon, an accountant, etc. ? 
(v) Other 'rights' - does the spouse have lhe 
right to insist that an at-risk partner have the 
test against their will? Can vital key relatives, 
whose blood is needed for an informative test and 
who refuse, be coerced to give blood? 
(vi) The ethics of using stored DNA - given 
purely for research and the DNA bank - in 
situations where relatives refuse to co-operate. 
(vii) What is the legal age of consent? Can a 
16 year old married woman request the test? 
In addition, it will be essential to establish a 
small standing committee to whom specific problems 
can be addressed if and when they arise. 
205 
SECTION IV: CONCLUSIONS, APPLICATIONS AND RECOMMENDATIONS 
CHAPTER 12 CONCLUDING COMMENTS: 
CHAPTER 13 PRACTICAL APPLICATIONS RESULTING 
FROM THIS PROJECT: 
CHAPTER 14 RECOMMENDATIONS: 
206 
SECTION IV 
CONCLUSIONS, PRACTICAL APPLICATIONS AND RECOMMENDATIONS 
Chapter lf CONCLUDING COMMENTS: 
Chapter~ PRACTICAL APPLICATIONS RESULTING FROM THIS PROJECT: 
Chapter .11 RECOMMENDATIONS: 
CHAPTER TWELVE 
CONCLUDING COMMENTS 
12.1 THE RFLP FREQUENCY STUDY 
The determination of RFLP frequencies at the D4Sl0 locus in 
different population groups is essential in order to establish 
which markers will be informative for predictive testing. It is 
noteworthy that this was the first study to be undertaken 
concerning GB allele frequencies in non-Caucasoid population 
groups. 
When a predictive testing service for HD is eventually 
established in SA, additional markers closer to the disease locus 
than GB will be used. Allele frequencies are presently being 
established by the author for D4S90 (Youngman et al., 1988) as 
well as two other markers that are being investigated for 
heterozygosity in SA in a collaborative study with the author and 
M Hayden, Vancouver (Chapter 6). 
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12.2 THE LINKAGE STUDY: 
During the four year period of this project, 22 probes on 
chromosome 4, known to be linked to HD, were acquired by the 
Department of Human Genetics, UCT. All these probes were 
isolated, purified and tested by the author and individuals from 
the initial three families that were selected for linkage studies 
(Chapter 5.4) were extensively investigated with these probes 
immediately following their acquisition. Some individuals were 
genotyped with ten different markers which required at least 100 
pg of DNA. It was not considered advisable to complete genotyping 
all individuals from the ten HD families in the study with more 
probes as sufficient DNA was not available for development in all 
these families. The DNA bank requires a minimum amount of 100 
pg of DNA for storage at any one time. The utilisation of more DNA 
would have depleted our stocks needed for predictive testing and 
it was therefore decided to restrict the project to the use of GB 
probes only. Until such time as all HD patients lymphocytes have 
been transformed and are safely stored in liquid nitrogen, the 
amount of DNA available for research will remain limited. 
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The results obtained from the study of the four probes that were 
selected for this project demonstrated that for accurate linkage 
analysis, it would be essential to use more markers, preferably 
ones closer to the HD locus. By using more markers, the 
individual informativeness will be improved with the use of 
haplotypes as was demonstrated by the family study with the new 
variant (Chapter 8). Also, the possibility of error in predictive 
testing, due to recombination between the markers and HD will be 
reduced by using markers closer to the HD gene locus. The use of 
additional markers will also result in a larger number of families 
becoming informative for linkage analysis. 
The use of additional markers in the SA black HD families 
indicated that, assuming linkage to the markers used, the HD gene 
in the two SA black families is not associated with the same 
markers. 
Furthermore, the possible positive genetic evidence in favour of a 
founder effect for HD in the SA population of mixed ancestry has 
very important implications for predictive testing of HD for 
families of this group. The use of linkage disequilibrium data 
could allow substantial risk modification for certain individuals 
and reduce the necessity for extended family linkage analysis 
(Chapter 7.4). 
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12.3 THE HETEROGENEITY QUESTION 
If different gene loci were to be found to cause HD (i.e. HD 
being heterogeneous), then the RFLPs identified with the markers 
on chromosome 4 would not be helpful in all HD families. To date, 
there have been no families in which non-linkage has been 
demonstrated. 
The SA black HD families investigated in this study were not large 
enough to obtain a positive lod score (>3) to confirm linkage. 
However, according to Ott's A test, there was no significant 
evidence in favour of heterogeneity for the ten SA families 
originating from different backgrounds that were studied (Chapter 
7.3). 
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12.4 THE QUESTIONNAIRE SURVEY 
Although the questionnaire survey was originally intended for 
fact-finding, it was also responsible for enlightening many HD 
families about the genetic implications of the disease. The long-
term impact of this knowledge on their lives was not easy to 
assess at that stage. In view of continued contact with the 
families and their increased awareness of the disease, it was 
felt necessary to offer counselling in advance of the predictive 
test. A special HD at-risk clinic was established in addition to 
the existing HD clinic for the medical management of HD patients. 
One of the reasons for this special clinic was that additional 
counselling of at-risk individuals at the existing HD clinic was 
very distracting for all concerned. It is possible that HD family 
members who have not yet seen an HD patient in the advanced stages 
of the disease could be unduly alarmed by suddenly being 
confronted with severely affected HD patients before appropriate 
counselling. HD family members are now referred to the at-risk 
clinic for counselling by a specially appointed psychologist who 
is familiar with the problems associated with the disease. 
The most striking finding of the survey was that in general, at-
risk individuals in Cape Town were well informed about HD and were 
knowledgeable about the genetics of the disorder. However, there 
was an unwillingness or inability to apply this theoretical 
knowledge to their own situation. Furthermore, there was evidence 
that many individuals denied knowledge of the possibility of a 
predictive test. 
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CHAPTER THIRTEEN 
PRACTICAL APPLICATIONS RESULTING FROM THIS PROJECT 
13.1 THE ESTABLISHMENT OF A SPECIAL AT-RISK CLINIC. 
The necessity for establishing a special at-risk counselling 
clinic has been discussed (Chapter 12.4). This clinic is now 
available to at-risk HD family members and has proven to be most 
successful. 
The clinic is run jointly by the Department of Human Genetics and 
the Department of Psychiatry, GSH. The staff comprises a 
psychologist, a medical genetic counsellor and a genetic nursing 
sister. There is also a psychiatrist on call for consultation. 
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13.2 THE FOUNDATION OF THE HUNTINGTON SOCIETY OF 
SOUTH AFRICA (HSSA). 
In 1986, the Huntington Society of SA (HSSA) was founded as a 
direct result of the establishment of the HD DNA banking centre. 
The aim of this lay society is to provide HD families an 
opportunity of meeting with one another to share experiences, 
discuss problems and act as a support group. In addition, it is 
their aim to educate the community at large as well as medical and 
professional health carers about the disease. The society has been 
very successful in its endeavours and is a member of the 
International Huntington Association (IHA). In 1989, two of their 
delegates attended the 8th International Meeting of the IHA in 
Vancouver, Canada. The author has addressed this lay organisation 
on a number of occasions and has had continued contact with many 
of their members. 
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13.3 SURVEY OF THE SERVICE NEEDS AND PROBLEMS OF HD 
PATIENTS AND THEIR FAMILIES IN CAPE TOWN. 
As a result of the questionnaire survey during the course of this 
project and the need to establish what services were available 
currently in Cape Town (CT) for HD families, the Department of 
Community Health (UCT) undertook a survey in 1988 of the service 
needs and problems of HD patients and their families in CT 
(Kvalsvig and Blockman, 1988). 
Their survey identified the available services as the HD clinic 
at GSH, the HD lay society, the two local Psychiatric Hospitals 
(Valkenberg and Lentegeur), the Cape Mental Health Society and 
private nursing services. The general overall impression gained 
during this survey was that the existing services were not being 
fully utilised by the HD community, mainly because of fear of 
stigmatization, lack of communication and knowledge about the 
these services as well as socioeconomic pressures. 
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It was found that many HD families were from the lower 
socioeconomic groups and could only afford services that were 
state-subsidised. There was a very poor understanding of existing 
services and it was felt that social workers were needed to 
direct individuals to these services, develop new resources and 
assist with the identification of problems facing HD patients and 
their families. The HD community requires constant support and 
guidance to help them overcome and cope with their feelings of 
despair and isolation, their frustration at the inaccessibility 
of the outside world, their fear of being a burden to others and 
the never ending struggle of day-to-day living. The one statement 
made by all was "No one really understands what it is 
likeH. 
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13.4 HD WORKSHOP AND LECTURES. 
An HD workshop, organised by the Department of Human Genetics, UCT 
was held in conjunction with the Second Congress of the Southern 
African Society of Human Genetics in Cape Town, 1988. This 
served as a very successful educational programme for the health 
workers, genetic state nurses and concerned medical geneticists 
who attended the Congress. 
As a result of the workshop, lectures and presentations given 
throughout the country by the author, on various aspects of this 
project, a new awareness and concern has been created for HD. 
Consequently there is a better general understanding of the 
disease and the associated social problems it creates (Abstracts 
of papers read at various national and international meetings on 
aspects of this project are in the appendix). 
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13.5 CO-ORDINATION OF EXISTING SERVICES. 
As a result of this research undertaking, two other Departments at 
GSH and UCT as well as the Department of National Health and 
Population Development, both on a regional and national level, 
have become increasingly involved with HD patients and the 
problems experienced by their families. The survey undertaken by 
the Department of Community Health (UCT) has been discussed (13.3) 
as well as the collaborative clinic established by the Department 
of Human Genetics (UCT) and Department of Psychiatry (GSH) (13.1). 
The interest in HD taken by the Department of National Health and 
Population Development and their financial and service commitment 
to the banking of DNA, must be maintained and is vital for the 
continuation of the HD DNA banking service. 
At a local level, the Department of National Health and Population 
Development formed a Co-ordinating Committee for Genetic Services 
in the Western Cape and a special meeting was held on the 6th 
March 1989, with the Department of Human Genetics (UCT) to discuss 
the co-ordination of services for HD in CT. At this meeting, the 
Department of Community Health (UCT) and the Community Mental 
Health Nursing Services undertook to establish a co-ordinating 
mechanism for dealing with HD families and their problems in the 
community. 
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13.6 dBASE III MANAGEMENT SYSTEM FOR HD DNA BANKING. 
In 1988, a dBase III management system was installed on a 
microcomputer in the laboratory of the Department of Human 
Genetics, UCT, in accordance with the system recommended by 
Sarfarazi et al. ( 1987) and the system used at the Canadian DNA 
banking centre at the University of British Columbia, Vancouver ( 
Amy Hedrik, personal communication). Details of all persons whose 
blood was taken for the HD DNA banking centre were stored using 
this program. The program and its data were maintained by the 
author and a constant check kept on the amount of DNA stored in 
the bank for the period that the developmental molecular programme 
was being completed. Whenever the level of DNA stored in the bank 
dropped to less than lOOug of DNA, genetic nurses throughout the 
country were notified to obtain more blood for banking. 
Confidentiality remains an important aspect of HD DNA banking and 
only authorised staff members are allowed access to the HD data 
on the microcomputer. A copy of the patient information stored on 
the computer is given in the appendix (Appendix X). 
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CHAPTER FOURTEEN 
RECOMMENDATIONS AND FUTURE RESEARCH 
14.1 RECOMMENDATIONS FOR THE EXISTING SERVICE 
The results of the survey conducted by the Department of Community 
Health (Chapter 13.3) indicated that the facilities available to 
HD patients and their families are presently concerned mainly 
with the medical care of the patients. The emphasis should now be 
concentrated on helping family members to cope with the problems 
of caring for the HD patient, informing them of the existing 
services and helping at-risk individuals to come to terms with 
their own risk status. 
There are a number of problems that have been identified by the 
aforementioned survey that need to be dealt with immediately, such 
as the lack of transportation, availability and accessibility of 
disability grants and full utilization of existing services. 
The lack of transportation for patients and at-risk individuals 
has made certain services inaccessible to HD families. An 
immediate possible solution would be for social workers to visit 
HD families at home. This would provide them with the opportunity 
to deal individually with family problems, applications for 
disability pensions, institutional placement and help with 
temporary care to relieve family stress. In addition, state-
subsidised home nursing services could alleviate the immediate 
pressures and stresses caused by caring for HD patients at home. 
Such services at present are privately run and are therefore out 
of reach of many financially crippled HD families. 
222 
Finally, by educating family members and the community at large, 
the stigma associated with HD would be minimised, thus enabling 
at-risk individuals to make informed, voluntary decisions about 
their lives and predictive testing for HD in an atmosphere of 
support and understanding. 
A committee consisting of representatives of the International 
Huntington Association (IHA) and the World Federation of Neurology 
(WFN) issued a policy statement on the HD molecular genetics 
predictive test (Went L, 1990 and World Federation of Neurology 
statement, 1989). The document provides some realistic ethical 
and moral principles based on the current knowledge and techniques 
in molecular genetics and will be used as a guideline for the 
eventual implementation of predictive testing for HD in SA. 
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14.2 FUTURE RESEARCH 
14.2.1 The linkage data indicating a possible founder effect for 
HD in the SA population of mixed ancestry needs further 
investigation. Haplotyping of further HD patients of mixed 
ancestry to determine whether the HD gene is cosegregating with 
the same haplotype, more frequently than would be expected if the 
genes were randomly distributed in the population, would help to 
confirm or refute this observation. The implications of the 
finding of a founder effect have been discussed and would 
influence the eventual approach to predictive testing for HD in 
a SA family of mixed ancestry. 
14.2.2 Once the HD gene has been cloned, it would be useful to 
investigate affected individuals from different origins at the 
intragenic level to determine whether there is true molecular 
heterogeneity or homogeneity for HD. 
14.2.3 Hayden et al. (1982) commented on the high frequency of 
juvenile HD in SA. Although the juvenile form of the condition 
is not a separate clinical entity but rather a reflection of the 
variable phenotypic expression (van Dijk et al., 1986), molecular 
investigations at the intragenic level of these individuals might 
reveal allelic heterogeneity. 
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In addition, two recent reports on genomic imprinting being a 
possible mechanism for the parental origin effect in juvenile HD 
would require a study of the methylation profile of the parental 
alleles in these families in order to examine this proposal (Reik, 
1988; Ridley et al., 1988). 
We have been approached to participate in a collaborative study 
with the Vancouver HD research group to determine whether there is 
any alteration in DNA methylation which may account for early 
onset of HD. For this project, DNA from our banking centre will be 
sent to M. Hayden, Vancouver for specialised molecular 
investigation. 
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INFORMATION SHEET FOR FAMILIES 
UNIVERSITY OF CAPE TOWN 
' 
Department of Human Genetics 
University of Cape Town · Medical School. ObseNatory. 7925 
Telephone 47-1250 Ext. 297 
Professor Peter Beighton. M.D .. Ph.D .. F.R.C .P .. D.C.H 
DNA BANKING CENTRE FOR HUNTINGTON'S CHOREA 
INFORMATION SHEET 
Huntington's chorea (HC) is a dominantly inherited disorder. This 
means that each child of an affected parent has a 50-50 chance of 
inheriting the condition. These children are therefore 'at· risk' 
of developing HC. Previously there have been no reliable markers 
to determine which of these 'at risk' children will indeed have the 
condition. However, a test has recently been developed in the USA 
which will determine which of the 'at risk' family members will 
probably develop Huntington's chorea and who are therefore at risk 
of passing the condition on to their children. 
Local research is being concentrated on finding out how accurate 
this test will be. It involves looking at the DNA (a normal com-
ponent in the blood) of blood specimens from affected and unaffected 
members of a family, as well as their spouses (husbands/wives). 
The DNA is isolated from the blood specimen and can be stored in 
a special refrigerator indefinitely. The test, in its present form . 
cannot be done on individuals alone and blood specimens from affec-
ted and unaffected family members are required. This research is 
conducted with strict concern for confidentiality and all specimens 
are coded so that only the scientists directly involved in the 
laboratory work are aware of the donor identity. 
Hopefully, this research will provide a reliable test for family 
members at risk of developing HC. For this reason, we have establish-
ed a storage facility, or "DNA bank", where blood specimens can be 
kept until such time as the test is available. 
In this way blood from numerous family members, who are crucial 
to the accuracy of the test, can be stored for an indefinite period 
while we assess the accuracy and reliability of this method. This 
will/ ..• 
We will avoid the possibility of the test being denied to 
individuals in the future because certain family members are not 
for various reasons. 
"at risk" 
available 
If you or other members of the family wish to use the services of the 
unique blocxi storage facility, or wt?uld like further informe.ti0r1 in this 
regard, please contact:-
Sister S Beatty or Mrs J Greenberg 
Department of Human Genetics 
Medical School 
University of Cape Town 
Observatory 7925 
Cape Town 
Telephone (012) 47-1250 Ext 304 or 456 
IT r-lJST BE EMRIA.SISED THAT AT nns TIME nm ~Km'~ IS STILL AT 'IHE 
DEVEI..OFMENT STAGE, THEREFORE !«> RB&JLTS WILL BE AVAILABLB. 
Also available in Afrikaans 
Ook verkrygbaar in Afrikaans 
INFORMATION SHEET FOR DOCTORS 
' 
Department of Human Genetics 
un1vers1ty of Cape Town Medical School · Observatory 7925 
Telephone 4 7-1250 Ext. 297 Fax No .. (021 ) 47-8955 
Professor Peter Beighton. M .D . Ph D . FR CP . DC H 
DNA BANKING CENTRE FOR HUNTINGTON DISEASE 
INFORMATION SHEET 
The finding of a DNA marker linked to the gene for Huntington Disease (HD) 
offers the prospect for preclinical testing and ante-natal diagnosis in the 
near future. This test will enable persons at risk for HD to determine 
whether or not they have a high probability of being presymptomatic carriers 
of this disease. 
HD is inherited as an autosomal dominant trait, therefore each child of an 
affected parent has an even chance (50-50) of inheriting the gene. Recent 
evidence suggests that the HD gene is located on chromosome No.4. A "marker" 
has been identified that is so close to the location of the HD gene that it 
tends to be inherited along with this gene. In all the families investigated 
thus far, coinheritance of the marker and the HD gene occur in 98% of cases. 
Thus, there is about a 2% error with this test; this is due to crossing over 
of DNA between chromosomes during meiosis and is directly related to the 
distance between the marker and the gene. 
The marker that is near the HD gene has different forms and for this reason 
it is essential to establish which form of the marker is inherited with the 
HD gene in a particular family. Thus, family studies are needed involving 
affected and unaffected (at negligible risk of developing HD) family members. 
If the affected persons have identical forms of the marker on each chromosome, 
it is not possible to determine which chromosome has the HD gene. For this 
reason it must be emphasised that this test will not be of use in all families. 
Many affected individuals who are crucial for family linkage studies may die 
prior to the availability of the test. To avoid family members subsequently 
being denied this test by virtue of the unavailability of DNA from deceased 
relatives, a DNA Banking Centre for Huntington disease in South Africa has 
been established. 
Specifically, blood is being stored from: 
i ) 
i i ) 
i i i ) 
i V) 
all affected persons 
their spouses 
persons at risk of HO but having a low probability of developing 
this disease in the future because of their advanced age 
persons at risk who are ill. 
2/ .. 
2 
For the past three years blood specimens have been collected from 
affected and unaffected members of Huntington disease families for the DNA Banking Centre. The purpose of this banking centre is to 
store DNA from Huntington disease family members for possible future l i nkage studies for presymptomatic testing of Huntington disease. At present no such test is available in Cape Town and due to the fact that people have had blood taken for DNA banking and the possibility of the test ha s been mentioned to them, we are receiving numerous telephone 
calls from families requesting results. 
It is therefore essential to explain to the families that NO tests have been done in Cape Town and that the DNA is simply being stored here. 
One of the biggest problems is that people are under the impression that the presymptomatic test is a diagnostic test. Essentially, all that the test could in fact do is alter the individual's risk status. If there is any question of possible onset of the disease this is a clinical diagnosis and the person must be referred to a Neurologist for 
assessment. 
Should you require more detailed infonnation in this regard, please 
contact Mrs J Greenberg ~t the above address. 
Also availbale in Afrikaans 
Ook verkrygbaar in Afrikaans 
COVERING LETTER TO DOCTORS 
' ~ I 
• ,, ! 
' 
Department of Human Genetics 
University of Cape Town · Medical School. Obseivatory. 7925 
Telephone 47-1250 Ext. 297 
Professor Peter Beighton. M.D .. Ph.D .. F.R.C.P .. D.C.H. 
DNA BANKING CENTRE FOR HUNTINGTON'S CHOREA 
Dear Dr 
We are establishing a DNA Bank for Huntington's Chorea for the 
reasons outlined in the information sheet. We understand that 
family, ...................... who are in your care, have a 
history of Huntington's Chorea. We have contacted a member of 
this family, .................. . ....... , with regard to obtaining 
blood from the following family members:-
1. 
2. 
3 . 
4 . 
5. 
Information on the purpose of the DNA Bank has been sent to these 
family members. 
We would appreciate your assistance in obtaining blood specimens 
from these persons, who will be contacting you in the near future. 
The DNA will be extracted from the blood, and then stored in our 
laboratory until such time when the test for Huntington's Chorea 
is available and is requested by "at risk" persons in the family. 
You have our assurance that strict confidentiality will be 
maintained. In view of the· ethical issues which are involved, it · 
is necessary for consent forms to be signed (enclosed). If you 
have any questions please do not hesitate to contact us. 
Yours sincerely 
SISTER GAIL ROSS 
Research Assistant 
DNA Banking Centre for Huntington's Chorea 
Also available in Afrikaans 
Ook verkrygbaar in Afrikaans 
;NlVERSlTY Of 
' 
Department of Human Genetics 
University of Cape Town · Medical School. ObseNatory, 7925 
Telephone 47-1250 Ext. 297 
Professor Peter Beighton. M.D .. Ph.D .. F.R.C.P. D.C.H. 
re: HUNTINGTON'S CHOREA IN SOUTH AFRICAN BLACKS 
Our department recently openend a DNA Banking Centre for Huntington's 
chorea. Our main aim is to store blood specimens indefinitely from 
persons affected with Huntington's chorea, as well as their at risk 
family membe r s for the purpose of genetic analysis when the presymp-
tomatic/pred i ctive test is generally available in South Africa. We 
currently have a research progranune assessing the applicability of 
this test to the local families and foresee this screening service 
becoming available in the near future. It is important to store 
these blood specimens because the future unavailability of family 
members, specifically affected individuals, would reduce the informa-
tion obtained and thus deny the at risk individuals the opportunity 
of having their genetic status determined. 
To date we have concentrated mainly on the Cape White and mixed ances-
try families due to their accessibility. Indeed, previously Huntington 
disease was reported as being extremely rare in South African Blacks, 
however we have recently encountered some affected individuals in the 
Transvaal. It would be extremely imp6rtant to clarify this situation 
for the purpose of counselling these families and future planning of 
this nationwide service. 
We would greatly appreciate your assistance in providing us with 
information on the numbers of affected Black patients with Huntington's 
chorea seen at your hospital, either in the neurology or psychiatry 
departments. We assure you that we have strict protocols to insure 
confidentiality and individuals are only documented in code with 
access limited to a few senior members of the banking progranune. 
I have also enclosed a few information brochures with details of our 
DNA Banking Centre. I would be grateful if this could be circulated 
amongst your hospital neurologists. 
Many thanks. 
Yours sincerely, 
GA ROSS (Mrs) 
Research Assistant 
DNA Banking Centre for Huntington's chorea 
Also available in Afrikaans 
Ook verkrygbaar in Afrikaans 
DNA BANKING CENTRE FOR HUNTINGTON'S CHOREA 
CONSENT FORM 
I, the undersigned .............................................. , being 
over 21 years of age agree to having a specimen of my blood drawn and 
stored in the DNA Banking Centre for Huntington's Chorea. 
I understand that a needle will be inserted into a vein and that 30cc of 
blood will be removed. DNA will later be extracted from this blood, 
subjected to preliminary analysis and then stored in the laboratory. I 
understand that no results will be given to me at the present. 
Donor's Signature 
Witness 
Date 
l. 
2. 
If donor is a minor or unable to give consent 
(To be completed by curator/legal guardian) 
I have read the above protocol and understand the nature of the procedure. 
I hereby give consent 
Curator/Legal Guardian 
Capacity 
Witness 
Date 
l. 
2. 
on behalf of . ................................... . 
Also available in Afrikaans 
Ook verkrygbaar in Afrikaans 
APPENDIX IV: Abstract of paper read at the 1st meeting 
of the SASHG, Rustenburg (1987). 
PREDICTIVE TESTING FOR HUNTINGTON DISEASE IN 
SOUTH AFRICA 
L.J.Schram (now Greenberg), J.Goldblatt, P.Beighton, 
G.Wallis. 
MRC Unit for Inherited Skeletal Disorders, Department of 
Human Genetics, UCT Medical School. 
Huntington's disease (HD) is a fatal, late onset, 
progressive neurodegenerative disorder of autosomal 
dominant inheritance. 
The recent discovery of a polymorphic DNA probe (G8) 
showing genetic linkage to HD has facilitated predictive 
testing and antenatal diagnosis of HD. However, before 
the implementation of a genetic service of this nature 
in South Africa several problems need to be resolved. 
These include :-
i) the degree of heterozygosity at the G8 locus and 
its suitability for linkage analysis 
ii) the exclusion of non-allelic heterogeneity for HD 
in the local kindreds 
iii) the provision of adequate psycho-social support 
systems for 'at-risk' individuals on implementation of 
the service. 
A DNA banking centre for HD has been established in the 
Department of Human Genetics at UCT and 280 blood 
specimens from 30 families with HD have been collected. 
Different ethnic groups are being screened to determine 
the RFLP frequencies and the estimated degree of 
heterozygosity at the G8 locus. Preliminary linkage 
analysis in families of different ethnic backgrounds has 
not suggested non-allelic heterogeneity. A questionnaire 
survey has been initiated to ascertain the attitudes of 
persons at risk for HD towards the advent of predictive 
and antenatal testing and to assess their psycho-social 
needs. 
Analysis of the data concerning heterozygosity of the 
probes, heterogeneity and attitudes of the 'at-
risk' individuals will facilitate the future 
implementation of a genetic service of this nature in 
South Africa. 
APPENDIX V: Copy of the original proposal. 
PROPOSED PROTOCOL FOR IMPLEMENTATION OF PREDICTIVE 
TESTING FOR HD IN SA. 
I. TECHNOLOGY: 
(1) establish a DNA bank for HD at UCT 
Medical School. (2) establish a programme to offer CVS for 
prenatal diagnosis. (3) establish contact with an overseas 
laboratory to assist with the interpretation 
of problematic results. 
II.COUNSELLING SERVICE; PRE AND POST TEST. 
In establishing this service it is envisaged that the 
following persons would be involved: 
(1) MEDICAL GENETICIST: 
a) to assess 'at-risk' individuals' knowledge about HD. 
b) to explain the predictive test and its limitations to 
the individual; also its immediate and long term 
implications and any other information needed by the 
patient to reach an informed decision about his future. 
c) to explain the options and consequences of prenatal 
diagnosis if requested. 
(2) GENETIC SISTER: 
a) to arrange appointments. 
b) to assist in drawing up pedigrees. 
c) to contact key relatives. 
d) to collect blood for DNA studies. 
e) to be the link between the patient, the medical 
technologist. 
f) to provide long term follow up. 
(3) NEUROLOGIST: 
a) to examine the 'at-risk' individual for any 
manifestation of HD which would preclude predictive 
testing. 
b) for management and long term follow up of HD 
patients. 
(4) PSYCHIATRIST AND PSYCHOLOGIST 
a) to test mental and emotional stability of 
'at-risk' individuals requesting predictive testing. 
b) to assess and advise the counsellor regarding 
patient response to pre-test counselling. 
c) to advise the counsellor in helping patients' coping 
with test results. 
d) to provide crisis intervention where necessary. 
e) to provide long term support if needed. 
(V) SOCIAL WORKER: to be involved with family and 
patient support and home visits. 
VI) OBSTETRICIAN/ GYNAECOLOGIST : contact to be 
established for advice when needed and referral of 
patients when necessary for: 
a) prenatal diagnosis; CVS or TOP. 
b) options about having children; AID, IVF or adoption 
c) contraception and sterilization. 
Structure and numberof counselling sessions both pre 
and post te~to be decided on. 
It is envisaged that a core team consisting of a Medical 
Geneticist, a Genetic Nurse,~sychologist and a Social 
Worker be involved in each counselling session with a 
Neurologist and a Psychiatrist being available for 
consultation when needed. 
~ QUESTIONNAIRE : to ascertain attitudes of 'at-risk' 
individuals towards predictive testing. 
a) to be compiled based on similar existing question-
naires 
b) venue to be arranged 
c) research number to be obtained. 
IV. EDUCATION : About HD and Predictive Testing. 
ar-Lay group - Huntington society. 
b) State Health Nurses. 
c) GPs. 
V. DIFFICULTIES TO BE RESOLVED: 
legal issues. 
Moral, ethical and 
a) limitations of the test - only 96% accuracy. There 
is a necessity for an appropriate family structure and 
involvement of numerous family members for linkage 
analysis. There is also the possibility of the 
individual not being informative with the markers used. 
b) no cure - prediction of a lethal condition with 
stigmatization. 
c) ethics of 'no news' 'good news' prenatal diagnosis. 
d) rights of the spouse to insist on the 'at-risk' 
partner having the predictive test against their will. 
e) rights of vital key relatives refusing to give blood 
for linkage studies. 
f) question of confidentiality: (i) other relatives (ii) life insurance (iii) employer disclosure 
g) the question of survivor guilt. 
h) the problem of the inability of poorly educated 
individuals to make informed decisions. 
SUMMARY 
Ultimately, it is the role of the Genetic Counsellor to 
inform the patients as to the consequences and all the 
options of the test giving them the opportunity to make 
their own decisions in a setting that provides diverse 
and continuing support where necessary. 
In the past, genetic counselling for the empiric risk of 
inheriting HD was based solely on family history and 
pedigree analysis. Now, prediction can be made with 96% 
certainty based on linkage analysis. It has been 
predicted that in the next two years the gene for HD 
will be isolated and characterized, which will 
ultimately lead to treatment and gene therapy. 
This provides us with an ideal opportunity to prepare 
ourselves for the time when we will be able to offer 
predictive testing with 100% accuracy and without having 
to involve the extended family. To date, eight countries 
are already offering predictive testing and by close 
collaboration with these centres we will eventually 
reach the stage where we too will be able to offer the 
test. This will be done in a prepared, secure 
environment where "at- risk" individuals will be able to 
make informed decisions in the knowledge that there will 
be the necessary continuing support for them if they 
should need it. 
IN CONCLUSION 
Are we not in danger of introducing a new psychiatric 
disease? A condition where the individual knows that he 
has a 96% chance of developing a dreadful lethal 
incurable condition in the future. This knowledge can 
immediately alter his entire life drastically and not just the last 10-15 years after the onset of HD. 
In view of the poor economic climate and state of 
medical services at the present, can the test be offered 
here in the near future, bearing in mind the 
considerable expense of medical personnel, technical 
expertise and back up services required? 
SUGGESTION 
A committee is needed to decide whether or not this test 
should be offered. 
This committee should include; 
Professor Beighton and representatives from the 
Department of Human Genetics 
The Medical Superintendent. 
Professor Benatar to deal with moral and ethical issues. 
A Psychiatrist. 
A Neurologist. 
The Chief Social Worker. 
HD CLINIC :Suggestions for improving the existing 
clinic. -
At present this clinic performs the following functions (i) is mainly diagnostic and therapeutic 
(ii) provides genetic counselling if needed 
(iii) collects blood for the DNA bank. 
There are additional needs to provide overall care for 
the HD patient. 
These are as follows: 
(a) A Social Worker to be attached to the clinic to deal 
with family problems, disability pensions, institutional 
placement and help with temporary care to relieve 
family stress. 
(b) Access to :- Dieticians, Physiotherapists, 
Occupational Therapists, Speech Therapists, and 
Dentists. 
(c) Day care or community centre to help family with 
everyday care and other problems. 
Also available in Afri kaa~s 
Ook v2rk rygba c.r : n Afr ·: \;Jans 
QUESTIONNAIRE 
A: PERSONAL INFORMATION 
Survey Number: 
Sex: Ethnic group: Date of birth: Religion: 
Occupation: 
Level of e~ucation obtained: 
Marital status : Date of marriage: 
Number of children: 
Year of birth: 1. 2. 3. 
4. 5. 6. 
7. 8. 9. 
Number of grandchildren: 
Year of birth: 1. 2. 3. 
4. 5. 6. 
7. 8. 9. 
Do you intend to have any/more children? 
If yes, how many? If no, why not? 
How are you related to the HD patient? 
Have you lived with or cared for the HD patient? (or any other contact): 
If yes, for how long? 
. How long has the patient had HD? 
How old was the patient when it first started? 
What do you consider to be the biggest problem for 
a) the patient with HD 
b) the family 
Are you at risk of inheriting HD? 
If yes, when did you learn this (what age) ? 
Where and how? 
Do you know of any test that shows whether you will get HD? 
2 
B. We would like to see how much you know about HD. 
1. From which source did you gain most of your knowledge of HD? 
Family doctor 
Specialist 
Friends or relatives 
Genetic counselling clinic 
Books or films 
Other (please specify) 
2. Which part of the body is involved in HD? 
Heart Kidneys 
3. How 1s HD contracted? 
Brain 
3 
Virus infection Inherited Alcoholism/Drug abuse 
4. What is the usual age group for HD to appear? 
24 years or less 25-44 yrs 45 years or over 
5. What are the most cotmnon changes to the body in HD? 
Jerky movements and twisting 
Gradual paralysis of arms and legs 
Painful, swollen joints 
6. Once the symptoms of HD appear, do they become: 
Gradually better Gradually worse 
Stay the same indefinitely Gradually worse, then better? 
7. What form of treatment 1s conmon for HD? 
X-ray treatment 
Surgery 
Physiotherapy 
Drug treatment 
4 
8. Does lID affect both male and females equally? 
Yes No Don't know 
9. What are the chances that a parent with HD will pass the condit i 
on to his children? 
257. chance 
757. chance 
07. chance 507. chance 
Not sure, but you know there is a risk 
10. Can a family member who does not yet show features of HD pass t h 
disease on to his/her children? 
Yes No Don't know 
11. Are you aware of any research going on in the field of HD? 
Yes No Don't know 
12. Who would you approach should you require information about HD f c 
yourself or family members? 
5 
C. PLEASE ANSWER THE FOLLOWING QUESTIONS 
At present there is no cure for HD. 
HD long before the onset of symptoms: 
If a test was available to diagnose 
1. Would you advise all people at risk to have such a test? 
2. Would you have the test done yourself? 
3 . Would yo u be willing to have a child of yours undertake this test? 
4 . Wou ld you discourage a child of yours from having such a test? If 
~o, why? 
5. How would you feel if your test was negative? 
6. How would you feel if your test was positive? 
7. Would you require help in coping with the result either way and if so, 
who would you go to? 
8. At present, if the test was available it would only be 95% accurate. 
Would you still take the test ? ....•.••..•..•....••.........•...... 
9. Would you only have the test if it was 100% accurate? 
10. If your test was positive for HD, would you have children? 
11. If your test was negative, would you have children? 
12. What age do you think it best for a child to have the test? 
13. Would you/your wife have a prenatal test if available? 
14. If this test was positive, would you/your wife have the pregnancy 
terminated (legal abortion) ? 
6 
D. ATTITUDES TOWARDS PREDICTIVE TESTS: 
In t he future a test will probably be available to you and other family 
members. This test, if informative, will tell you whether yo u will 
develop HD in the future or not but there still 1s no cure. This test 
wi ll not be compulsory and will onl y be done if you ask for it, and all 
results when available will be kept strictly confidential. 
Now that we have completed the questionnaire and discussed HD and the 
new test with you, please answer the following questions: 
When the test becomes availa j le: 
1. Would you have the test done yourself? 
2 . Would you advise all people at risk to have such a test? 
3. Would you be willing to have a child of yours undertake this test? 
4. Would you discourage a child of yours from having such a test? 
If ~o , why ? ......................••............•................ 
5. How would you feel if your test was negative? 
7 
6. How would you feel if your test was positive? 
7. Would you require help in coping with the result either way, and if 
so, who would you go to? 
8. At present, if the test was available it would only be 95% accurate. 
Would you still take the test? 
9. Would you only have the test if it was 100% accurate? 
10 . If your test was positive for HD, would you have children? 
11. If your test was negative, would you have children? 
12~ What age do you think it best for a child to have the test? 
13. Would you/your wife have a prenatal test if available? 
14. If this test was positive, would you/your wife have the pregnancy 
terminated (legal abortion) ? 
8 
APPENDIX VII: Abstract of paper read at the 7th IHA 
workshop and conference, Genoa (1987). 
PREPARATION FOR PREDICTIVE TESTING 
FOR HD IN SOUTH AFRICA 
LJ Schram [LJ Greenberg], P Beighton, J Goldblatt, 
G Wallis 
At present we have about 85 South African families with 
Huntington's Disease documented by the Department of 
Human Genetics, University of Cape Town. A DNA banking 
centre has been established to obtain specimens from the 
family members and 330 bloods from 30 families with 
Huntington's Disease have been collected. 
Most of these families are of European origin or mixed 
ancestry but in the rural Black populations, where 
Huntington's Disease is rare, there is no evidence of 
European admixture. For this reason the possibility of 
heterogeneity is being investigated. 
Linkage analysis in South African families from 
different population groups has not as yet revealed any 
instances of discordance between the GB locus and HD. 
In anticipation of predictive testing for Huntington's 
Disease, various issues relating to its practical 
implementation in South Africa's multi-ethnic society 
have been addressed. Recommendations to date for the 
implementation of predictive testing have been based on 
studies of informed sophisticated societies. These 
guidelines are not generally applicable to the South 
African situation where social and ethnic background 
differences, the lack of counselling facilities and 
logistics of back-up services in rural areas are of 
major concern. 
A questionnaire survey is currently underway to assess 
the understanding and attitudes of at risk individuals 
to predictive testing and antenatal diagnosis in order 
to provide adequate psycho-social support systems based 
on their needs. The Huntington's Disease Association of 
South Africa was founded at our instigation and assists 
in the dissemination of accurate information regarding 
HD to its members. Special clinics have been established 
for the counselling of at risk individuals. Data arising 
from this survey will be used for the preliminary 
planning and future implementation of a preventative 
programme for HD based on the specific needs of the 
persons concerned. 
It is essential that these results be considered in the 
international discussion of predictive testing 
guidelines as they represent the third world situation. 
APPENDIX VIII: Abstract of paper read at the 3rd 
~- meeting of the SASHG, Durban (1989). 
'AT-RISK' PERSONS KNOWLEDGE OF AND ATTITUDES TOWARD 
HUNTINGTON DISEASE AND PREDICTIVE TESTING 
RESULTS OF A SURVEY IN CAPE TOWN 
GREENBERG L J 
MRC Unit for Inherited Skeletal Disorders, Department 
of Human Genetics, UCT Medical School, CAPE TOWN. 
Forty questionnaires were distributed to Huntington 
Disease (HD) families throughout the greater Cape Town 
area. 20 individuals, at risk of inheriting HD, 
volunteered to complete the in depth structured 
questionnaires to determine their knowledge about HD 
and assess their attitudes towards predictive testing. 
In terms of genealogical data, 17 (85%) were at 50% 
risk and 3 (15%) were at 25% risk of having inherited 
the gene for HD at the time of the survey. Of the 20 
respondents, 15 (75%) were of mixed ancestry and 5 (25%) 
from the white population group. 
The initial results of the survey indicate the 
limited extent of the individuals' knowledge about the 
genetics of HD and the implications for themselves. 10 (50%) were totally unaware of their own risk status 
while only 6 (30%) of these were unsure of the 
mathematical risk of inheriting the disorder if there 
was a history of HD in a family. Only 6 (30%) knew about 
the possibility of a predictive test. 
It is evident that there is a strong element of 
denial in this 'at-risk' population group. Whereas 
individuals are informed about the genetics of the 
disorder they are often unable to apply this information 
to their own risk status. The anticipated demand for 
predictive testing, should it be available in South 
Africa, is much smaller than in previously published 
international studies. This situation is possibly due to 
the lack of awareness and basic knowledge of the 
implications of HD. The survey was probably responsible 
for drawing the attention of many HD families to the 
genetic implications of the disorder. The long term 
impact of this knowledge on their quality of life is 
not easy to assess at this stage. 
The data indicates the need for a well organised 
programme designed to address the genetic, psychological 
and ethical issues that may arise in the use of 
presymptomatic testing for HD. Any prediction service 
of this nature must have adequate pre-test counselling 
with the main emphasis on education and enlightenment as 
well as follow-up support. Of utmost importance is the 
availablity of professional and community resources to 
deal with the issues and the final impact of predictive 
testing. It is clear that strategies need to be 
developed to care for otherwise healthy persons who can 
be given a diagnosis years before the onset of the 
condition. In HD, more than in any other genetic 
disorder, an integrated professional team approach to 
counselling is essential. 
APPENDIX IX: Abstract of the poster presented at the 
~ March of Dimes Congress, Boston (1989). 
CLINICAL APPLICATIONS OF MOLECULAR GENETICS. 
PREPARATION FOR A MOLECULAR SERVICE FOR HUNTINGTON 
DISEASE IN SOUTHERN AFRICA. 
Greenberg LJ, MRC Unit for Inherited Skeletal Disorders, 
Department of Human Genetics, University of Cape Town 
Medical School, South Africa. 
Huntington Disease (HD) is a fatal, late onset, 
progressive neurodegenerative disorder inherited as an 
autosomal dominant trait. 
The discovery of a polymorphic DNA probe (G8) 
showing genetic linkage to HD has facilitated 
presymptomatic testing and antenatal diagnosis of HD. 
Before the implementation of a genetic service of this 
nature in Southern Africa however, several problems need 
to be resolved. These issues include the usefulness or 
frequency of heterozygosity of the marker in the 
different South African population groups, the 
possibility of non-allelic mutations causing the HD 
phenotype and the ethical, psychological and 
sociological problems that might arise from the clinical 
application of such a preclinical test. 
A DNA banking centre for HD was established in the 
Department of Human Genetics at the University of Cape 
Town in 1986 and 370 blood specimens from 39 families 
with HD have been collected. Different ethnic groups are 
being screened to determine the RFLP frequencies and the 
estimated degree of heterozygosity at the GB locus. 
Other probes closer to the HD gene are also being 
applied to determine their suitability for linkage 
analysis in the various populations of this country. 
Preliminary linkage analysis in families of 
different ethnic backgrounds has not suggested non-
allelic heterogeneity. 
A questionnaire survey has been undertaken to 
ascertain the knowledge and attitudes of persons at risk 
for HD in Cape Town in preparation for the advent of 
predictive and antenatal testing. The main objective of 
this undertaking is to provide adequate psycho-social 
support systems based on the specific needs of the 
persons concerned. 
Predictive testing guidelines have been laid down 
by American and European investigators who are often 
unfamiliar with the culture, customs and economic 
pressures within developing countries. In terms of the 
ethical considerations related to HD a careful 
examination of cross-cultural ethics is critical and 
basic ethical principles need to be interpreted and 
applied within different cultural settings. 
Analysis of the data concerning heterozygosity of 
the probes, heterogeneity and the attitudes of 'at-risk' 
individuals will facilitate the future implementation of 
a molecular genetic service for HD in Southern Africa. 
APPENDIX X: 
Computer form of the Huntington disease dBase file. 
NAME DOE JOHN 
FAMNAME ALLEMAN Hl6 
BIRTHDATE 401110 
SEX M 
ETHGROUP E 
NUMBERCHIL 5 
CENTRE CT 
CLINIC GSH HD 
REASON FAMILY HISTORY OF HD SHOWING SIGNS 
OF HD 
EXAMINER DR.SMITH 
DIAGCODE AFFECTED 
DCONFIRM y 
ONSETAGE 38 
DIAGAGE 34 
PARENTDNAN H 110/86SED 
SPOUSEDNAN H 120/86ALI 
BLOODDATE 860612 
AMNTBLOOD 30 
DNAISODATE 860816 
CONC 150 A 3 30 
DNAISODAT2 871107 
CONC2 200 B 5 49 
DNAISODAT3 871211 
CONC3 200 F 5 47 
DNAREMAIN 550 UG 
ASOF 880110 
DNASTORED A 3 30 
DNANUMBER H 95/86JOH 
FOLDERNO 34509878 
LASTDATE 880110 
DEATHDATE 0 
DEATHAGE 0 
RECORDNO 101 
